US20230414706A1 - Compositions and methods for treating metabolic diseases - Google Patents
Compositions and methods for treating metabolic diseases Download PDFInfo
- Publication number
- US20230414706A1 US20230414706A1 US18/296,454 US202318296454A US2023414706A1 US 20230414706 A1 US20230414706 A1 US 20230414706A1 US 202318296454 A US202318296454 A US 202318296454A US 2023414706 A1 US2023414706 A1 US 2023414706A1
- Authority
- US
- United States
- Prior art keywords
- polypeptide
- cmyr
- serum
- subject
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000030159 metabolic disease Diseases 0.000 title claims abstract description 99
- 238000000034 method Methods 0.000 title claims abstract description 58
- 239000000203 mixture Substances 0.000 title abstract description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 520
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 507
- 229920001184 polypeptide Polymers 0.000 claims abstract description 502
- 241000700721 Hepatitis B virus Species 0.000 claims abstract description 101
- 208000016097 disease of metabolism Diseases 0.000 claims abstract description 80
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 41
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 40
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 34
- 210000002966 serum Anatomy 0.000 claims description 245
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 116
- 108091006611 SLC10A1 Proteins 0.000 claims description 105
- 102100021988 Sodium/bile acid cotransporter Human genes 0.000 claims description 105
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 103
- 150000001413 amino acids Chemical group 0.000 claims description 93
- 235000001014 amino acid Nutrition 0.000 claims description 91
- 229940024606 amino acid Drugs 0.000 claims description 89
- 230000000694 effects Effects 0.000 claims description 87
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 80
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 77
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 73
- 239000008103 glucose Substances 0.000 claims description 68
- 210000004369 blood Anatomy 0.000 claims description 54
- 239000008280 blood Substances 0.000 claims description 54
- 235000012000 cholesterol Nutrition 0.000 claims description 50
- 239000003814 drug Substances 0.000 claims description 50
- 201000010099 disease Diseases 0.000 claims description 49
- 102000004877 Insulin Human genes 0.000 claims description 40
- 108090001061 Insulin Proteins 0.000 claims description 40
- 229940125396 insulin Drugs 0.000 claims description 40
- 235000019197 fats Nutrition 0.000 claims description 33
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 31
- 108010028554 LDL Cholesterol Proteins 0.000 claims description 31
- 210000003734 kidney Anatomy 0.000 claims description 29
- 230000008482 dysregulation Effects 0.000 claims description 26
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 22
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 22
- 108010023302 HDL Cholesterol Proteins 0.000 claims description 21
- 229960002297 fenofibrate Drugs 0.000 claims description 21
- 230000004060 metabolic process Effects 0.000 claims description 21
- 230000000087 stabilizing effect Effects 0.000 claims description 21
- 208000008589 Obesity Diseases 0.000 claims description 20
- 235000005911 diet Nutrition 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 20
- 230000004153 glucose metabolism Effects 0.000 claims description 20
- 210000002216 heart Anatomy 0.000 claims description 20
- 230000037356 lipid metabolism Effects 0.000 claims description 20
- 235000020824 obesity Nutrition 0.000 claims description 19
- 201000001320 Atherosclerosis Diseases 0.000 claims description 18
- 241000285424 HBV genotype C Species 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 18
- 238000011191 terminal modification Methods 0.000 claims description 18
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 17
- 230000037396 body weight Effects 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 14
- 210000004899 c-terminal region Anatomy 0.000 claims description 14
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 14
- 150000003626 triacylglycerols Chemical class 0.000 claims description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- 206010061218 Inflammation Diseases 0.000 claims description 12
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims description 12
- 239000003472 antidiabetic agent Substances 0.000 claims description 12
- 230000004054 inflammatory process Effects 0.000 claims description 12
- 125000001165 hydrophobic group Chemical group 0.000 claims description 11
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 11
- 239000011707 mineral Substances 0.000 claims description 11
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 10
- 208000019622 heart disease Diseases 0.000 claims description 10
- 230000003284 homeostatic effect Effects 0.000 claims description 10
- 230000004066 metabolic change Effects 0.000 claims description 10
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 9
- 238000005576 amination reaction Methods 0.000 claims description 9
- 230000036772 blood pressure Effects 0.000 claims description 9
- 230000006735 deficit Effects 0.000 claims description 9
- 235000021588 free fatty acids Nutrition 0.000 claims description 9
- 229940088597 hormone Drugs 0.000 claims description 9
- 239000005556 hormone Substances 0.000 claims description 9
- 201000001421 hyperglycemia Diseases 0.000 claims description 9
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 8
- 235000021355 Stearic acid Nutrition 0.000 claims description 8
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 8
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 8
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims description 8
- 239000008117 stearic acid Substances 0.000 claims description 8
- 235000021314 Palmitic acid Nutrition 0.000 claims description 7
- 230000003143 atherosclerotic effect Effects 0.000 claims description 7
- 208000029078 coronary artery disease Diseases 0.000 claims description 7
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 7
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 239000004471 Glycine Substances 0.000 claims description 6
- 241000285370 HBV genotype E Species 0.000 claims description 6
- 241000285576 HBV genotype G Species 0.000 claims description 6
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 6
- 230000009435 amidation Effects 0.000 claims description 6
- 238000007112 amidation reaction Methods 0.000 claims description 6
- 229940125708 antidiabetic agent Drugs 0.000 claims description 6
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 6
- 229960003105 metformin Drugs 0.000 claims description 6
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 5
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 5
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 claims description 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 5
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 5
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 5
- 229920002905 Colesevelam Polymers 0.000 claims description 5
- 239000005642 Oleic acid Substances 0.000 claims description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 5
- 235000021342 arachidonic acid Nutrition 0.000 claims description 5
- 229940114079 arachidonic acid Drugs 0.000 claims description 5
- 235000009582 asparagine Nutrition 0.000 claims description 5
- 229960001230 asparagine Drugs 0.000 claims description 5
- 229960005370 atorvastatin Drugs 0.000 claims description 5
- 230000007812 deficiency Effects 0.000 claims description 5
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 5
- 235000001968 nicotinic acid Nutrition 0.000 claims description 5
- 229960003512 nicotinic acid Drugs 0.000 claims description 5
- 239000011664 nicotinic acid Substances 0.000 claims description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 5
- 235000021313 oleic acid Nutrition 0.000 claims description 5
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims description 4
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 4
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 4
- 206010008635 Cholestasis Diseases 0.000 claims description 4
- 241000285387 HBV genotype A Species 0.000 claims description 4
- 241000285452 HBV genotype B Species 0.000 claims description 4
- 241000285366 HBV genotype D Species 0.000 claims description 4
- 241000285563 HBV genotype F Species 0.000 claims description 4
- 241000285579 HBV genotype H Species 0.000 claims description 4
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 4
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 4
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
- 239000000883 anti-obesity agent Substances 0.000 claims description 4
- 239000003524 antilipemic agent Substances 0.000 claims description 4
- 229940125710 antiobesity agent Drugs 0.000 claims description 4
- 229960001152 colesevelam Drugs 0.000 claims description 4
- 230000000378 dietary effect Effects 0.000 claims description 4
- 229960000815 ezetimibe Drugs 0.000 claims description 4
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims description 4
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 4
- 201000008980 hyperinsulinism Diseases 0.000 claims description 4
- 208000003532 hypothyroidism Diseases 0.000 claims description 4
- 230000002989 hypothyroidism Effects 0.000 claims description 4
- 238000007912 intraperitoneal administration Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- XTTZERNUQAFMOF-QMMMGPOBSA-N lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 claims description 4
- 229960005060 lorcaserin Drugs 0.000 claims description 4
- ZXERDUOLZKYMJM-ZWECCWDJSA-N obeticholic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]21 ZXERDUOLZKYMJM-ZWECCWDJSA-N 0.000 claims description 4
- 229960001601 obeticholic acid Drugs 0.000 claims description 4
- 229960001243 orlistat Drugs 0.000 claims description 4
- 229960003562 phentermine Drugs 0.000 claims description 4
- 229960004034 sitagliptin Drugs 0.000 claims description 4
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims description 4
- 229960004394 topiramate Drugs 0.000 claims description 4
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims description 4
- 229960001661 ursodiol Drugs 0.000 claims description 4
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims description 3
- 206010000599 Acromegaly Diseases 0.000 claims description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 208000014311 Cushing syndrome Diseases 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 201000001376 Familial Combined Hyperlipidemia Diseases 0.000 claims description 3
- 206010059183 Familial hypertriglyceridaemia Diseases 0.000 claims description 3
- 102000019267 Hepatic lipases Human genes 0.000 claims description 3
- 108050006747 Hepatic lipases Proteins 0.000 claims description 3
- 208000013016 Hypoglycemia Diseases 0.000 claims description 3
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims description 3
- 235000021360 Myristic acid Nutrition 0.000 claims description 3
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 3
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 3
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 3
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims description 3
- 208000035707 autosomal dominant type B hypercholesterolemia Diseases 0.000 claims description 3
- 239000002876 beta blocker Substances 0.000 claims description 3
- 229940097320 beta blocking agent Drugs 0.000 claims description 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
- 231100000359 cholestasis Toxicity 0.000 claims description 3
- 230000007870 cholestasis Effects 0.000 claims description 3
- 208000020832 chronic kidney disease Diseases 0.000 claims description 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 3
- 229940011871 estrogen Drugs 0.000 claims description 3
- 239000000262 estrogen Substances 0.000 claims description 3
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims description 3
- 229960001381 glipizide Drugs 0.000 claims description 3
- 208000007345 glycogen storage disease Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 208000000522 hyperlipoproteinemia type IV Diseases 0.000 claims description 3
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 3
- 206010022498 insulinoma Diseases 0.000 claims description 3
- 238000001361 intraarterial administration Methods 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 208000014384 isolated congenital growth hormone deficiency Diseases 0.000 claims description 3
- 201000002022 isolated growth hormone deficiency Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 208000021255 pancreatic insulinoma Diseases 0.000 claims description 3
- 208000003068 pituitary dwarfism Diseases 0.000 claims description 3
- 230000003234 polygenic effect Effects 0.000 claims description 3
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 3
- 239000000583 progesterone congener Substances 0.000 claims description 3
- 229960002855 simvastatin Drugs 0.000 claims description 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 3
- 239000003451 thiazide diuretic agent Substances 0.000 claims description 3
- 108010003524 sodium-bile acid cotransporter Proteins 0.000 claims description 2
- 239000003613 bile acid Substances 0.000 description 127
- 238000011282 treatment Methods 0.000 description 103
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 83
- 241001465754 Metazoa Species 0.000 description 71
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 65
- 108010036949 Cyclosporine Proteins 0.000 description 63
- 229930105110 Cyclosporin A Natural products 0.000 description 61
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 61
- 239000002953 phosphate buffered saline Substances 0.000 description 61
- 210000004027 cell Anatomy 0.000 description 55
- 238000013293 zucker diabetic fatty rat Methods 0.000 description 55
- 230000001404 mediated effect Effects 0.000 description 54
- -1 e.g. Substances 0.000 description 52
- 125000003275 alpha amino acid group Chemical group 0.000 description 48
- 210000003494 hepatocyte Anatomy 0.000 description 46
- 230000004071 biological effect Effects 0.000 description 41
- 239000003925 fat Substances 0.000 description 31
- 208000035475 disorder Diseases 0.000 description 26
- 230000001965 increasing effect Effects 0.000 description 26
- 239000013641 positive control Substances 0.000 description 25
- 230000032258 transport Effects 0.000 description 24
- 239000007924 injection Substances 0.000 description 22
- 238000002347 injection Methods 0.000 description 22
- 238000001727 in vivo Methods 0.000 description 21
- 229940124597 therapeutic agent Drugs 0.000 description 21
- 239000003112 inhibitor Substances 0.000 description 20
- 208000024891 symptom Diseases 0.000 description 20
- 241000282472 Canis lupus familiaris Species 0.000 description 19
- 241000700159 Rattus Species 0.000 description 19
- 241000699673 Mesocricetus auratus Species 0.000 description 18
- 238000000338 in vitro Methods 0.000 description 18
- 150000002632 lipids Chemical class 0.000 description 18
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 17
- 230000037213 diet Effects 0.000 description 16
- 230000001105 regulatory effect Effects 0.000 description 15
- 238000006467 substitution reaction Methods 0.000 description 14
- 229920005989 resin Polymers 0.000 description 13
- 239000011347 resin Substances 0.000 description 13
- 238000003556 assay Methods 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 231100000132 chronic toxicity testing Toxicity 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 229910001868 water Inorganic materials 0.000 description 11
- 241000699800 Cricetinae Species 0.000 description 10
- 230000002457 bidirectional effect Effects 0.000 description 10
- 230000033228 biological regulation Effects 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 10
- 231100000673 dose–response relationship Toxicity 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 235000009200 high fat diet Nutrition 0.000 description 10
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 9
- 241000124008 Mammalia Species 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 125000000539 amino acid group Chemical group 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 230000008878 coupling Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000008214 LDL Cholesterol Methods 0.000 description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 description 6
- 102000007330 LDL Lipoproteins Human genes 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 230000008085 renal dysfunction Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000010171 animal model Methods 0.000 description 5
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 230000003345 hyperglycaemic effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 229960001404 quinidine Drugs 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- 208000037273 Pathologic Processes Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 230000037354 amino acid metabolism Effects 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 229960002027 evolocumab Drugs 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 230000009054 pathological process Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 102100025668 Angiopoietin-related protein 3 Human genes 0.000 description 3
- 101710085848 Angiopoietin-related protein 3 Proteins 0.000 description 3
- 102000002148 Diacylglycerol O-acyltransferase Human genes 0.000 description 3
- 108010001348 Diacylglycerol O-acyltransferase Proteins 0.000 description 3
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 3
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 3
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 3
- 241000288669 Tupaia Species 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000013401 experimental design Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 3
- 108091005995 glycated hemoglobin Proteins 0.000 description 3
- 238000011553 hamster model Methods 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 102000045205 Angiopoietin-Like Protein 4 Human genes 0.000 description 2
- 101710085845 Angiopoietin-related protein 4 Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 2
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 2
- 229920001268 Cholestyramine Polymers 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- BMOVQUBVGICXQN-UHFFFAOYSA-N Clinofibrate Chemical compound C1=CC(OC(C)(CC)C(O)=O)=CC=C1C1(C=2C=CC(OC(C)(CC)C(O)=O)=CC=2)CCCCC1 BMOVQUBVGICXQN-UHFFFAOYSA-N 0.000 description 2
- 229920002911 Colestipol Polymers 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 108010046315 IDL Lipoproteins Proteins 0.000 description 2
- 108010089308 Insulin Detemir Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000001796 Melanocortin 4 receptors Human genes 0.000 description 2
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 2
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 229940122392 PCSK9 inhibitor Drugs 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 108091006277 SLC5A1 Proteins 0.000 description 2
- 108010041191 Sirtuin 1 Proteins 0.000 description 2
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 description 2
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 description 2
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 210000000579 abdominal fat Anatomy 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229960004539 alirocumab Drugs 0.000 description 2
- 230000006229 amino acid addition Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 description 2
- 229960002837 benzphetamine Drugs 0.000 description 2
- 229960000516 bezafibrate Drugs 0.000 description 2
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229950011350 bococizumab Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000007211 cardiovascular event Effects 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229950003072 clinofibrate Drugs 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229960003345 empagliflozin Drugs 0.000 description 2
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960003627 gemfibrozil Drugs 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000003370 grooming effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000001596 intra-abdominal fat Anatomy 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 238000010150 least significant difference test Methods 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 108091060283 mipomersen Proteins 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 229960000436 phendimetrazine Drugs 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 229940063122 sandimmune Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- QDGIAPPCJRFVEK-UHFFFAOYSA-N (1-methylpiperidin-4-yl) 2,2-bis(4-chlorophenoxy)acetate Chemical compound C1CN(C)CCC1OC(=O)C(OC=1C=CC(Cl)=CC=1)OC1=CC=C(Cl)C=C1 QDGIAPPCJRFVEK-UHFFFAOYSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- FIDRAVVQGKNYQK-UHFFFAOYSA-N 1,2,3,4-tetrahydrotriazine Chemical compound C1NNNC=C1 FIDRAVVQGKNYQK-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 1
- 229940126558 11β-HSD1 inhibitor Drugs 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical compound OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
- FJEJHJINOKKDCW-INIZCTEOSA-N 3-[5-(azetidine-1-carbonyl)pyrazin-2-yl]oxy-5-[(2s)-1-methoxypropan-2-yl]oxy-n-(5-methylpyrazin-2-yl)benzamide Chemical compound C=1C(C(=O)NC=2N=CC(C)=NC=2)=CC(O[C@@H](C)COC)=CC=1OC(N=C1)=CN=C1C(=O)N1CCC1 FJEJHJINOKKDCW-INIZCTEOSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 description 1
- 229940127110 AZD1656 Drugs 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical compound CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 229940096916 Apolipoprotein B inhibitor Drugs 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100038495 Bile acid receptor Human genes 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 1
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 1
- 102100035294 Chemokine XC receptor 1 Human genes 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 238000008620 Cholesterol Assay Methods 0.000 description 1
- 102000011413 Chondroitinases and Chondroitin Lyases Human genes 0.000 description 1
- 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- DVJAMEIQRSHVKC-BDAKNGLRSA-N Dutogliptin Chemical compound OB(O)[C@@H]1CCCN1C(=O)CN[C@H]1CNCC1 DVJAMEIQRSHVKC-BDAKNGLRSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 206010014486 Elevated triglycerides Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 229940080349 GPR agonist Drugs 0.000 description 1
- ZWPRRQZNBDYKLH-VIFPVBQESA-N Gemigliptin Chemical compound C([C@@H](N)CC(=O)N1CC2=C(C(=NC(=N2)C(F)(F)F)C(F)(F)F)CC1)N1CC(F)(F)CCC1=O ZWPRRQZNBDYKLH-VIFPVBQESA-N 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 229940122904 Glucagon receptor antagonist Drugs 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- HNSCCNJWTJUGNQ-UHFFFAOYSA-N Glyclopyramide Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)NC(=O)NN1CCCC1 HNSCCNJWTJUGNQ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 description 1
- 101000804783 Homo sapiens Chemokine XC receptor 1 Proteins 0.000 description 1
- 101001041117 Homo sapiens Hyaluronidase PH-20 Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 108010073961 Insulin Aspart Proteins 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 108010081368 Isophane Insulin Proteins 0.000 description 1
- 102000005237 Isophane Insulin Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- 229940122591 Microbiome modulator Drugs 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229940126033 PPAR agonist Drugs 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 229940122985 Peptide agonist Drugs 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 101150010882 S gene Proteins 0.000 description 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
- 108091006269 SLC5A2 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- JLRNKCZRCMIVKA-UHFFFAOYSA-N Simfibrate Chemical compound C=1C=C(Cl)C=CC=1OC(C)(C)C(=O)OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 JLRNKCZRCMIVKA-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 102100020888 Sodium/glucose cotransporter 2 Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010045254 Type II hyperlipidaemia Diseases 0.000 description 1
- 238000008083 Urea Assay Methods 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960003526 acipimox Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 description 1
- 229960004733 albiglutide Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229960001667 alogliptin Drugs 0.000 description 1
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 229940000806 amaryl Drugs 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- MZZLGJHLQGUVPN-HAWMADMCSA-N anacetrapib Chemical compound COC1=CC(F)=C(C(C)C)C=C1C1=CC=C(C(F)(F)F)C=C1CN1C(=O)O[C@H](C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]1C MZZLGJHLQGUVPN-HAWMADMCSA-N 0.000 description 1
- 229950000285 anacetrapib Drugs 0.000 description 1
- 229950009977 anagliptin Drugs 0.000 description 1
- LDXYBEHACFJIEL-HNNXBMFYSA-N anagliptin Chemical compound C=1N2N=C(C)C=C2N=CC=1C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N LDXYBEHACFJIEL-HNNXBMFYSA-N 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 229940120049 belviq Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 108091022863 bile acid binding Proteins 0.000 description 1
- 102000030904 bile acid binding Human genes 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- RSMSFENOAKAUJU-UHFFFAOYSA-L bis[[2-(4-chlorophenoxy)-2-methylpropanoyl]oxy]aluminum;hydrate Chemical compound O.C=1C=C(Cl)C=CC=1OC(C)(C)C(=O)O[Al]OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 RSMSFENOAKAUJU-UHFFFAOYSA-L 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960004111 buformin Drugs 0.000 description 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
- YSMHTFWPDRJCMN-UHFFFAOYSA-N butan-2-yl carbonochloridate Chemical compound CCC(C)OC(Cl)=O YSMHTFWPDRJCMN-UHFFFAOYSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 229960001713 canagliflozin Drugs 0.000 description 1
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 1
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229960003362 carbutamide Drugs 0.000 description 1
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- TZRFSLHOCZEXCC-HIVFKXHNSA-N chembl2219536 Chemical compound N1([C@H]2C[C@@H]([C@H](O2)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C(C)=C2)=O)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2CO)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(NC(=O)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP(O)(=O)OC[C@H]2O[C@H](C[C@@H]2SP(O)(=O)OC[C@H]2O[C@H](C[C@@H]2SP(O)(=O)OC[C@H]2O[C@H](C[C@@H]2SP(O)(=O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)SP(O)(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP(O)(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C3=NC=NC(N)=C3N=C2)OCCOC)SP(O)(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP(O)(=O)OC[C@H]2[C@H](O)[C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)C=C(C)C(N)=NC1=O TZRFSLHOCZEXCC-HIVFKXHNSA-N 0.000 description 1
- GXALXAKNHIROPE-QAQDUYKDSA-N chembl2364624 Chemical compound C1C[C@@H](CC(=O)O)CC[C@@H]1C1=CC=C(C=2N=CC(NC=3C=NC(=CC=3)C(F)(F)F)=CC=2)C=C1 GXALXAKNHIROPE-QAQDUYKDSA-N 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 108700043024 cholylsarcosine Proteins 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
- 229950009226 ciglitazone Drugs 0.000 description 1
- 229960002174 ciprofibrate Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940097479 colestid Drugs 0.000 description 1
- 229960002604 colestipol Drugs 0.000 description 1
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 208000012696 congenital leptin deficiency Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960003834 dapagliflozin Drugs 0.000 description 1
- QQKNSPHAFATFNQ-UHFFFAOYSA-N darglitazone Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCC(=O)C(C=C1)=CC=C1CC1SC(=O)NC1=O QQKNSPHAFATFNQ-UHFFFAOYSA-N 0.000 description 1
- 229950006689 darglitazone Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000011697 diabetes animal model Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- FPUQGCOBYOXAED-UHFFFAOYSA-N diethyl 2-[[2-[3-(dimethylcarbamoyl)-4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]phenyl]acetyl]oxymethyl]-2-phenylpropanedioate Chemical compound C=1C=CC=CC=1C(C(=O)OCC)(C(=O)OCC)COC(=O)CC(C=C1C(=O)N(C)C)=CC=C1NC(=O)C1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1 FPUQGCOBYOXAED-UHFFFAOYSA-N 0.000 description 1
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 1
- 229960004890 diethylpropion Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229960005175 dulaglutide Drugs 0.000 description 1
- 108010005794 dulaglutide Proteins 0.000 description 1
- 229950003693 dutogliptin Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229950002375 englitazone Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 229950009036 etofylline clofibrate Drugs 0.000 description 1
- KYAKGJDISSNVPZ-UHFFFAOYSA-N etofylline clofibrate Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KYAKGJDISSNVPZ-UHFFFAOYSA-N 0.000 description 1
- IHIUGIVXARLYHP-YBXDKENTSA-N evacetrapib Chemical compound C1([C@@H](N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCC2)=CC(C)=CC(C)=C1N2C[C@H]1CC[C@H](C(O)=O)CC1 IHIUGIVXARLYHP-YBXDKENTSA-N 0.000 description 1
- 229950000005 evacetrapib Drugs 0.000 description 1
- 229950004341 evinacumab Drugs 0.000 description 1
- 238000010228 ex vivo assay Methods 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 208000031842 familial 2 hypercholanemia Diseases 0.000 description 1
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000003626 gastrointestinal polypeptide Substances 0.000 description 1
- 229960002458 gemigliptin Drugs 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960001764 glibornuride Drugs 0.000 description 1
- RMTYNAPTNBJHQI-LLDVTBCESA-N glibornuride Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)N[C@H]1[C@H](C2(C)C)CC[C@@]2(C)[C@H]1O RMTYNAPTNBJHQI-LLDVTBCESA-N 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 229960003468 gliquidone Drugs 0.000 description 1
- 229960003236 glisoxepide Drugs 0.000 description 1
- ZKUDBRCEOBOWLF-UHFFFAOYSA-N glisoxepide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NN2CCCCCC2)=N1 ZKUDBRCEOBOWLF-UHFFFAOYSA-N 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 description 1
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 description 1
- 229940124828 glucokinase activator Drugs 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229950002888 glyclopyramide Drugs 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229940044700 hylenex Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960005436 inositol nicotinate Drugs 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 238000012528 insulin ELISA Methods 0.000 description 1
- 229960004717 insulin aspart Drugs 0.000 description 1
- 229960003948 insulin detemir Drugs 0.000 description 1
- 229960002869 insulin glargine Drugs 0.000 description 1
- 229960002068 insulin lispro Drugs 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229950000991 ipragliflozin Drugs 0.000 description 1
- AHFWIQIYAXSLBA-RQXATKFSSA-N ipragliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(F)C(CC=2SC3=CC=CC=C3C=2)=C1 AHFWIQIYAXSLBA-RQXATKFSSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229940098262 kynamro Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 1
- 229950009619 lifibrate Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960002397 linagliptin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 229960001093 lixisenatide Drugs 0.000 description 1
- 108010004367 lixisenatide Proteins 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- CHHXEZSCHQVSRE-UHFFFAOYSA-N lobeglitazone Chemical compound C1=CC(OC)=CC=C1OC1=CC(N(C)CCOC=2C=CC(CC3C(NC(=O)S3)=O)=CC=2)=NC=N1 CHHXEZSCHQVSRE-UHFFFAOYSA-N 0.000 description 1
- 229950007685 lobeglitazone Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229960003566 lomitapide Drugs 0.000 description 1
- MBBCVAKAJPKAKM-UHFFFAOYSA-N lomitapide Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1(C(=O)NCC(F)(F)F)CCCCN(CC1)CCC1NC(=O)C1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1 MBBCVAKAJPKAKM-UHFFFAOYSA-N 0.000 description 1
- 229940063720 lopid Drugs 0.000 description 1
- WRZCAWKMTLRWPR-VSODYHHCSA-N lorcaserin hydrochloride hemihydrate Chemical compound O.Cl.Cl.C[C@H]1CNCCC2=CC=C(Cl)C=C12.C[C@H]1CNCCC2=CC=C(Cl)C=C12 WRZCAWKMTLRWPR-VSODYHHCSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 description 1
- PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- 229950009116 mevastatin Drugs 0.000 description 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 229960004778 mipomersen Drugs 0.000 description 1
- OSGPYAHSKOGBFY-KMHHXCEHSA-A mipomersen sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].N1([C@H]2C[C@@H]([C@H](O2)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C(C)=C2)=O)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2CO)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(NC(=O)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP([O-])(=O)OC[C@H]2O[C@H](C[C@@H]2SP([O-])(=O)OC[C@H]2O[C@H](C[C@@H]2SP([O-])(=O)OC[C@H]2O[C@H](C[C@@H]2SP([O-])(=O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)SP([O-])(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP([O-])(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C3=NC=NC(N)=C3N=C2)OCCOC)SP([O-])(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP([O-])(=O)OC[C@H]2[C@H](O)[C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)C=C(C)C(N)=NC1=O OSGPYAHSKOGBFY-KMHHXCEHSA-A 0.000 description 1
- 229960003365 mitiglinide Drugs 0.000 description 1
- WPGGHFDDFPHPOB-BBWFWOEESA-N mitiglinide Chemical compound C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)O)C1=CC=CC=C1 WPGGHFDDFPHPOB-BBWFWOEESA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- MFZCIDXOLLEMOO-GYSGTQPESA-N myo-inositol hexanicotinate Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](OC(=O)C=2C=NC=CC=2)[C@@H](OC(=O)C=2C=NC=CC=2)[C@@H]1OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 MFZCIDXOLLEMOO-GYSGTQPESA-N 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- GACQNVJDWUAPFY-UHFFFAOYSA-N n'-[2-[2-(2-aminoethylamino)ethylamino]ethyl]ethane-1,2-diamine;hydrochloride Chemical compound Cl.NCCNCCNCCNCCN GACQNVJDWUAPFY-UHFFFAOYSA-N 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 1
- 229950001628 netoglitazone Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- MKMPWKUAHLTIBJ-ISTRZQFTSA-N omarigliptin Chemical compound C1([C@H]2OC[C@@H](C[C@@H]2N)N2CC3=CN(N=C3C2)S(=O)(=O)C)=CC(F)=CC=C1F MKMPWKUAHLTIBJ-ISTRZQFTSA-N 0.000 description 1
- 229950000074 omarigliptin Drugs 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 description 1
- 229960000903 pantethine Drugs 0.000 description 1
- 235000008975 pantethine Nutrition 0.000 description 1
- 239000011581 pantethine Substances 0.000 description 1
- 238000004810 partition chromatography Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003243 phenformin Drugs 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 102000035123 post-translationally modified proteins Human genes 0.000 description 1
- 108091005626 post-translationally modified proteins Proteins 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229950002887 pradigastat Drugs 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 229940073095 questran Drugs 0.000 description 1
- 108700027806 rGLP-1 Proteins 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- XMSXOLDPMGMWTH-UHFFFAOYSA-N rivoglitazone Chemical compound CN1C2=CC(OC)=CC=C2N=C1COC(C=C1)=CC=C1CC1SC(=O)NC1=O XMSXOLDPMGMWTH-UHFFFAOYSA-N 0.000 description 1
- 229950010764 rivoglitazone Drugs 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229960004058 simfibrate Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 1
- WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical compound O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 description 1
- 229950000034 teneligliptin Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- IWYJYHUNXVAVAA-OAHLLOKOSA-N trelagliptin Chemical compound C=1C(F)=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 IWYJYHUNXVAVAA-OAHLLOKOSA-N 0.000 description 1
- 229950010728 trelagliptin Drugs 0.000 description 1
- 229940055755 tricor Drugs 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 229940111503 welchol Drugs 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
- 229940051223 zetia Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
Definitions
- CsA can induce hyperlipidemia in patients by increasing the total cholesterol level, primarily due to an increase in the low-density lipoprotein (LDL) cholesterol level (Ballantyne et al., JAMA, 262(1):53-56 (1989)).
- LDL low-density lipoprotein
- Various other compounds have been shown to bind to NTCP, but they do not produce a uniform effect on NTCP as some of those compounds function as an inhibitor while others function as an enhancer (Kim et al, J. Pharmacol. Exp. Ther., 291(3):1204-09 (1999)).
- HBV viral envelope contains three surface antigen proteins: large (L), medium (M), and small (S). These proteins are coded by a single open reading frame on the S gene, starting from three different translation initiating sites, i.e., L (Pre-S1+Pre-S2+S), M (Pre-S2+S), and S (S).
- L Pre-S1+Pre-S2+S
- M Pre-S2+S
- S S
- the HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on its envelope proteins, and into eight genotypes (A-H) according to overall nucleotide sequence variation of the genome.
- A-H genotypes
- the disclosure provides a pharmaceutical composition comprising a polypeptide described herein, wherein when administered to a subject in need thereof, the pharmaceutical composition provides serum concentrations of the polypeptide that allow for bidirectional regulation of NTCP-mediated bile acid uptake in the subject.
- the disclosure provides methods of treating a metabolic disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the polypeptide described herein or a pharmaceutical composition comprising the polypeptide such that the serum concentrations of the administered polypeptide allow for bidirectional regulation of NTCP-mediated bile acid uptake in the subject, wherein the polypeptide comprises an amino acid sequence derived from Hepatitis B virus (HBV).
- HBV Hepatitis B virus
- the disclosure relates to methods of lowering a serum lipid level in a subject in need thereof by administering to the subject a therapeutically effective amount of the polypeptide described herein or of a pharmaceutical composition comprising the polypeptide such that the serum concentrations of the administered polypeptide allow for bidirectional regulation of NTCP-mediated bile acid uptake in the subject.
- the serum lipid may include, e.g., total cholesterol (“TC”), triglyceride (“TG”), and LDL-C.
- the disclosure also relates to methods of lowering a blood glucose level in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the polypeptide described herein or a pharmaceutical composition comprising such polypeptide.
- the polypeptide when the serum concentration of the administered polypeptide in the subject is at or below 93 nmol/L, the polypeptide enhances NTCP-mediated bile acid uptake in the subject. In some embodiments, when the serum concentration of the administered polypeptide in the subject is above 93 nmol/L, the polypeptide inhibits NTCP-mediated bile acid uptake in the subject. In some embodiments, the serum concentration of the polypeptide in the subject reaches a peak concentration (i.e., C max ) at about 20 minutes after the administration. Thus, in some embodiments, T max of the polypeptide described herein is about 20 minutes. In some embodiments, the peak concentration is more than 93 nmol/L.
- a subject administered with the polypeptide described herein suffers from or is at risk of developing a metabolic disease.
- the metabolic disease involves dysregulation of lipid metabolism.
- the metabolic disease is a cholesterol-related disorder.
- the metabolic disease is hyperlipidemia (e.g., hypertriglyceridemia, hypercholesterolemia, or a combination thereof).
- the metabolic disease involves dysregulation of glucose metabolism.
- the metabolic disease is hyperglycemia.
- the metabolic disease is diabetes or obesity.
- the subject suffers from or is at risk of developing cardiovascular diseases (e.g., atherosclerotic diseases), heart diseases, or kidney impairment.
- the polypeptide described herein is capable of reducing or stabilizing the level or activity of one or more chemical or biological molecules associated with metabolism in the subject.
- the chemical or biological molecule associated with metabolism is chosen from glucose, cholesterol, triglyceride, free fatty acids, amino acids, hormones, LDL-C, HDL-C, HbA1c, blood urea nitrogen, and minerals.
- the polypeptide described herein is also capable of reducing or stabilizing the level or value of one or more physiological parameters that measure metabolic changes.
- the physiological parameter is chosen from glycemia, blood pressure, body weight, fat mass, body mass index (BMI), inflammation, atherosclerosis index, heart index, kidney index, total fat index, and homeostatic model assessment (HOMA) index.
- the polypeptide described herein comprises an amino acid sequence derived from the pre-S1 region of HBV genotype A, B, C, D, E, F, G, or H. In certain embodiments, the polypeptide described herein comprises the sequence of amino acids 13-59 of the pre-S1 region of HBV genotype C. In additional embodiments, the polypeptide described herein comprises an amino acid sequence derived from the pre-S1 region of any other HBV genotype that corresponds to amino acids 13-59 of the pre-S1 region of HBV genotype C. In some embodiments, the polypeptide comprises an amino acid sequence selected from SEQ ID NOs: 21-40.
- one or more amino acid residues of the polypeptide described herein are deleted, substituted, or inserted while maintaining the ability to bind to NTCP and bidirectionally regulate NTCP-mediated transport of bile acid into hepatocytes.
- the polypeptide described herein comprises a native flanking amino acid sequence from the pre-S1 region of HBV genotype A, B, C, D, E, F, G, or H.
- the polypeptide described herein has at least about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to any one of the amino acid sequences selected from SEQ ID NOs: 21-40.
- the polypeptide comprises the glycine corresponding to amino acid 13 of the pre-S1 region of HBV genotype C and/or the asparagine corresponding to amino acid 20 of the pre-S1 region of HBV genotype C.
- the polypeptide described herein comprises an N-terminal modification with a hydrophobic group and/or a C-terminal modification that is capable of stabilizing the polypeptide.
- the hydrophobic group may be chosen from, e.g., myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, cholesterol, and arachidonic acid.
- the C-terminal modification may be chosen from, e.g., amidation (amination), isopentanediolization, and any C-terminal modification that is capable of stabilizing the polypeptide.
- the polypeptide described herein comprises an N-terminal modification with myristic acid and/or a C-terminal modification with amination. In some embodiments, the polypeptide described herein comprises an amino acid sequence chosen from SEQ ID NOs: 21-40. In some embodiments, the polypeptide described herein comprises the amino acid sequence of SEQ ID NO: 23.
- the polypeptide described herein is capable of reducing one or more symptoms associated with the metabolic disease.
- the polypeptide described herein or the pharmaceutical composition comprising such polypeptide is administered to the subject before, concurrently with, or after the administration of a therapeutically effective amount of at least one a second agent.
- the second agent may be chosen from, e.g., an antihyperlipidemic agent, an antihyperglycemic agent, an antidiabetic agent, an antiobesity agent, and a bile acid analogue.
- the polypeptide described herein or the pharmaceutical composition comprising such polypeptide is administered to the subject by at least one mode including, e.g., parenteral, intrapulmonary, intranasal, intralesional, intramuscular, intravenous, intraarterial, intraperitoneal, and subcutaneous administration. In some embodiments, the polypeptide described herein or the pharmaceutical composition comprising such polypeptide is administered to the subject subcutaneously.
- FIG. 1 A shows an exemplary graph depicting the purity of Cmyr-47 as measured by high pressure liquid chromatography (HPLC).
- FIG. 1 B shows an exemplary graph depicting the molecular weight of Cmyr-47 as confirmed by Mass Spectrometry.
- FIG. 2 A shows that Cmyr-47 labeled with FIFC binds to tupaia primary hepatocytes.
- FIG. 2 B shows that Cmyr-47 labeled with FIFC binds to HepG2 cells, a human hepatocyte derived cell line.
- FIG. 3 A shows that Cmyr-47 labeled with FIFC does not bind to control L02 cells (“BLANK-L02”).
- FIG. 3 B shows that Cmyr-47 labeled with FIFC binds to NTCP expressing L02 cells (“NTCP-L02”).
- FIG. 4 shows that Cmyr-47 labeled with FIFC binds to NTCP expressing HEK293 cells (“NTCP-293”) but does to bind to control HEK293 cells (“BLANK-293”).
- NTCP-293 NTCP expressing HEK293 cells
- BLANK-293 control HEK293 cells
- FIG. 5 A shows the effect of Cmyr-47 on bile acids uptake in vitro. Cyclosporine A (“CsA”) was used as a positive control.
- FIG. 5 B illustrates the bidirectional effect of Cmyr-47 on bile acids uptake.
- FIGS. 5 C and 5 D show the effect of CsA on bile acids uptake in vitro and confirm the inhibitory effect of CsA.
- 5 E and 5 F show the effect of HBV-derived polypeptides on bile acids uptake in vitro at a low concentration molarly equivalent to 62.5 ng/ml (11.58 nmol/L) Cmyr-47 and at a high concentration molarly equivalent to 1 ⁇ g/ml (185.23 nmol/L) Cmyr-47, respectively.
- FIG. 6 shows the changes of serum total cholesterol (“TC”) in hyperlipidemic golden hamsters treated with Cmyr-47 or CsA for 4 weeks.
- Golden hamsters fed with regular diet were treated with PBS and used as a “Normal Control” while hyperlipidemic golden hamsters treated with PBS were used as a “Model Control.”
- Hyperlipidemic golden hamsters treated with Fenofibrate (“Positive Treatment”) were used as a positive control.
- FIG. 8 depicts the changes of serum triglycerides (“TG”) of hyperlipidemic golden hamsters during 4 weeks of Cmyr-47 treatment.
- TG serum triglycerides
- FIG. 9 A shows the level of serum TG prior to treatments with polypeptides derived from HBV.
- FIG. 9 B shows the level of serum TG after 4 weeks of the treatments.
- FIG. 10 depicts the level of serum LDL-C of hyperlipidemic golden hamsters after 4 weeks of Cmyr-47 treatment.
- FIG. 11 A shows the level of serum LDL-C before being treated with polypeptides derived from HBV.
- FIG. 11 B shows the level of serum LDL-C after 4 weeks of the treatments.
- FIG. 12 shows the level of serum HDL-C of hyperlipidemic golden hamsters after 4 weeks of Cmyr-47 treatment.
- FIG. 13 depicts atherosclerosis index (“AI”) of hyperlipidemic golden hamsters after 4 weeks of Cmyr-47 treatment.
- AI atherosclerosis index
- FIG. 14 shows the changes of serum total bile acids (TBA) of hyperlipidemic golden hamsters after 4 weeks of Cmyr-47 treatment. Fenofibrate and CsA were also tested for comparison.
- TAA serum total bile acids
- FIG. 18 A shows the level of serum GLU before being treated with polypeptides derived from HBV.
- FIG. 18 B shows the level of serum GLU after 4 weeks of the treatments.
- FIG. 19 shows the changes of HbA1c of Zucker diabetic fatty rats during 4 weeks of Cmyr-47 treatment.
- FIG. 23 A shows the level of serum TC prior to treatments with polypeptides derived from HBV.
- FIG. 23 B shows the level of serum TC after 4 weeks of the treatments.
- FIG. 25 A shows the level of serum TG prior to treatments with polypeptides derived from HBV.
- FIG. 25 B shows the level of serum TG after 4 weeks of the treatments.
- FIG. 26 shows the level of blood urea nitrogen (“BUN”) in Zucker diabetic fatty rats after 4 weeks of Cmyr-47 treatment.
- BUN blood urea nitrogen
- FIGS. 27 A-C depict heart index, kidney index, and total fat index of Zucker diabetic fatty rats after 4 weeks of Cmyr-47 treatment.
- “Cmyr-47(L)” indicates the dose of 10 mg/kg/d of Cmyr-47 while “Cmyr-47(Hi)” indicates the dose of 30 mg/kg/d of Cmyr-47.
- an element means one element or more than one element.
- the term “about” means a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length that varies by as much as 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1% to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.
- the term “about” is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term “about” is intended to modify a numerical value above and below the stated value by a variance of 510%.
- polypeptide “peptide,” and “protein” are used interchangeably and encompass full-length proteins and fragments, as well as variants of the full-length proteins and the fragments. Such fragments and variants of the polypeptide described herein retain at least the biological activities of the polypeptide to bind to NTCP and bidirectionally regulate NTCP-mediated transport of bile acid into hepatocytes.
- the “polypeptide,” “peptide,” and “protein” can include natural and/or non-natural amino acid residues. Those terms also include post-translationally modified proteins, including, e.g., glycosylated, sialylated, acetylated, and/or phosphorylated proteins.
- the terms also include chemically modified proteins at one or more amino acid residues, such as, e.g., at the N-terminus and/or at the C-terminus.
- the N-terminus of the polypeptide disclosed herein can be modified by a hydrophobic group such as, e.g., myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, cholesterol, and arachidonic acid.
- the C-terminus of the polypeptide disclosed herein can be modified to stabilize the polypeptide.
- the C-terminus modification may be chosen from amidation (amination), isopentanediolization, and any other C-terminal modification capable of stabilizing the polypeptide.
- polypeptide derived from HBV or “HBV-derived polypeptide” refers to the origin or source of the polypeptide as being from HBV, and may include native, recombinant, synthesized, or purified polypeptides.
- polypeptide derived from HBV or “HBV-derived polypeptide” refers to a full-length native HBV polypeptide or fragments thereof, as well as variants of the full-length native polypeptide or its fragments.
- the polypeptide described herein may be derived from the pre-S1 region of the L protein of any one of HBV genotypes A, B, C, D, E, F, G, and H.
- the genomic sequences of these HBV genotypes can be found in GenBank Accession Nos. KC875260 (SEQ ID NO: 41), AY220704 (SEQ ID NO: 42), AF461363 (SEQ ID NO: 43), AY796030 (SEQ ID NO: 44), AB205129 (SEQ ID NO: 45), DQ823095 (SEQ ID NO: 46), HE981176 (SEQ ID NO: 47), and AB179747 (SEQ ID NO: 48), respectively.
- the polypeptide described herein may be derived from the pre-S1 region of the L protein of HBV genotype C.
- the polypeptide derived from HBV described herein retains one or more biological activities described herein of the corresponding native HBV polypeptide, including at least the biological activities of the polypeptide to bind to NTCP and bidirectionally regulate NTCP-mediated transport of bile acid into hepatocytes.
- a polypeptide derived from HBV, or an HBV-derived polypeptide means a polypeptide that differs from a given polypeptide (i.e., the polypeptide described herein, the polypeptide derived from HBV, or the HBV-derived polypeptide) in amino acid sequence, but retains one or more biological activities described herein of the given polypeptide.
- the variant polypeptide described herein retains at least at least the biological activities of the polypeptide to bind to NTCP and bidirectionally regulate NTCP-mediated transport of bile acid into hepatocytes.
- variant also includes a polypeptide that has certain identity, such as, e.g., at least about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to the given polypeptide.
- variant as used herein also includes a polypeptide comprising the portion of the given polypeptide that corresponds to a native sequence of HBV proteins. “Variant” may also refer to a fusion protein or chimeric protein, comprising polypeptides derived from two or more different sources.
- variant herein is intended to encompass fragments of a variant unless otherwise contradicted by context.
- variant also encompasses the homologous polypeptide sequences found in the different viral species, strains, or subtypes of the hepadnavirus genus. HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on its envelope proteins, and into eight genotypes (A-H) according to overall nucleotide sequence variation of the genome.
- A-H genotypes
- the term “variant” therefore includes homologous polypeptides found in any of these HBV subtypes.
- variant can also include polypeptides having native flanking amino acid sequences from any of these HBV subtypes added to the N and/or C terminus.
- Families of amino acid residues having similar side chains are known in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).
- basic side chains e.g., lysine, arginine, histidine
- acidic side chains e.g., aspartic acid,
- a “percentage identity” may be calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical amino acids occur in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison, and multiplying the result by 100 to yield the percentage of sequence identity.
- Optimal alignment of sequences for aligning a comparison window may be conducted by computerized implementations of algorithms available in the art, such as, e.g., the BLAST® family of programs, or by visual inspection and the best alignment (i.e., resulting in the highest percentage homology over the comparison window) generated by any of the various methods selected.
- sequence comparison For sequence comparison, one sequence acts as a reference sequence, to which test sequences are compared.
- test and reference sequences are input into a computer, subsequence coordinates may be designed, if necessary, and sequence algorithm program parameters are designated.
- sequence comparison algorithm then calculates the present sequence identity for the test sequences relative to the reference sequence, based on the designated program parameters.
- sequence algorithm program parameters is well within the knowledge in the art.
- the window of comparison may be designated as over the entire length of either or both comparison sequences, such as, e.g., over the entire length of the reference sequence, and gaps of up to 5% of the total number of amino acids in the reference sequence may be allowed.
- the polypeptide described herein may bind to NTCP and promote NTCP-mediated bile acid uptake in hepatocytes (i.e., functions as an “enhancer” of NTCP) at or below a certain concentration.
- the same polypeptide may also bind to NTCP but inhibit NTCP-mediated bile acid uptake (i.e., functions as an “inhibitor” of NTCP) above that concentration.
- the polypeptide described herein may function as an enhancer of NTCP at or below 93 nmol/L and as an inhibitor of NTCP above 93 nmol/L.
- the Cmyr-47 polypeptide described herein may function as an enhancer of NTCP at or below 500 ng/ml and as an inhibitor of NTCP above 500 ng/ml.
- the polypeptide described herein may bidirectionally regulate NTCP-mediated uptake of bile acids into hepatocytes in vitro.
- the polypeptide described herein may promote in vitro NTCP-mediated bile acid uptake at or below a certain concentration, while the polypeptide may inhibit in vitro NTCP-mediated bile acid uptake above that concentration.
- the polypeptide described herein may promote in vitro NTCP-mediated bile acid uptake at or below 93 nmol/L, while the polypeptide may inhibit in vitro NTCP-mediated bile acid uptake above 93 nmol/L.
- the Cmyr-47 polypeptide described herein may promote in vitro NTCP-mediated bile acid uptake at or below 500 ng/ml and inhibit in vitro NTCP-mediated bile acid uptake above 500 ng/ml.
- the polypeptide described herein may promote NTCP-mediated bile acid uptake in a subject treated with the polypeptide at or below a certain serum concentration of the administered polypeptide.
- the polypeptide may inhibit NTCP-mediated bile acid uptake in a subject treated with the polypeptide above that serum concentration of the administered polypeptide.
- the polypeptide when the serum concentration of the polypeptide described herein is at or below 93 nmol/L in a subject treated with the polypeptide, the polypeptide is capable of enhancing NTCP-mediated uptake of bile acids in the subject.
- the polypeptide when the serum concentration of the polypeptide described herein is above 93 nmol/L in a subject treated with the polypeptide, the polypeptide is capable of inhibiting NTCP-mediated uptake of bile acids in the subject.
- the Cmyr-47 polypeptide described herein may be capable of enhancing NTCP-mediated uptake of bile acids in the subject at or below a serum concentration of 500 ng/ml, and inhibiting NTCP-mediated uptake of bile acids in the subject above a serum concentration of 500 ng/ml.
- the biological activity of the polypeptide described herein may also include the ability to treat a metabolic disease or to ameliorate one or more symptoms associated with the metabolic disease.
- the biological activity may further include the ability of the polypeptide described herein to prevent the development of a metabolic disease.
- the biological activity of the polypeptide described herein may include the ability of the polypeptide to modulate the level or activity of one or more chemical or biological molecules associated with metabolism, and/or to modulate the level or value of one or more physiological parameters that measure metabolic changes.
- the “biological activity” of the polypeptide described herein includes the ability of the polypeptide to reduce or stabilize the level or activity of one or more such chemical or biological molecules or physiological parameters.
- metabolism refers to bile acid metabolism, glucose metabolism, lipid metabolism, and/or amino acid metabolism.
- the chemical or biological molecules associated with metabolism may include, e.g., glucose, triglyceride, cholesterol, free fatty acids, bile acids, amino acids, hormones, such as, e.g., insulin, LDL-C, HDL-C, HbA1c, blood urea nitrogen, and minerals.
- the physiological parameters that measure metabolic changes may include, e.g., glycemia, blood pressure, body weight, fat mass, body mass index (BMI), inflammation, atherosclerosis index (AI), heart index, kidney index, total fat index, and homeostatic model assessment (HOMA) index.
- the “biological activity” of the polypeptide described herein includes the ability of the polypeptide to increase the level of serum bile acid in a subject. In certain embodiments, the “biological activity” of the polypeptide described herein includes the ability of the polypeptide to enhance cholesterol elimination through bile acid synthesis in hepatocytes.
- the biological activity of the polypeptide described herein may include the ability to lower the serum level of one or more chemical or biological molecules associated with lipid metabolism in a subject administered with the polypeptide.
- the biological activity of the polypeptides described herein may include the ability to lower the serum level of serum lipids, such as, e.g., triglyceride, total cholesterol, or LDL-C in a subject administered with the polypeptide.
- the “biological activity” of the polypeptide described herein includes the ability of the polypeptide to treat a metabolic disorder in a subject.
- the metabolic disorder involves dysregulation of lipid metabolism.
- the metabolic disease may include a cholesterol-related disorder, such as, e.g., hyperlipidemia (including hypertriglyceridemia, hypercholesterolemia, or both).
- the metabolic disorder involves dysregulation of glucose metabolism.
- the metabolic disease may include, e.g., diabetes and obesity.
- the “biological activity” of the polypeptide described herein includes the ability of the polypeptide to ameliorate or prevent one or more symptoms or complications of such disorders. In certain embodiments, the “biological activity” of the polypeptide described herein includes the ability of the polypeptide to mitigate the negative impact of such disorders on the health of a patient or reduce the risk of developing such disorders. In certain embodiments, the “biological activity” of the polypeptide described herein also includes the ability of the polypeptide to reduce the severity of or the risk of developing other associated diseases, such as, e.g., atherosclerosis and/or cardiovascular diseases, heart diseases, kidney impairment, or obesity.
- these biological activities of the polypeptide described herein may result from bidirectional regulation of NTCP-mediated bile acid uptake in the subject by the polypeptide at the serum concentrations following administration of the polypeptide to the subject.
- concentration of the polypeptide described herein in the blood stream of a subject administered with such polypeptide is at or below a certain concentration, bile acid uptake in the subject is enhanced.
- concentration of the polypeptide described herein in the blood stream of the subject is above a certain concentration, bile acid uptake in the subject is inhibited.
- bile acid uptake in the subject when the concentration of the polypeptide described herein in the blood stream of a subject administered with such polypeptide is at or below 93 nmol/L, bile acid uptake in the subject is enhanced. In some embodiments, when the concentration of the polypeptide described herein in the blood stream of the subject is above 93 nmol/L, bile acid uptake in the subject is inhibited. For example, when the concentration of the Cmyr-47 polypeptide described herein in the blood stream of a subject administered with such polypeptide is at or below 500 ng/ml, bile acid uptake in the subject is enhanced. When the concentration of the Cmyr-47 polypeptide described herein in the blood stream of the subject is above 500 ng/ml, bile acid uptake in the subject is inhibited.
- the biological activity of the polypeptide described herein may be confirmed in vitro, by contacting the polypeptide described herein with a cell that is either a transformed cell line or a cell isolated from an animal.
- the cell may be a primary hepatocyte isolated from an animal.
- NTCP e.g., mammalian cells overexpressing NTCP or hepatocytes
- cells expressing NTCP may be treated in vitro with bile acids and increasing amounts of the polypeptide described herein.
- Bile acids added to the cells may be radiolabeled or chemically labeled for detection.
- the cells may be then harvested and the amount of bile acids taken up by the cells may be measured.
- the ability of the polypeptide described herein to bidirectionally regulate NTCP may be confirmed when the polypeptide enhances bile acid uptake at or below a certain concentration while inhibits bile acid uptake above that concentration.
- the exemplary assays useful to confirm the biological activity of the polypeptide may also include a functional analysis with a sample collected from a subject treated with the polypeptide described herein, including, e.g., glucose production assay, glucose uptake assay, fatty acid oxidation assay, cholesterol assay, bile acids assay, urea assay, and triglyceride assay.
- a functional analysis with a sample collected from a subject treated with the polypeptide described herein including, e.g., glucose production assay, glucose uptake assay, fatty acid oxidation assay, cholesterol assay, bile acids assay, urea assay, and triglyceride assay.
- the assays may also include, e.g., a binding analysis between the polypeptide and NTCP, an activity assay of NTCP for transporting bile acids, and an expression, localization, or activity analysis of molecular factors involved in metabolism, such as, e.g., bile acid metabolism, glucose metabolism, lipid metabolism, and amino acid metabolism.
- a binding analysis between the polypeptide and NTCP an activity assay of NTCP for transporting bile acids
- an expression, localization, or activity analysis of molecular factors involved in metabolism such as, e.g., bile acid metabolism, glucose metabolism, lipid metabolism, and amino acid metabolism.
- pre-S1 amino acids 13-59 of HBV genotype A (SEQ ID NO: 34) GTNLSVPNPLGFFPDHQLDPAFGANSNNPDWDFNPVKDDWPAANQVG, pre-S1 amino acids 13-59 of HBV genotype B: (SEQ ID NO: 35) GTNLSVPNPLGFFPDHQLDPAFKANSENPDWDLNPNKDNWPDANKVG, pre-S1 amino acids 2-48 of the HBV genotype D: (SEQ ID NO: 36) GQNLSTSNPLGFFPDHQLDPAFRANTANPDWDFNPNKDTWPDANKVG, pre-S1 amino acids 12-58 of the HBV genotype E: (SEQ ID NO: 37) GKNISTTNPLGFFPDHQLDPAFRANTRNPDWDHNPNKDHWTEANKVG, pre-S1 amino acids 13-59 of the HBV genotype F: (SEQ ID NO: 38) GQNLSVPNPLGFFPDHQLDPLFRANSSSPDWDFNTNKDSWPMANKVG
- the polypeptide described herein may comprise a portion of the pre-S1 region of HBV, said portion comprising at least an amino acid sequence chosen from SEQ ID NOs: 23 and 34-40. In some embodiments, the polypeptide described herein may comprise the entire pre-S1 region of HBV.
- the polypeptide described herein may be 10-100 amino acids in length.
- the polypeptide may be 15-100, 15-80, 20-100, 20-80, 20-60, 25-60, 30-60, 35-60, or 40-60 amino acids in length, including all integers in between these ranges.
- the polypeptide described herein may be at least 20, such as, e.g., at least 25, 30, 35, 40, amino acids in length.
- the polypeptide described herein may be 20, 25, 30, 35, 40, 47, 55, 60 amino acids in length.
- the polypeptide described herein may be 47 amino acids in length.
- the polypeptide described herein may comprise an amino acid sequence chosen from SEQ ID NOs: 23 and 34-40, wherein the N terminus may be modified with a hydrophobic group chosen from myristic acid, palmitic acid, stearic acid, and cholesterol.
- the polypeptide described herein may comprise an amino acid sequence chosen from SEQ ID NOs: 23 and 34-40, wherein the N terminus may be myristoylated.
- the polypeptide described herein may comprise the amino acid sequence of SEQ ID NO: 23, wherein the N terminus may be myristoylated.
- the polypeptide described herein may comprise a C-terminal modification to stabilize the polypeptide.
- the C-terminal modification may be chosen from amidation (amination), isopentanediolization, and any other C-terminal modification capable of stabilizing the polypeptide described herein.
- the C-terminal modification may be amidation (amination).
- the polypeptide described herein may comprise the amino acid sequence of NO: 23, wherein the N terminus may be myristoylated, and/or the C terminus may be amidated (aminated).
- the polypeptide described herein may comprise the amino acid sequence of NO: 3 (Cmyr-47).
- the polypeptide described herein may comprise an amino acid sequence chosen from SEQ ID NOs: 34-40, wherein the N terminus may be myristoylated, and/or the C terminus may be modified by amidated (aminated).
- the polypeptide described herein may comprise an amino acid sequence chosen from SEQ ID NOs: 14-20.
- the variants of the polypeptide described herein that are modified at the N-terminus and/or the C-terminus retain one or more biological activities of the corresponding polypeptides that are not modified in the same manner, including at least the biological activity of binding to NTCP and bidirectionally regulating NTCP-mediated transport of bile acid into hepatocytes.
- Variants of the polypeptides described herein are also contemplated in the present disclosure, including variants with one or more amino acid deletions, substitutions, or insertions that retain one or more biological activities of the polypeptides, including at least the biological activity of binding to NTCP and bidirectionally regulating NTCP-mediated transport of bile acid into hepatocytes.
- the polypeptides described herein preferably retain the glycine corresponding to amino acid 13 of the pre-S1 region of HBV genotype C (i.e., the N-terminal glycine of SEQ ID NO: 23). In some embodiments, the polypeptides described herein retain the asparagine corresponding to amino acid 20 of the pre-S1 region of HBV genotype C.
- the polypeptide described herein may have 1-30, such as, e.g., 1-20, 1-10, 1-8, 1-5, or 1-3, amino acid deletions, substitutions, or insertions relative to an amino acid sequence chosen from SEQ ID NOs: 23 and 34-40, including all integers in between these ranges. In some embodiments, the polypeptide described herein may have 1-30, such as, e.g., 1-20, 1-10, 1-8, 1-5, or 1-3, amino acid deletions, substitutions, or insertions relative to the amino acid sequence of SEQ ID NO: 23, including all integers in between these ranges.
- the polypeptide described herein may have 1-3 amino acid deletions, substitutions, or insertions from the amino acid sequence of SEQ ID NO: 23.
- the polypeptide described herein may have 1-30, such as, e.g., 1-20, 1-10, 1-8, 1-5, or 1-3, amino acid deletions or insertions at the C terminus of an amino acid sequence chosen from SEQ ID NOs: 23 and 34-40, including all integers in between these ranges.
- the polypeptide described herein may comprise an amino acid sequence chosen from SEQ ID NOs: 21, 22, and 24-28.
- the polypeptide described herein may comprise the amino acid sequence of any one of the polypeptides listed in Table 1.
- the polypeptide described herein may be chosen from any one of the post-translationally modified polypeptides listed in Table 1.
- the polypeptide may comprise an amino acid sequence at least about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 23 and 34-40. In some embodiments, the polypeptide may comprise an amino acid sequence at least about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 23.
- variants having certain sequence identity to the polypeptides described herein retain one or more biological activities of the corresponding polypeptides, including at least the biological activity of binding to NTCP and bidirectionally regulating NTCP-mediated transport of bile acid into hepatocytes.
- aspects of the present disclosure also include variants of the polypeptides described herein having a native flanking amino acid sequence from the HBV L protein, such as, e.g., from the pre-S1 region of the L protein, added to the N and/or C terminus.
- the native flanking amino acid sequence refers to the native sequence flanking the N or C terminus of the polypeptide described herein in the pre-S1 region of the corresponding HBV genotype or any other HBV genotypes.
- the polypeptide described herein may comprise an amino acid sequence chosen from SEQ ID NOs: 23 and 34-40, and a native flanking amino acid sequence at the N and/or C terminus derived from the pre-S1 region of any one of HBV genotypes A-H.
- polypeptide described herein may comprise the amino acid sequence of SEQ ID NO: 23, and a native flanking amino acid sequence at the N and/or C terminus derived from the pre-S1 region of HBV genotype C.
- polypeptide described herein may comprise the amino acid sequence of SEQ ID NO: 23, and a native flanking amino acid sequence at the N and/or C terminus derived from the pre-S1 region of any one of HBV genotypes A, B, D, E, F, G, and H.
- the N and/or C terminus of the polypeptide described herein may independently comprise a native flanking amino acid sequence having a length of 1-10, such as, e.g., 1-8, 1-5, or 1-3 amino acids, including all integers in between these ranges.
- the polypeptide described herein may comprise the amino acid sequence of SEQ ID NO: 23 and a native flanking amino acid sequence of 10 amino acids at the N terminus from the pre-S1 region of HBV genotype C.
- the polypeptide may comprise amino acids 2-59 of the pre-S1 region of HBV genotype C (SEQ ID NO: 29).
- any polypeptides described herein can have native flanking amino acid sequences of any length extended from the N and/or C terminus, and the resulting polypeptides retain one or more biological activities of the original polypeptides, including at least the biological activity of binding to NTCP and bidirectionally regulating NTCP-mediated transport of bile acid into hepatocytes.
- the polypeptides described herein are capable of bidirectionally regulating NTCP-mediated transport of bile acids into hepatocytes.
- NTCP-mediated transport of bile acid into the hepatocytes may be enhanced as compared with hepatocytes that are not in contact with such polypeptide.
- NTCP-mediated transport of bile acid into the hepatocytes may be inhibited as compared with hepatocytes that are not in contact with such polypeptide.
- NTCP-mediated transport of bile acid into the hepatocytes may be enhanced as compared with hepatocytes that are not in contact with such polypeptide.
- NTCP-mediated transport of bile acid into the hepatocytes may be inhibited as compared with hepatocytes that are not in contact with such polypeptide.
- NTCP-mediated transport of bile acid into the hepatocytes may be enhanced as compared with hepatocytes that are not in contact with such polypeptide.
- NTCP-mediated transport of bile acid into the hepatocytes may be inhibited as compared with hepatocytes that are not in contact with such polypeptide.
- the polypeptides described herein may be capable of reducing the serum level of total cholesterol in a subject. In further embodiments, the polypeptides described herein may be capable of reducing the serum level of LDL-cholesterol in a subject. In some embodiments, the polypeptides described herein may be capable of reducing the serum level of triglyceride in a subject. In some embodiments, the polypeptides described herein may be capable of reducing the serum level of glucose in a subject. In some embodiments, the polypeptides described herein may be capable of reducing the serum level of HbA1c in a subject. In some embodiments, the polypeptides described herein may be capable of stabilizing the serum level of insulin in a subject. In some embodiments, the subject may be a mammal. In some embodiments, the subject may be a human. In some embodiments, the subject may suffer from a metabolic disease or may be at risk of developing such disease.
- module or “alter,” all used interchangeably, includes “reducing,” “decreasing,” “lowering,” “down-regulating,” or “inhibiting” one or more quantifiable parameters optionally by a defined and/or statistically significant amount.
- modulate also includes “enhancing,” “increasing,” “elevating,” “up-regulating,” or “promoting” one or more quantifiable parameters optionally by a defined and/or statistically significant amount.
- reduce mean that the level or activity of one or more chemical or biological molecules associated with metabolism such as, e.g., glucose, triglyceride, cholesterol, free fatty acids, bile acids, amino acids, or hormones, including, e.g., insulin, LDL-C, HDL-C, HbA1c, blood urea nitrogen, and minerals, is reduced below the level or activity observed in the absence of the polypeptides described herein or lower than a control polypeptide.
- chemical or biological molecules associated with metabolism such as, e.g., glucose, triglyceride, cholesterol, free fatty acids, bile acids, amino acids, or hormones, including, e.g., insulin, LDL-C, HDL-C, HbA1c, blood urea nitrogen, and minerals.
- “reduce” may mean that the level or value of one or more physiological parameters that measure metabolic changes, such as, e.g., glycemia, blood pressure, body weight, fat mass, body mass index (BMI), inflammation, atherosclerosis index (AI), heart index, kidney index, total fat index, and homeostatic model assessment (HOMA) index, are reduced below the level or activity observed in the absence of the polypeptides described herein or lower than a control polypeptide.
- reduction with a polypeptide described herein is below the level or activity observed in the presence of an inactive or attenuated molecule.
- the polypeptides described herein are capable of reducing the level of glucose, insulin, cholesterol, or triglyceride in the serum and/or in another tissue or organ, such as, e.g., liver, heart, muscle, visceral fat, subcutaneous fat, intestine, and brain.
- the level of inflammation can be measured by following various clinical tests available in the art. For instance, the level of C-reactive protein (CRP) in blood can be measured to quantitatively measure the level of inflammation in a subject.
- CRP C-reactive protein
- An erythrocyte sedimentation rate (ESR) test is another example of tests that measure the level of inflammation in a subject. The ESR test measures the rate of erythrocytes sediment in a set period.
- homeostatic model assessment (HOMA) index may refer HOMA-IR (quantifying the level of insulin resistance) index and/or HOMA- ⁇ index (quantifying the level of ⁇ -cell function).
- the terms “enhance,” “increase,” “elevate,” “up-regulate,” and “promote” all used interchangeably, mean that the level or activity of one or more chemical or biological molecules associated with metabolism, such as, e.g., glucose, triglyceride, cholesterol, free fatty acids, bile acids, amino acids, hormones, including, e.g., insulin, LDL-C, HDL-C, HbA1c, blood urea nitrogen, and minerals, is increased above the level or activity observed in the absence of the polypeptides described herein or higher than a control polypeptide.
- metabolism such as, e.g., glucose, triglyceride, cholesterol, free fatty acids, bile acids, amino acids, hormones, including, e.g., insulin, LDL-C, HDL-C, HbA1c, blood urea nitrogen, and minerals.
- the polypeptides described herein are capable of increasing the level of bile acid in the serum and/or in another tissue or organ, such as, e.g., liver, heart, muscle, visceral fat, subcutaneous fat, intestine, and brain.
- stabilize are used interchangeably in connection with one or more chemical or biological molecules associated with metabolism, and mean that the level or activity of the one or more chemical or biological molecules associated with metabolism, such as, e.g., glucose, triglyceride, cholesterol, free fatty acids, bile acids, amino acids, hormones, including, e.g., insulin, LDL-C, HDL-C, HbA1c, blood urea nitrogen, and minerals, shows a minimal difference from the level or activity observed in a healthy subject or a subject who is not suffering from a metabolic disease, or from the level or activity observed in the presence of a positive control polypeptide.
- level or activity of the one or more chemical or biological molecules associated with metabolism such as, e.g., glucose, triglyceride, cholesterol, free fatty acids, bile acids, amino acids, hormones, including, e.g., insulin, LDL-C, HDL-C, HbA1c, blood urea nitrogen, and minerals, shows a minimal difference from the
- “stabilize” may mean that the level or value of one or more physiological parameters that measure metabolic changes, such as, e.g., glycemia, blood pressure, body weight, fat mass, body mass index (BMI), inflammation, atherosclerosis index (AI), heart index, kidney index, total fat index, and homeostatic model assessment (HOMA) index, shows a minimal difference from the level or value observed in a healthy subject or a subject who is not suffering from a metabolic disease, or from the level or value observed in the presence of a positive control polypeptide.
- the polypeptides described herein are capable of stabilizing the level of insulin in the serum and/or insulin production from pancreas.
- polypeptides described herein can be made by chemical synthesis or by employing recombinant technology.
- DNA sequence encoding a polypeptide described herein is cloned and manipulated so that it may be expressed in a convenient host.
- DNA encoding parent polypeptides can be obtained from an HBV genomic library, from cDNA derived from mRNA from cells expressing the polypeptide, or by synthetically constructing the DNA sequence.
- the parent DNA is then inserted into an appropriate plasmid or vector which is used to transform a host cell.
- plasmid vectors containing replication and control sequences which are derived from species compatible with the host cell are used in connection with those hosts.
- the vector ordinarily carries a replication site, as well as sequences which encode proteins or peptides that are capable of providing phenotypic selection in transformed cells.
- the vector may be those commonly used in the art, or constructed using standard techniques by combining functional fragments of the vectors commonly used in the art.
- the host cell may be prokaryotic or eukaryotic.
- prokaryotic host cells may include E. coli, Bacillus subtilis , and other enterobacteriaceae such as, e.g., Salmonella typhimurium or Serratia marcesans , and various Pseudomonas species.
- eukaryotic organisms such as yeast cultures, or cells derived from multicellular organisms, such as insect or mammalian cell cultures, may be used. Examples of such eukaryotic host cell lines include VERO and HeLa cells, Chinese Hamster Ovary (CHO) cell lines, W138, 293, BHK, COS-7, and MDCK cell lines.
- the polypeptides described herein may be prepared using solid-phase synthesis, or other equivalent chemical syntheses known in the art.
- solid-phase synthesis is initiated from the C-terminus of the peptide by coupling a protected ⁇ -amino acid to a suitable resin.
- a suitable resin such a starting material can be prepared by attaching an ⁇ -amino-protected amino acid by an ester linkage to a chloromethylated resin or a hydroxymethyl resin, or by an amide bond to a BHA resin or IBHA resin.
- the amino acids are coupled to the peptide chain using techniques well known in the art for the formation of peptide bonds.
- One method involves converting the amino acid to a derivative that will render the carboxyl group more susceptible to reaction with the free N-terminal amino group of the peptide fragment.
- the amino acid can be converted to a mixed anhydride by reaction of a protected amino acid with ethylchloroformate, phenyl chloroformate, sec-butyl chloroformate, isobutyl chloroformate, pivaloyl chloride or like acid chlorides.
- the amino acid can be converted to an active ester such as a 2,4,5-trichlorophenyl ester, a pentachlorophenyl ester, a pentafluorophenyl ester, a p-nitrophenyl ester, a N-hydroxysuccinimide ester, or an ester formed from 1-hydroxybenzotriazole.
- an active ester such as a 2,4,5-trichlorophenyl ester, a pentachlorophenyl ester, a pentafluorophenyl ester, a p-nitrophenyl ester, a N-hydroxysuccinimide ester, or an ester formed from 1-hydroxybenzotriazole.
- Another coupling method involves use of a suitable coupling agent such as N,N′-dicyclohexylcarbodiimide or N,N′-diisopropylcarbodiimide.
- the ⁇ -amino group of each amino acid employed in the peptide synthesis may be protected during the coupling reaction to prevent side reactions involving their active ⁇ -amino function.
- certain amino acids that contain reactive side-chain functional groups e.g., sulfhydryl, amino, carboxyl, and hydroxyl
- suitable protecting groups to prevent a chemical reaction from occurring at that site during both the initial and subsequent coupling steps.
- the selection of a suitable side-chain protecting group is within the skill of the art. The protecting group will be readily removable upon completion of the desired amino acid peptide under reaction conditions that will not alter the structure of the peptide chain.
- the remaining ⁇ -amino and side-chain protected amino acids are coupled stepwise within the desired order.
- some may be coupled to one another prior to addition to the solid-phase synthesizer. The selection of an appropriate coupling reagent is within the skill of the art.
- Each protected amino acid or amino acid sequence is introduced into the solid-phase reactor in excess, and the coupling is suitably carried out in a medium of dimethylformamide (DMF) or CH 2 Cl 2 or mixtures thereof. If incomplete coupling occurs, the coupling procedure is repeated before removal of the N-amino protecting group prior to the coupling of the next amino acid. The success of the coupling reaction at each stage of the synthesis may be monitored.
- the coupling reactions can be performed automatically using well known methods, for example, a BIOSEARCH 9500TM peptide synthesizer.
- the protected peptide Upon completion of the desired peptide sequence, the protected peptide must be cleaved from the resin support, and all protecting groups must be removed. The cleavage reaction and removal of the protecting groups is suitably accomplished simultaneously or stepwise.
- the bond anchoring the peptide to the resin is an ester linkage formed between the free carboxyl group of the C-terminal residue and one of the many chloromethyl groups present on the resin matrix. It will be appreciated that the anchoring bond can be cleaved by reagents that are known to be capable of breaking an ester linkage and of penetrating the resin matrix.
- polypeptides may be modified (such as, e.g., modified at the N-terminus with a hydrophobic group, including, e.g., myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, cholesterol, arachidonic acid; modified at the C-terminus by amidation (amination), isopentanediolization, or other stabilizing C-terminal modification) either before or after the polypeptide is cleaved from the support.
- a hydrophobic group including, e.g., myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, cholesterol, arachidonic acid
- modified at the C-terminus by amidation (amination), isopentanediolization, or other stabilizing C-terminal modification either before or after the polypeptide is cleaved from the support.
- compositions of the polypeptides described herein may be prepared by mixing such polypeptide having the desired degree of purity with one or more optional pharmaceutically acceptable carriers.
- Pharmaceutically acceptable carriers may include, e.g.: buffers (such as, e.g., phosphate, citrate, and other organic acids); antioxidants (such as, e.g., ascorbic acid and methionine); preservatives (such as, e.g., octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride, benzalkonium chloride, benzethonium chloride, phenol, butyl or benzyl alcohol, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, and m-cresol); low molecular weight (such as, e.g., less than about 10 residues) polypeptides; proteins (
- Exemplary pharmaceutically acceptable carriers may further include interstitial drug dispersion agents such as soluble neutral-active hyaluronidase glycoproteins (sHASEGP), for example, human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX®, Baxter International, Inc.).
- sHASEGP soluble neutral-active hyaluronidase glycoproteins
- rHuPH20 HYLENEX®, Baxter International, Inc.
- a sHASEGP may be combined in the pharmaceutical composition with one or more additional glycosammoglycanases, such as, e.g., chondroitinases.
- compositions may also comprise more than one active ingredient suitable for the particular indication being treated, for example, those with complementary activities that do not adversely affect each other.
- active ingredients may be suitably present in combination in amounts that are effective for the purpose intended.
- the active ingredients may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, such as, e.g., hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (such as e.g., liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules), or in macroemulsions.
- colloidal drug delivery systems such as e.g., liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules
- the metabolic disease involves dysregulation of glucose metabolism.
- the metabolic disease is diabetes.
- the metabolic disease is type II diabetes.
- the metabolic disease is obesity.
- use of the polypeptides described herein in treating conditions associated with elevated serum level of glucose or HbA1c is also provided.
- the metabolic disease described herein may be chosen from hyperglycemia; hypoglycemia; hyperinsulinemia; obesity, hyperlipidemia; hypertriglyceridemia; hypercholesterolemia; heart disease; metabolic syndrome; atherosclerotic disease; coronary heart disease; coronary artery disease; peripheral arterial disease; angina pectoris; cerebrovascular disease; acute coronary syndrome; myocardial infarction; stroke; cardiovascular disease; Alzheimer's disease; dyslipidemias; familial combined hyperlipidemia; familial hypertriglyceridemia; familial hypercholesterolemia; heterozygous hypercholesterolemia; homozygous hypercholesterolemia; familial defective apolipoprotein B-100; polygenic hypercholesterolemia; remnant removal disease; hepatic lipase deficiency; dyslipidemia caused by dietary indiscretion, hypothyroidism, drugs including estrogen and progestin therapy, beta-blockers, and thiazide diuretics; nephrotic syndrome; chronic renal failure; Cushing
- hyperlipidemia refers to a condition characterized by an abnormal increase in serum lipids.
- the lipids fractions in the circulating blood include, e.g., total cholesterol, certain lipoproteins, and triglycerides.
- Serum lipoproteins serve as carriers for lipids in the circulation and are classified by their density, including: chylomicrons, very low density lipoproteins (“LDL”), intermediate density lipoproteins (“IDL”), low density lipoproteins (“LDL”), and high density lipoproteins (“HDL”).
- LDL very low density lipoproteins
- IDL intermediate density lipoproteins
- LDL low density lipoproteins
- HDL high density lipoproteins
- the term “hyperlipidemia” encompasses primary and secondary hyperlipidemia.
- Primary hyperlipidemia is generally caused by genetic defects, while secondary hyperlipidemia is generally caused by other factors, such as various disease states, drugs, and dietary factors.
- hyperlipidemia may be caused by diabetes.
- hyperlipidemia can result from a combination of primary and secondary causes.
- Hyperlipidemia may encompass hypertriglyceridemia, hypercholesterolemia, or a combination thereof.
- hypertriglyceridemia refers to a condition in which serum total triglyceride levels are elevated above a desired level.
- hypercholesterolemia refers to a condition in which serum cholesterol levels are elevated above a desired level.
- the serum total cholesterol, HDL cholesterol (“HDL-C”), or LDL cholesterol (“LDL-C”) levels are elevated above the desired level in hypercholesterolemia.
- cardiovascular disease encompasses a disease of the blood vessels of the circulation system caused by abnormally high concentrations of lipids in the vessels.
- atherosclerosis refers to a disease of the arteries in which fatty plaques develop on the inner walls, with eventual obstruction of blood flow.
- “Patient” and “subject” may be used interchangeably to refer to an animal, such as a mammal or a human, being treated or assessed for a disease, disorder, or condition, at risk of developing a disease, disorder, or condition, or having or suffering from a disease, disorder, or condition.
- such disease, disorder, or condition may include a metabolic disease.
- the metabolic disease may involve dysregulation of lipid metabolism.
- the metabolic disease may be a cholesterol-related disorder, such as hyperlipidemia (e.g., hypercholesterolemia, hypertriglyceridemia, or a combination thereof).
- the metabolic disease may involve dysregulation of glucose metabolism.
- the metabolic disease may be diabetes, including type I and type II diabetes.
- the term may also include an amount of the polypeptide described herein that is effective in lowering the level of serum lipids, such as, e.g., the total cholesterol, total triglycerides, LDL cholesterol level, in a subject suffering from or at a risk of developing a metabolic disease, such as, e.g., hyperlipidemia, including hypercholesterolemia, hypertriglyceridemia, or both.
- serum lipids such as, e.g., the total cholesterol, total triglycerides, LDL cholesterol level
- a metabolic disease such as, e.g., hyperlipidemia, including hypercholesterolemia, hypertriglyceridemia, or both.
- the “therapeutically effective amount” of the polypeptide described herein may allow the administered polypeptide to reach a concentration in the blood stream of the subject at which the polypeptide is capable of inhibiting NTCP-mediated bile acid uptake in the subject.
- a therapeutically effective amount of the polypeptide described herein may allow the administered polypeptide to reach at least about 93 nmol/L in the blood stream of a subject administered with that amount.
- a therapeutically effective amount of the Cmyr-47 polypeptide described herein may allow the administered polypeptide to reach at least about 500 ng/ml in the blood stream of a subject administered with that amount.
- a therapeutically effective amount of the polypeptide described herein refers to an amount such that the serum concentrations of the administered polypeptide allow for bidirectional regulation of NTCP-mediated bile acid uptake in the subject.
- the initial serum concentration of the polypeptide in the subject may be above a certain concentration where the polypeptide inhibits NTCP-mediated bile acids uptake.
- the serum concentration of the polypeptide in the subject may gradually reduce and fall to or below a value where the polypeptide begins enhancing NTCP-mediated bile acids uptake.
- the serum concentration of the administered polypeptide may be assessed at least about 10, 20, 40, 60, 90, 120, 180, 240, or 360 minutes after the administration.
- the therapeutically effective amount of the polypeptide described herein allows the polypeptide to reach a serum concentration above 93 nmol/L by certain time following the administration.
- the therapeutically effective amount of the polypeptide described herein allows the polypeptide to reach a serum concentration at or below 93 nmol/L after that certain time following the administration.
- the therapeutically effective amount of the Cmyr-47 polypeptide described herein allows the polypeptide to reach a serum concentration above 500 ng/ml by certain time following the administration.
- treatment includes treatment of a subject (e.g. a mammal, such as a human) or a cell to alter the current course of the subject or cell.
- Treatment includes, e.g., administration of a polypeptide described herein or a pharmaceutical composition comprising such polypeptide, and may be performed either prophylactically or subsequent to the initiation of a pathologic event or contact with an etiologic agent.
- prophylactic treatments which can be directed to reducing the rate of progression of the disease or condition being treated, delaying the onset of that disease or condition, or reducing the severity of its onset.
- Such pathological processes or symptoms may include, e.g., excessive or increased levels compared with healthy subjects of one or more chemical or biological molecules associated with metabolism, such as, e.g., glucose, triglyceride, cholesterol, free fatty acids, bile acids, amino acids, hormones, including, e.g., insulin, LDL-C, HDL-C, HbA1c, blood urea nitrogen, and minerals; or of one or more physiological parameters that measure metabolic changes, such as, e.g., glycemia, blood pressure, body weight, fat mass, body mass index (BMI), inflammation, atherosclerosis index (AI), heart index, kidney index, total fat index, and homeostatic model assessment (HOMA) index.
- chemical or biological molecules associated with metabolism such as, e.g., glucose, triglyceride, cholesterol, free fatty acids, bile acids, amino acids, hormones, including, e.g., insulin, LDL-C, HDL-C, HbA1c, blood
- the present disclosure provides use of the polypeptides described herein in modulating, such as, e.g., reducing or stabilizing, the level or value of one or more physiological parameters that measure metabolic changes such as, e.g., glycemia, blood pressure, body weight, fat mass, body mass index (BMI), inflammation, atherosclerosis index (AI), heart index, kidney index, total fat index, and homeostatic model assessment (HOMA) index.
- glycemia blood pressure
- body weight fat mass
- body mass index BMI
- inflammation atherosclerosis index
- AI atherosclerosis index
- heart index heart index
- kidney index total fat index
- HOMA homeostatic model assessment
- the present disclosure provides use of the polypeptides described herein in reducing the risk of developing a metabolic disease. In certain embodiments, the present disclosure also provides use of the polypeptides described herein in reducing the risk of developing one or more symptoms or complications associated with a metabolic disease.
- the metabolic disease involves dysregulation of lipid metabolism. In some embodiments, the metabolic disease is a cholesterol-related disorder. In some embodiments, the metabolic disease is hyperlipidemia. The hyperlipidemia may include hypertriglyceridemia, hypercholesterolemia, or both. In some embodiments, the metabolic disease involves dysregulation of glucose metabolism. In some embodiments, the metabolic disease is diabetes. The diabetes may include type I and type II diabetes. In some embodiments, the metabolic disease is obesity.
- the symptoms or complications associated with the metabolic disease may include, e.g., cardiovascular diseases such as atherosclerosis diseases, heart diseases, kidney impairment, or obesity, in a subject having such metabolic disease (such as, e.g., diabetes, hyperlipidemia, including hypertriglyceridemia, hypercholesterolemia, or both).
- cardiovascular diseases such as atherosclerosis diseases, heart diseases, kidney impairment, or obesity
- hyperlipidemia including hypertriglyceridemia, hypercholesterolemia, or both.
- the present disclosure also provides methods to carry out the above uses of the polypeptides described herein in a subject. Such methods may comprise administering to the subject a therapeutically effective amount of a polypeptide described herein or of a pharmaceutical composition comprising such polypeptide.
- the subject may be a mammal.
- the subject may be a human.
- the subject may suffer from a metabolic disease or may be at risk of developing such disease.
- the present disclosure provides for the use of the polypeptides described herein in the manufacture or preparation of a medicament.
- the medicament may be for treatment of a metabolic disease.
- the metabolic disease may involve dysregulation of lipid metabolism.
- the medicament may be for treatment of a cholesterol-related disorder.
- the cholesterol-related disorder may be hyperlipidemia.
- the hyperlipidemia may be hypertriglyceridemia, hypercholesterolemia, or a combination thereof.
- the medicament is for use in a method of lowering the level of serum lipids, such as, e.g., the total cholesterol, total triglyceride, or LDL cholesterol level, in a subject, comprising administering to the subject a therapeutically effective amount of the medicament.
- serum lipids such as, e.g., the total cholesterol, total triglyceride, or LDL cholesterol level
- the metabolic disease may involve dysregulation of glucose metabolism.
- the medicament may be for treatment of diabetes e.g., type I or type II diabetes.
- the medicament may be for treatment of obesity.
- the medicament is for use in a method of lowering the blood glucose or HbA1c level in a subject, comprising administering to the subject a therapeutically effective amount of the medicament.
- the disorder treated may be any disease or condition which can be improved, ameliorated, inhibited, or prevented by bidirectionally regulating NTCP activity.
- disorders or disease that can benefit from the regulation of bile acid intake by hepatocytes can also be treated by the polypeptides described herein.
- subjects treatable by the polypeptides and methods and uses described herein may include subjects indicated for LDL apheresis, subjects with diabetes, subjects with primary hyperlipidemia (including hypercholesterolemia, hypertriglyceridemia, or a combination thereof) who are intolerant or uncontrolled by other therapeutic agent, and subjects at risk for developing hyperlipidemia who may be preventably treated.
- dyslipidemia associated with secondary causes such as Type 2 diabetes mellitus, cholestatic liver diseases (primary biliary cirrhosis), nephrotic syndrome, hypothyroidism, obesity, and the prevention and treatment of cardiovascular diseases (e.g., atherosclerotic diseases), heart diseases, and kidney impairment.
- the methods and uses described herein may further comprise administering to the subject an effective amount of at least one additional therapeutic agent.
- the additional therapeutic agent may be for preventing and/or treating one or more diseases associated with the metabolic diseases described herein, such as, e.g., one or more diseases associated with diabetes or hyperlipidemia.
- the additional therapeutic agent may be for preventing and/or treating cardiovascular diseases (e.g., atherosclerotic diseases).
- the additional therapeutic agent may be for reducing the risk of recurrent cardiovascular events.
- the additional therapeutic agent may be for preventing and/or treating heart diseases, kidney impairment, or obesity.
- the polypeptides described herein can be used either alone or in combination with other agents in a therapy.
- the antihyperglycemic agent may be chosen from, e.g., a biduanide (e.g., metformin, phenformin, and buformin), insulin (e.g., regular human insulin, NPH insulin, insulin aspart, insulin lispro, insulin glargine, insulin detemir, and insulin levemir), a glucagon-like peptide 1 receptor agonist (GLP-1RA; e.g., albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, and extended-release glucagon), a sodium-glucose cotransporter 2 inhibitor (SGLR2I; e.g., canagliflozin, empagliflozin, dapagliflozin, empagliflozin, and ipragliflozin), a dipeptidyl peptidase 4 inhibitor (DPP4I; e.g., bromocript
- Micronase glibornuride, gliquidone, glisoxepide, glyclopyramide, glimepiride, amaryl, and glimiprime
- an amylin analogue e.g., pramlinitide
- PCSK9I proprotein convertase subtilisin/kexin type 9 inhibitor
- PCSK9I proprotein convertase subtilisin/kexin type 9 inhibitor
- PCSK9I proprotein convertase subtilisin/kexin type 9 inhibitor
- GKA glucokinase activator
- PPAR agonist/modulator e.g., MK-0941, RO-28-1675, and AZD1656
- PPAR agonist/modulator e.g., MK-0941, RO-28-1675, and AZD1656
- PPAR agonist/modulator e.g., MK-0941, RO-28-1675, and AZD1656
- the additional therapeutic agent is an antihyperlipidemic agent and may be chosen from, e.g., a statin (e.g., HMG-CoA reductase inhibitor; e.g., smvastatin, atorvastatin, rosuvastatin, pravastatin, pitavastatin, lovastatin, atorvastatin, fluvastatin, cerivastatin, mevastatin, pantethine, elastase, and probucol), a fibric acid (e.g., bezafibrate (e.g., Bezalip), ciprofibrate (e.g., Modalim), clofibrate, gemfibrozil (e.g., Lopid), fenofibrate (e.g., TriCor), clinofibrate (e.g., Lipoclin), lifibrate, alufibrate, simfibrate, etof
- Such combination therapies described herein may encompass combined administration (where two or more therapeutic agents are included in the same or separate formulations), and separate administration, in which case, administration of the polypeptides described herein can occur prior to, simultaneously, and/or following, administration of the additional therapeutic agent.
- polypeptides described herein can be administered by any suitable means, including parenteral, intrapulmonary, and intranasal, and, if desired for local treatment or intralesional administration.
- the polypeptides described herein may be parenterally administered.
- Parenteral administration may include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.
- the polypeptides described herein may administered subcutaneously.
- the polypeptides described herein may administered intravenously.
- Dosing can be by any suitable route, such as, e.g., by injections or infusions, such as intravenous or subcutaneous injections or infusions, depending in part on whether the administration is brief or chronic.
- Various dosing schedules including e.g. single or multiple administrations over various time-points, bolus administration, and pulse infusion are also contemplated.
- polypeptides described herein would be formulated, dosed, and administered in a fashion consistent with common medical practice. Factors for consideration in this context may include, e.g., the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
- the polypeptides described herein need not be but can be optionally formulated with one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents depends on the amount of the polypeptide described herein present in the formulation, the type of disorder or treatment, and other factors discussed above.
- a flat-fixed dosing regimen may be used to administer the polypeptide described herein to a subject.
- other dosage regimens may also be useful depending on the factors discussed above. The progress of this therapy can be easily monitored by conventional techniques and assays for the disease or condition treated.
- Cmyr-47 was determined to have an IC 50 value of 0.15 ⁇ M in blocking bile acids transport.
- a blood sample from each rat was collected by tail-bleeding. Serums from the blood samples were further separated out by centrifugation at 3,000 rpm for 10 min. The serum samples were then analyzed a total bile acid assay kit (Nanjing Jiancheng Bioengineering Institute) in order to determine the level of total bile acids (TBA). As shown in Tables 3 and 4, both female and male rats treated with Cmyr-47 displayed an increased level of total bile acids in the serum as compared with the control group, indicating that Cmyr-47 is capable of effectively blocking the bile acids uptake in vivo. The increase of total bile acids was dose-dependent.
- a hyperlipidemic golden hamster model was established by feeding hamsters with a high-fat diet for 2 weeks (after adaptive feeding for 10 days).
- TC total cholesterol
- 10 hamsters fed with the normal chow diet were used as a normal control group (10 mL/kg PBS, sc).
- the serum TG levels in the model controls were significantly higher than the normal controls throughout the experiment (all values of P ⁇ 0.01). Measurements at week 2 and week 4 confirmed that FENO significantly decreased the serum TG levels in the animals (all of P values less than 0.01).
- the high dose of Cmyr-47 also significantly lowered the serum TG levels in the animals as compared with the model controls. Similar to the effect on serum TC, the effect of Cmyr-47 on serum TG were also dose-dependent.
- CsA treatment increased the serum TG levels in the animals as compared with the model controls.
- Table 16 and FIG. 10 summarize the measurements of serum LDL-C levels from the animals treated with PBS, FENO, or Cmyr-47.
- the serum LDL-C levels in the model controls significantly increased as compared with the normal controls, confirming the hyperlipidemic phenotype (P ⁇ 0.01).
- the positive controls treated with FENO displayed significantly lower serum LDL-C levels than the model controls.
- animals treated with Cmyr-47 did not have significantly decreased serum LDL-C levels as compared with the model controls.
- the serum LDL-C levels of animals treated with additional polypeptides derived from HBV were also measured by following the protocol described above. As shown in FIGS. 11 A and 11 B , the serum LDL-C levels of those animals were lower than that of the model controls.
- Table 17 and FIG. 12 provide the measurements of serum HDL-C levels. Based on the values obtained in this study, an AI value of each animal was calculated by following the formula discussed above. The average AI value of each group is provided in Table 17 and FIG. 13 . Although Cmyr-47 did not lower serum HDL-C in vivo, the average AI value of animals treated with Cmyr-47 was significantly lower than the average value of the model controls, indicating that Cmyr-47 may be protective against atherosclerosis and other vascular disease including cardiovascular diseases that are caused by accumulation of fat.
- Table 18 and FIG. 14 provide the measurements of serum TBA levels.
- the serum TBA levels in the model controls were higher than the normal controls.
- the serum TBA levels of animals treated with Cmyr-47 were further elevated in a dose-dependent fashion, confirming that Cmyr-47 is capable of inhibiting bile acid uptake in vivo.
- Measurements at week 4 confirmed that the high dose of Cmyr-47 significantly increased the serum TBA levels (P values less than 0.05).
- CsA and the low dose of Cmyr-47 also moderately elevated the serum TBA levels after 4 weeks of treatment, though the significance was not reached.
- hyperlipidemic animals did not show any significant hyperglycemic phenotype as compared with the normal controls (all values of P>0.05).
- the high and low doses of Cmyr-47 did not reduce the serum GLU levels below the normal glycemia displayed in the normal controls and the model controls (all values of P>0.05).
- the hyperlipidemic golden hamster model was established as described in Example 3.1. After 2 weeks of the high-fat diet treatment, the hyperlipidemic phenotype of hamsters was confirmed when the animals had serum total cholesterol (TC) levels higher than 10 mmol/L.
- Eight hamsters fed with the normal chow diet were used as a normal control group (10 mL/kg PBS, sc).
- Cmyr-47 was administered for 4 consecutive weeks.
- all animals in the model control group, low, middle and high dose groups were fed with the high fat diet, while the normal control group was fed with the normal chow diet.
- Cmyr-47 or PBS was subcutaneously injected to the hamsters twice a day (9:00-10:00 in the morning and 16:00-17:00 in the afternoon). Each morning, food and water consumption, feces, and animal grooming were monitored.
- the serum TC and TG levels of all animals were measured on week 2 and week 4 of treatment as described in Example 3.1 and the results are summarized in Tables 20 and 21. The data was analyzed as described in Example 3.1.
- the serum TC levels in the model controls were significantly higher than those in the normal controls during the experiment (all values of P ⁇ 0.01).
- the treatment with Cmyr-47 at a dose of 1 mg/kg or 3 mg/kg had no effect on serum TC.
- hyperlipidemic animals treated with 10 mg/kg Cmyr-47 for 4 weeks showed moderately reduced levels of serum TC as compared with the model control group (P ⁇ 0.05).
- Example 4.1 Methods and Materials Used in Treatment of Zucker Diabetic Fatty Rats with Cmyr-47
- Cmyr-47 as an anti-diabetic, anti-hyperlipidemic, and/or anti-hypercholesterolemic agent was tested in Zucker Diabetic Fatty (ZDF) rats, a spontaneous type II diabetes animal model.
- ZDF Zucker Diabetic Fatty
- HbA1c glycated hemoglobin
- mice with the fasting serum GLU levels close to the average level were selected and randomly divided into 5 groups: a model control group (10 ml ⁇ kg ⁇ 1 PBS), a low-dose treatment group (10 mg ⁇ kg ⁇ 1 Cmyr-47), a high-dose treatment group (30 mg ⁇ kg ⁇ 1 Cmyr-47), a positive control group (300 mg ⁇ kg ⁇ 1 Metformin), and a CsA treatment group (20 mg ⁇ kg ⁇ 1 CSA) with 6 animals per group.
- Six ZL rats were used as a normal control group (10 ml ⁇ kg ⁇ 1 PBS).
- PBS or Cmyr-47 was injected to animals subcutaneously twice per day (at 09:00 and 17:00).
- Meformin (MET) and CsA solutions were given via oral gavage twice per day in the morning and afternoon. The dosing was conducted for 4 weeks. During the experiment, ZDF rats were fed with Purina #5008 diet while ZL rats were fed the normal chow diet.
- Cmyr-47 was synthesized as described above, purified as a white powder by Shanghai HEP Pharmaceutical Co., Ltd (Shanghai, China; Lot number 14011801), and stored at ⁇ 20° C. Cmyr-47 was weighed and dissolved in PBS right before use. MET was manufactured by Bristol-Myers Squibb Co., Ltd. (Shanghai, China) with approval number H20023370 and lot number of AAD7878. CsA (Sandimmune®) was purchased from Novartis.
- the animals were fasted for 10 h with free access to water, and 0.3 mL of blood from each animal was collected via tail vein bleeding for measuring serum GLU, total cholesterol (TC), triglycerides (TG) and blood urea nitrogen (BUN).
- the animals were fasted for 10 h and the blood was then collected for the measurement of serum GLU, TC, TG and BUN, HbA1c and insulin.
- the animals were fasted for 12 h and then anesthetized via intraperitoneal injection of 3% sodium pentobarbital and cervical dislocation.
- Heart, kidneys, scapular fat, and abdominal fat of each animal were dissected for visual observation and weighed to calculate heart, kidney, and total fat index.
- Pentobarbital sodium (content ⁇ 95.0%; Lot number 20130112) was purchased from Merck.
- TC, TG, GLU and BUN kits were purchased from DiaSys Diagnostic Systems (Shanghai, China).
- HbA1c detection reagent was purchased from Trinity Biotech Inc., Ireland.
- Insulin ELISA detection kit (Lot number: 0469636-1) was purchased from Bertin Pharma (France). All measurements using the purchased kits were conducted following the manufacturers' protocols provided in the kits.
- SPSS 19.0 software SPSS, Chicago, IL was used for statistical analysis. All data were presented as mean ⁇ standard error mean ( ⁇ ⁇ SEM). ANOVA variance analysis was used to evaluate the data from the test results. LSD test was used for pairwise comparisons. Values of the statistical analyses were rounded to 2 decimal places.
- polypeptides derived from HBV listed in Table 1 were also tested in order to analyze their effects on glycemia in vivo by following the same protocol described above. All polypeptide was administrated at a dose molarly equivalent to 30 mg/kg/day of Cmyr-47.
- HbA1c refers to glycated hemoglobin, and its level significantly increases when a subject is experiencing chronic hyperglycemia. As shown in Table 23 and FIG. 19 , consistent with hyperglycemic phenotype of ZDF rats, the HbA1c levels in the model controls were significantly higher than the normal control throughout the study (all values of P ⁇ 0.01). Also, consistent with the effect of MET on glycemia, the treatment with MET significantly decreased the HbA1c levels in ZDF rats (P ⁇ 0.01).
- diabetic phenotypes include lipid dysregulation including elevated cholesterol and triglycerides in the blood stream.
- the serum TC levels in the model controls were consistently elevated as compared with the normal controls (all values of P ⁇ 0.05).
- MET appeared to be completely ineffective in lowering the serum TC levels in ZDF rats.
- CsA was also ineffective in lowering the serum TC levels in ZDF rats and by 4 weeks of treatment, CsA significantly increased the serum TC levels as compared with the model control.
- the high dose of Cmyr-47 significantly reduced the serum TC levels in ZDF rats as compared with the model controls, confirming that Cmyr-47 can regulate a wide array of biomarkers that are severely elevated in diabetic patients.
- Additional polypeptides derived from HBV were also capable of reducing serum TG in vivo when tested in the same animal model described above. As shown in FIGS. 25 A and 25 B , the serum TG levels of the model controls remained higher than ZDF rats treated with HBV-derived peptides (Cmyr-60, Cmyr-55, Cmyr-40, Cmyr-35, Cmyr-30, Cmyr-25, Cmyr-20, Cmyr-47+( ⁇ 10), Cmyr-47+( ⁇ 9), Cplam-47, Cstea-47, Cchol-47, Amyr-47, Bmyr-47, Dmyr-47, Emyr-47, Fmyr-47, Gmyr-47 or Hmyr-47), further confirming that polypeptides derived from HBV are capable of regulating glucose metabolism and lipid metabolism simultaneously.
- Elevated serum BUN reflects impaired renal function, which often occurs in human diabetic patients.
- diabetic phenotypes lead to renal dysfunction and the correlative elevation of serum BUN.
- Table 27 and FIG. 26 show that the serum BUN levels in the model controls were significantly higher than that of the normal controls throughout the study.
- the treatment of MET was not capable of reversing renal dysfunction as no significant BUN difference was found between the model controls and the positive controls.
- the high dose of Cmyr-47 significantly lowered the serum BUN levels in ZDF rats at week 4 (P ⁇ 0.01), indicating that Cmyr-47 may protect a diabetic subject against kidney damage and renal dysfunction.
- HI heart index
- KI kidney index
- TBI total fat index
- Table 28 and FIG. 27 C show that the TFI values of the model controls were significantly higher than normal controls (P ⁇ 0.01), indicating that ZDF rats reached morbid obesity. Although not significant, ZDF rats treated with Cmyr-47 showed a trend of TFI values lower than the model controls. Of note, MET did not show the similar trend and rather, it appeared to increase the TFI values in ZDF rats.
- the serum TBA level of each animal was measured. As shown in Table 29 and FIG. 28 , the serum TBA levels in the model controls were higher than the normal controls. As compared with the model control group, the serum TBA levels of ZDF rats treated with Cmyr-47 were further elevated in a dose-dependent fashion. Measurements at week 4 confirmed that the high dose of Cmyr-47 significantly increased the serum TBA levels (P values less than 0.05). Also, CsA significantly elevated the serum TBA levels after 4 weeks of treatment (P values less than 0.01).
- MET is a widely used antidiabetic drug that can efficiently modulate glycemia in vivo.
- efficacy of MET in glycemia regulation was also confirmed in this study.
- MET failed to provide benefits against lipid dysregulation and associated diseases, as evident by the results that MET was not capable of lowering serum TC, TG, and BUN levels, and HI values in ZDF rats.
- CsA treatment not only increased the serum TG and TC levels, but further increased the serum GLU levels, suggesting that effective inhibition of bile acid uptake in vitro does not always translate to a therapeutic effect on lipid and glucose metabolism in vivo.
- Cmyr-47 performed well all across the tests.
- Cmyr-47 was capable of modulating glycemia and lipid metabolism while providing protection against pancreas damage, renal dysfunction, and cardiovascular diseases.
- Cmyr-47 performed superior as an anti-hyperglycemia, anti-hypercholesterolemia, anti-hyperlipidemia, and anti-adiposity agent over MET and showed a comprehensive effect on multiple diabetic phenotypes simultaneously.
Abstract
The disclosure provides compositions and methods of treating a metabolic disease, such as, e.g., diabetes and hyperlipidemia, in a subject, by administering to the subject a therapeutically effective amount of a polypeptide derived from hepatitis B virus or a pharmaceutical composition comprising the polypeptide.
Description
- This application is a divisional application filing under 35 U.S.C. § 121 of U.S. application Ser. No. 16/305,790, filed on Nov. 29, 2018, which claims the priority to and benefits of Chinese Application No. 201610370442.4, filed May 30, 2016, and International Application PCT/CN2017/086558, filed on May 31, 2017. The content of these applications is incorporated herein by reference.
- This application contains a Sequence Listing as an XML file entitled “13230.0001-01000 Sequence Listing” having a size of 94,823 bytes and created on Aug. 10, 2023. The information contained in the Sequence Listing is incorporated by reference herein.
- This disclosure relates to compositions and methods for treating a metabolic disease such as diabetes and hyperlipidemia. In certain embodiments, the disclosure relates to the treatment of a metabolic disease with a polypeptide derived from hepatitis B virus.
- Metabolic diseases are caused by an imbalance of metabolites including carbohydrates, fats, lipids, and minerals that are crucial for well-being of a living organism. For example, type II diabetes and hyperlipidemia represent two most common metabolic diseases. The imbalance of metabolites may occur as a result of various factors including aging, behavior, genetics, and environmental influences, and often multiple factors in combination contribute the manifestation of the disease. Patients suffering from metabolic diseases may display a wide range of symptoms including, for example, hyperglycemia, hyperinsulinemia, hyperlipidemia, insulin resistance, and dysregulation of other metabolites such as amino acids and minerals. It is often difficult to identify the underlying cause of metabolic diseases, making them difficult to treat effectively. Furthermore, patients suffering from metabolic diseases may have a risk of developing serious complications associated with the diseases, such as hypertension, cardiovascular diseases, kidney damages, and nerve damages.
- Due to the heterogeneity of these diseases, patients suffering from metabolic diseases may require a number of different medications, targeting multiple metabolic pathways in an attempt to address multiple symptoms simultaneously. For instance, one study showed that the type II diabetic patients surveyed in the study were taking an average of 8.4 different drug compounds per day (see, e.g., Bauer et al, Diabetic Medicine, 31:1078-85 (2014)). One of the reasons that the patients suffering from metabolic diseases have to take various different medicines is because those medicines are often specialized to address a particular symptom or pathway of the metabolic disease and thus are not capable of targeting other related symptoms. Unfortunately, taking multiple medicines can affect the life quality of the patients and ultimately worsen the course of disease progression. Indeed, as statistics show, type II diabetic patients experience difficulty adhering to their medication regimens partially because of the complexity of these regimens (see, e.g., Garcia-Perez et al, Diabetes Therapy, 4:175-94 (2013)).
- Furthermore, metabolic diseases often involves a complicated network of signaling pathways, and therefore targeting one particular pathway by one agent does not always lead to a therapeutically relevant effect in patients. For instance, cyclosporine A (CsA), an immunosuppressant drug widely used in organ transplantation to prevent rejection, has been shown to inhibit bile acid uptake and HBV entry into cultured hepatocytes mediated sodium taurocholate cotransporting polypeptide (NTCP), which is a Na+-dependent bile acid transporter that transports bile acids from blood stream to hepatocytes (Watashi et al, Hpatology, 59:1726-37 (2014)). However, treatment with CsA can produce deleterious effects on glucose metabolism and impair insulin response (Dresner et al, Surgery, 106(2):163-69 (1989)). In addition, CsA can induce hyperlipidemia in patients by increasing the total cholesterol level, primarily due to an increase in the low-density lipoprotein (LDL) cholesterol level (Ballantyne et al., JAMA, 262(1):53-56 (1989)). Various other compounds have been shown to bind to NTCP, but they do not produce a uniform effect on NTCP as some of those compounds function as an inhibitor while others function as an enhancer (Kim et al, J. Pharmacol. Exp. Ther., 291(3):1204-09 (1999)). While most of those drugs have not been validated for their therapeutic outcomes in treating metabolic diseases to date, some enhancers of NTCP produce opposite effects on glucose or lipid metabolism (see, e.g., Beaudoin et al., Appl. Physiol. Nutr. Metab. 38(2):140-47 (2013); Thelle et al., N. Engl. J. Med. 308(24):1454-57 (1983); Phillips et al., Br. Med. J. 292:1319-21 (1986); Boden et al., Circulation, 85(6):2039-44 (1992)). It is also unclear whether regulating NTCP in vivo would result in any therapeutically relevant effect, because subjects with NTCP deficiency did not exhibit any clear clinical phenotype (see Vaz et al, Hepatology, 61(1):260-267 (2015)). Thus, there is an urgent need to develop a new medication for metabolic diseases, potentially capable of addressing multiple symptoms simultaneously with a potent therapeutic efficacy.
- HBV viral envelope contains three surface antigen proteins: large (L), medium (M), and small (S). These proteins are coded by a single open reading frame on the S gene, starting from three different translation initiating sites, i.e., L (Pre-S1+Pre-S2+S), M (Pre-S2+S), and S (S). The HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on its envelope proteins, and into eight genotypes (A-H) according to overall nucleotide sequence variation of the genome. During viral infection, the Pre-S1 region on the L protein of HBV was shown to bind to NTCP (Yan et al, eLife, 1:e00049 (2012)).
- This disclosure provides compositions and methods for treating a metabolic disease with a polypeptide derived from HBV. In some embodiments, the polypeptides described herein include polypeptides derived from the pre-S1 region of any one of HBV genotypes A, B, C, D, E, F, G, and H. The disclosure further provides HBV-derived polypeptides that are capable of altering metabolism such as glucose and lipid metabolism in a subject, including humans as well as pharmaceutically relevant animal models.
- In some aspects, the disclosure provides a pharmaceutical composition comprising a polypeptide described herein, wherein when administered to a subject in need thereof, the pharmaceutical composition provides serum concentrations of the polypeptide that allow for bidirectional regulation of NTCP-mediated bile acid uptake in the subject.
- In some aspects, the disclosure provides methods of treating a metabolic disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the polypeptide described herein or a pharmaceutical composition comprising the polypeptide such that the serum concentrations of the administered polypeptide allow for bidirectional regulation of NTCP-mediated bile acid uptake in the subject, wherein the polypeptide comprises an amino acid sequence derived from Hepatitis B virus (HBV).
- In some aspects, the disclosure relates to methods of lowering a serum lipid level in a subject in need thereof by administering to the subject a therapeutically effective amount of the polypeptide described herein or of a pharmaceutical composition comprising the polypeptide such that the serum concentrations of the administered polypeptide allow for bidirectional regulation of NTCP-mediated bile acid uptake in the subject. In some embodiments, the serum lipid may include, e.g., total cholesterol (“TC”), triglyceride (“TG”), and LDL-C.
- In certain aspects, the disclosure also relates to methods of lowering a blood glucose level in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the polypeptide described herein or a pharmaceutical composition comprising such polypeptide.
- In some embodiments, when the serum concentration of the administered polypeptide in the subject is at or below 93 nmol/L, the polypeptide enhances NTCP-mediated bile acid uptake in the subject. In some embodiments, when the serum concentration of the administered polypeptide in the subject is above 93 nmol/L, the polypeptide inhibits NTCP-mediated bile acid uptake in the subject. In some embodiments, the serum concentration of the polypeptide in the subject reaches a peak concentration (i.e., Cmax) at about 20 minutes after the administration. Thus, in some embodiments, Tmax of the polypeptide described herein is about 20 minutes. In some embodiments, the peak concentration is more than 93 nmol/L.
- In some embodiments, a subject administered with the polypeptide described herein suffers from or is at risk of developing a metabolic disease. In some embodiments, the metabolic disease involves dysregulation of lipid metabolism. In some embodiments, the metabolic disease is a cholesterol-related disorder. In some embodiments, the metabolic disease is hyperlipidemia (e.g., hypertriglyceridemia, hypercholesterolemia, or a combination thereof). In some embodiments, the metabolic disease involves dysregulation of glucose metabolism. In some embodiments, the metabolic disease is hyperglycemia. In some embodiments, the metabolic disease is diabetes or obesity. In some embodiments, the subject suffers from or is at risk of developing cardiovascular diseases (e.g., atherosclerotic diseases), heart diseases, or kidney impairment.
- In some embodiments, the polypeptide described herein is capable of reducing or stabilizing the level or activity of one or more chemical or biological molecules associated with metabolism in the subject. The chemical or biological molecule associated with metabolism is chosen from glucose, cholesterol, triglyceride, free fatty acids, amino acids, hormones, LDL-C, HDL-C, HbA1c, blood urea nitrogen, and minerals. In some embodiments, the polypeptide described herein is also capable of reducing or stabilizing the level or value of one or more physiological parameters that measure metabolic changes. The physiological parameter is chosen from glycemia, blood pressure, body weight, fat mass, body mass index (BMI), inflammation, atherosclerosis index, heart index, kidney index, total fat index, and homeostatic model assessment (HOMA) index.
- In some embodiments, the polypeptide described herein comprises an amino acid sequence derived from the pre-S1 region of HBV genotype A, B, C, D, E, F, G, or H. In certain embodiments, the polypeptide described herein comprises the sequence of amino acids 13-59 of the pre-S1 region of HBV genotype C. In additional embodiments, the polypeptide described herein comprises an amino acid sequence derived from the pre-S1 region of any other HBV genotype that corresponds to amino acids 13-59 of the pre-S1 region of HBV genotype C. In some embodiments, the polypeptide comprises an amino acid sequence selected from SEQ ID NOs: 21-40.
- In some embodiments, one or more amino acid residues of the polypeptide described herein are deleted, substituted, or inserted while maintaining the ability to bind to NTCP and bidirectionally regulate NTCP-mediated transport of bile acid into hepatocytes. In certain embodiments, the polypeptide described herein comprises a native flanking amino acid sequence from the pre-S1 region of HBV genotype A, B, C, D, E, F, G, or H. In other embodiments, the polypeptide described herein has at least about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to any one of the amino acid sequences selected from SEQ ID NOs: 21-40. In some embodiments, the polypeptide comprises the glycine corresponding to
amino acid 13 of the pre-S1 region of HBV genotype C and/or the asparagine corresponding toamino acid 20 of the pre-S1 region of HBV genotype C. - In some embodiments, the polypeptide described herein comprises an N-terminal modification with a hydrophobic group and/or a C-terminal modification that is capable of stabilizing the polypeptide. The hydrophobic group may be chosen from, e.g., myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, cholesterol, and arachidonic acid. The C-terminal modification may be chosen from, e.g., amidation (amination), isopentanediolization, and any C-terminal modification that is capable of stabilizing the polypeptide. In certain embodiments, the polypeptide described herein comprises an N-terminal modification with myristic acid and/or a C-terminal modification with amination. In some embodiments, the polypeptide described herein comprises an amino acid sequence chosen from SEQ ID NOs: 21-40. In some embodiments, the polypeptide described herein comprises the amino acid sequence of SEQ ID NO: 23.
- In one aspect, the polypeptide described herein is capable of reducing one or more symptoms associated with the metabolic disease. In some embodiments, the polypeptide described herein or the pharmaceutical composition comprising such polypeptide is administered to the subject before, concurrently with, or after the administration of a therapeutically effective amount of at least one a second agent. The second agent may be chosen from, e.g., an antihyperlipidemic agent, an antihyperglycemic agent, an antidiabetic agent, an antiobesity agent, and a bile acid analogue. For example, the second agent may be chosen from, e.g., insulin, metformin, sitagliptin, colesevelam, glipizide, simvastatin, atorvastatin, ezetimibe, fenofibrate, nicotinic acid, orlistat, lorcaserin, phentermine, topiramate, obeticholic acid, and ursodeoxycholic acid.
- In some embodiments, the polypeptide described herein or the pharmaceutical composition comprising such polypeptide is administered to the subject by at least one mode including, e.g., parenteral, intrapulmonary, intranasal, intralesional, intramuscular, intravenous, intraarterial, intraperitoneal, and subcutaneous administration. In some embodiments, the polypeptide described herein or the pharmaceutical composition comprising such polypeptide is administered to the subject subcutaneously.
-
FIG. 1A shows an exemplary graph depicting the purity of Cmyr-47 as measured by high pressure liquid chromatography (HPLC).FIG. 1B shows an exemplary graph depicting the molecular weight of Cmyr-47 as confirmed by Mass Spectrometry. -
FIG. 2A shows that Cmyr-47 labeled with FIFC binds to tupaia primary hepatocytes. -
FIG. 2B shows that Cmyr-47 labeled with FIFC binds to HepG2 cells, a human hepatocyte derived cell line. -
FIG. 3A shows that Cmyr-47 labeled with FIFC does not bind to control L02 cells (“BLANK-L02”).FIG. 3B shows that Cmyr-47 labeled with FIFC binds to NTCP expressing L02 cells (“NTCP-L02”). -
FIG. 4 shows that Cmyr-47 labeled with FIFC binds to NTCP expressing HEK293 cells (“NTCP-293”) but does to bind to control HEK293 cells (“BLANK-293”). A polypeptide derived from heron HBV, labeled with FIFC, was used as a control polypeptide. -
FIG. 5A shows the effect of Cmyr-47 on bile acids uptake in vitro. Cyclosporine A (“CsA”) was used as a positive control.FIG. 5B illustrates the bidirectional effect of Cmyr-47 on bile acids uptake.FIGS. 5C and 5D show the effect of CsA on bile acids uptake in vitro and confirm the inhibitory effect of CsA.FIGS. 5E and 5F show the effect of HBV-derived polypeptides on bile acids uptake in vitro at a low concentration molarly equivalent to 62.5 ng/ml (11.58 nmol/L) Cmyr-47 and at a high concentration molarly equivalent to 1 μg/ml (185.23 nmol/L) Cmyr-47, respectively. -
FIG. 6 shows the changes of serum total cholesterol (“TC”) in hyperlipidemic golden hamsters treated with Cmyr-47 or CsA for 4 weeks. Golden hamsters fed with regular diet were treated with PBS and used as a “Normal Control” while hyperlipidemic golden hamsters treated with PBS were used as a “Model Control.” Hyperlipidemic golden hamsters treated with Fenofibrate (“Positive Treatment”) were used as a positive control. -
FIG. 7A shows the level of serum TC prior to treatments with polypeptides derived from HBV.FIG. 7B shows the level of serum TC after 4 weeks of the treatments. -
FIG. 8 depicts the changes of serum triglycerides (“TG”) of hyperlipidemic golden hamsters during 4 weeks of Cmyr-47 treatment. -
FIG. 9A shows the level of serum TG prior to treatments with polypeptides derived from HBV.FIG. 9B shows the level of serum TG after 4 weeks of the treatments. -
FIG. 10 depicts the level of serum LDL-C of hyperlipidemic golden hamsters after 4 weeks of Cmyr-47 treatment. -
FIG. 11A shows the level of serum LDL-C before being treated with polypeptides derived from HBV.FIG. 11B shows the level of serum LDL-C after 4 weeks of the treatments. -
FIG. 12 shows the level of serum HDL-C of hyperlipidemic golden hamsters after 4 weeks of Cmyr-47 treatment. -
FIG. 13 depicts atherosclerosis index (“AI”) of hyperlipidemic golden hamsters after 4 weeks of Cmyr-47 treatment. -
FIG. 14 shows the changes of serum total bile acids (TBA) of hyperlipidemic golden hamsters after 4 weeks of Cmyr-47 treatment. Fenofibrate and CsA were also tested for comparison. -
FIG. 15 shows the changes of serum TC of hyperlipidemic golden hamsters treated with three different doses (1 mg/kg, 3 mg/kg, and 10 mg/kg) of Cmyr-47 for 4 weeks. Golden hamsters fed with regular diet were treated with PBS and used as a “Normal Control,” while hyperlipidemic golden hamsters treated with PBS were used as a “Model Control.” -
FIG. 16 shows the changes of serum TG of hyperlipidemic golden hamsters treated with 1 mg/kg, 3 mg/kg, or 10 mg/kg of Cmyr-47 for 4 weeks. -
FIG. 17 shows the changes of serum glucose (“GLU”) in Zucker diabetic fatty rats during 4 weeks of Cmyr-47 or CsA treatment. Zucker lean rats treated with PBS were used as a “Normal Control” while Zucker diabetic fatty rats treated with PBS were used as a “Model Control.” Zucker diabetic fatty rats treated with metformin (“Positive Treatment”) were used as a positive control. -
FIG. 18A shows the level of serum GLU before being treated with polypeptides derived from HBV.FIG. 18B shows the level of serum GLU after 4 weeks of the treatments. -
FIG. 19 shows the changes of HbA1c of Zucker diabetic fatty rats during 4 weeks of Cmyr-47 treatment. -
FIG. 20A shows the level of HbA1c prior to treatments with polypeptides derived from HBV.FIG. 20B shows the level of HbA1c after 4 weeks of the treatments. -
FIG. 21 shows the changes of insulin in Zucker diabetic fatty rats during 4 weeks of Cmyr-47 treatment. -
FIG. 22 shows the changes of serum TC in Zucker diabetic fatty rats during 4 weeks of Cmyr-47 treatment. -
FIG. 23A shows the level of serum TC prior to treatments with polypeptides derived from HBV.FIG. 23B shows the level of serum TC after 4 weeks of the treatments. -
FIG. 24 shows the changes of serum TG in Zucker diabetic fatty rats during 4 weeks of Cmyr-47 treatment. -
FIG. 25A shows the level of serum TG prior to treatments with polypeptides derived from HBV.FIG. 25B shows the level of serum TG after 4 weeks of the treatments. -
FIG. 26 shows the level of blood urea nitrogen (“BUN”) in Zucker diabetic fatty rats after 4 weeks of Cmyr-47 treatment. -
FIGS. 27A-C depict heart index, kidney index, and total fat index of Zucker diabetic fatty rats after 4 weeks of Cmyr-47 treatment. “Cmyr-47(L)” indicates the dose of 10 mg/kg/d of Cmyr-47 while “Cmyr-47(Hi)” indicates the dose of 30 mg/kg/d of Cmyr-47. -
FIG. 28 shows the level of serum TBA in Zucker diabetic fatty rats after 4 weeks of Cmyr-47 treatment. - Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the disclosure belongs. For the purposes of the present disclosure, the following terms are defined below.
- The articles “a” and “an” refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. For example, “an element” means one element or more than one element.
- The term “or” means, and is used interchangeably with, the term “and/or,” unless context clearly indicates otherwise.
- To the extent that the term “contain,” “include,” “have,” or grammatical variants of such term are used in either the disclosure or the claims, such term is inclusive in a manner similar to the term “comprising” as “comprising” is interpreted when employed as a transitional word in a claim. The term “including” or its grammatical variants mean, and are used interchangeably with, the phrase “including but not limited to.”
- The term “about” means a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length that varies by as much as 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1% to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length. When the term “about” is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term “about” is intended to modify a numerical value above and below the stated value by a variance of 510%.
- Certain aspects of the present disclosure provide polypeptides derived from HBV for treating a metabolic disease including, e.g., diabetes and hyperlipidemia. The polypeptides may be derived from the pre-S1 region of HBV and may be capable of binding to NTCP in vitro, such as, e.g., in a solution or a cell-free system (e.g., a cell lysate or in a reconstituted system), or in a cell, such as, e.g., ex vivo in a cell in culture (e.g., a cell expressing NTCP, or a hepatocyte), or in vivo in a cell within a subject. The subject may be a mammal. In some embodiments, the subject may be a human.
- The terms “polypeptide,” “peptide,” and “protein” are used interchangeably and encompass full-length proteins and fragments, as well as variants of the full-length proteins and the fragments. Such fragments and variants of the polypeptide described herein retain at least the biological activities of the polypeptide to bind to NTCP and bidirectionally regulate NTCP-mediated transport of bile acid into hepatocytes. The “polypeptide,” “peptide,” and “protein” can include natural and/or non-natural amino acid residues. Those terms also include post-translationally modified proteins, including, e.g., glycosylated, sialylated, acetylated, and/or phosphorylated proteins. The terms also include chemically modified proteins at one or more amino acid residues, such as, e.g., at the N-terminus and/or at the C-terminus. For instance, the N-terminus of the polypeptide disclosed herein can be modified by a hydrophobic group such as, e.g., myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, cholesterol, and arachidonic acid. In some embodiments, the C-terminus of the polypeptide disclosed herein can be modified to stabilize the polypeptide. The C-terminus modification may be chosen from amidation (amination), isopentanediolization, and any other C-terminal modification capable of stabilizing the polypeptide.
- As used herein, the term “polypeptide derived from HBV” or “HBV-derived polypeptide” refers to the origin or source of the polypeptide as being from HBV, and may include native, recombinant, synthesized, or purified polypeptides. The term “polypeptide derived from HBV” or “HBV-derived polypeptide” refers to a full-length native HBV polypeptide or fragments thereof, as well as variants of the full-length native polypeptide or its fragments. In some embodiments, the fragment may consist of at least 3-5 amino acids, at least 5-10 amino acids, at least 10-20 amino acids, at least 20-30 amino acids, at least 30-50 amino acids, or the entire amino acids of the native sequence, or may be otherwise identifiable to one of ordinary skill in the art as having its origin in the native sequence. In some embodiments, the polypeptide described herein may be derived from the pre-S1 region of the L protein of any HBV subtype. In some embodiment, the polypeptide described herein may comprise the entire pre-S1 region of the L protein of any HBV subtype. In certain embodiments, the polypeptide described herein may be derived from the pre-S1 region of the L protein of any one of HBV genotypes A, B, C, D, E, F, G, and H. The genomic sequences of these HBV genotypes can be found in GenBank Accession Nos. KC875260 (SEQ ID NO: 41), AY220704 (SEQ ID NO: 42), AF461363 (SEQ ID NO: 43), AY796030 (SEQ ID NO: 44), AB205129 (SEQ ID NO: 45), DQ823095 (SEQ ID NO: 46), HE981176 (SEQ ID NO: 47), and AB179747 (SEQ ID NO: 48), respectively. In certain embodiments, the polypeptide described herein may be derived from the pre-S1 region of the L protein of HBV genotype C. The polypeptide derived from HBV described herein retains one or more biological activities described herein of the corresponding native HBV polypeptide, including at least the biological activities of the polypeptide to bind to NTCP and bidirectionally regulate NTCP-mediated transport of bile acid into hepatocytes.
- “Variant” as used herein in connection with the polypeptide described herein, a polypeptide derived from HBV, or an HBV-derived polypeptide means a polypeptide that differs from a given polypeptide (i.e., the polypeptide described herein, the polypeptide derived from HBV, or the HBV-derived polypeptide) in amino acid sequence, but retains one or more biological activities described herein of the given polypeptide. The variant polypeptide described herein retains at least at least the biological activities of the polypeptide to bind to NTCP and bidirectionally regulate NTCP-mediated transport of bile acid into hepatocytes. The variant polypeptide described herein may have one or more amino acid additions (e.g., insertion), deletions, or substitutions from the given polypeptide. In some embodiments, the variant polypeptide described herein may have 1-30, 1-20, 1-10, 1-8, 1-5, or 1-3 amino acid additions (e.g., insertion), deletions, or substitutions from the given polypeptide, including all integers in between these ranges. For example, the polypeptide sequence may contain conservative substitution of amino acids. A conservative substitution of an amino acid, i.e., replacing an amino acid with a different amino acid of similar properties (e.g., hydrophilicity and degree and distribution of charged regions), typically involves a minor change and therefore does not significantly alter the biological activity of the polypeptide. These minor changes can be identified, in part, by considering the hydropathic index of amino acids based on a consideration of the hydrophobicity and charge of the amino acid. Amino acids of similar hydropathic indexes and hydrophilicity values can be substituted and still retain protein function. Both the hydrophobicity index and the hydrophilicity value of amino acids are influenced by the particular side chain of that amino acid. Consistent with that observation, amino acid substitutions that are compatible with biological function depend on the relative similarity of the amino acids, and particularly the side chains of those amino acids, as revealed by the hydrophobicity, hydrophilicity, charge, size, and other properties.
- The term “variant” also includes a polypeptide that has certain identity, such as, e.g., at least about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to the given polypeptide. “Variant” as used herein also includes a polypeptide comprising the portion of the given polypeptide that corresponds to a native sequence of HBV proteins. “Variant” may also refer to a fusion protein or chimeric protein, comprising polypeptides derived from two or more different sources. Non-limiting examples of the fusion protein described herein may include, e.g., a fusion protein of one polypeptide derived from HBV and another polypeptide derived from a non-HBV protein, a fusion protein of two polypeptides derived from different HBV subtypes, and a fusion protein of two polypeptides derived from different regions of the L protein of any one of HBV subtypes, or from different sequences within the pre-S1 region of the L protein of any one of HBV subtypes.
- The term “variant” also includes a polypeptide that comprises the same amino acid sequence of a given polypeptide (i.e., the polypeptide described herein, the polypeptide derived from HBV, or the HBV-derived polypeptide) and retains one or more biological activities of the given polypeptide, but chemically and/or post-translationally modified in a manner different from the given polypeptide. “Variant” can also be used to describe a polypeptide or a fragment thereof that has been differentially processed, such as by proteolysis, phosphorylation, or other post-translational modification, yet retains its biological activity of binding to NTCP and bidirectionally regulating NTCP-mediated transport of bile acid into hepatocytes. Use of “variant” herein is intended to encompass fragments of a variant unless otherwise contradicted by context. The term “variant” also encompasses the homologous polypeptide sequences found in the different viral species, strains, or subtypes of the hepadnavirus genus. HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on its envelope proteins, and into eight genotypes (A-H) according to overall nucleotide sequence variation of the genome. The term “variant” therefore includes homologous polypeptides found in any of these HBV subtypes. “Variant” can also include polypeptides having native flanking amino acid sequences from any of these HBV subtypes added to the N and/or C terminus.
- The terms “conservative amino acid substitutions” and “conservative substitutions” are used interchangeably herein to refer to intended amino acid swaps within a group of amino acids wherein an amino acid is exchanged with a different amino acid of similar size, structure, charge, and/or polarity. Families of amino acid residues having similar side chains are known in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, in some embodiments, an amino acid residue in a polypeptide can be replaced with another amino acid residue from the same side chain family. In other embodiments, a string of amino acids can be replaced with a structurally similar string that differs in order and/or composition of side chain family members. In yet other embodiments, mutations can be introduced randomly along all or part of the polypeptide. Examples of conservative amino acid substitutions include, e.g., exchange of one of the aliphatic or hydrophobic amino acids Ala, Val, Leu, and Ile for one of the other amino acids in that group of four; exchange between the hydroxyl-containing residues Ser and Thr; exchange between the acidic residues Asp and Glu; exchange between the amide residues Asn and Gln; exchange between the basic residues Lys, Arg, and His; exchange between the aromatic residues Phe, Tyr, and Trp; and exchange between the small-sized amino acids Ala, Ser, Thr, Met, and Gly. Conservative substitutions, such as substituting a conserved amino acid with a similar, structurally related amino acid would not be reasonably expected to impose a substantial influence on the biological activity of the polypeptide.
- The term “sequence identity” (e.g., a “
sequence 50% identical to”) refers to the extent that a sequence is identical on an amino acid-by-amino acid basis over a window of comparison. In some embodiments, the polypeptide described herein may comprise an amino acid sequence at least about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of a given polypeptide and still retain one or more biological activities of the given polypeptide. A “percentage identity” (or “% identity”) may be calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical amino acids occur in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison, and multiplying the result by 100 to yield the percentage of sequence identity. Optimal alignment of sequences for aligning a comparison window may be conducted by computerized implementations of algorithms available in the art, such as, e.g., the BLAST® family of programs, or by visual inspection and the best alignment (i.e., resulting in the highest percentage homology over the comparison window) generated by any of the various methods selected. For sequence comparison, one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates may be designed, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the present sequence identity for the test sequences relative to the reference sequence, based on the designated program parameters. The designation of sequence algorithm program parameters is well within the knowledge in the art. For example, the window of comparison may be designated as over the entire length of either or both comparison sequences, such as, e.g., over the entire length of the reference sequence, and gaps of up to 5% of the total number of amino acids in the reference sequence may be allowed. - As used herein, the “biological activity” of the polypeptides described herein encompasses the ability of the polypeptides to bind to NTCP and bidirectionally regulate NTCP-mediated bile acid uptake in hepatocytes. As used herein, “bidirectional regulation” of a molecule or pathway means that the HBV-derived polypeptides described herein enhances the activity of the molecule or pathway (i.e., functions as an enhancer) at or below a certain concentration, and inhibits the activity of the molecule or pathway (i.e., functions as an inhibitor) above the concentration. For instance, the polypeptide described herein may bind to NTCP and promote NTCP-mediated bile acid uptake in hepatocytes (i.e., functions as an “enhancer” of NTCP) at or below a certain concentration. The same polypeptide may also bind to NTCP but inhibit NTCP-mediated bile acid uptake (i.e., functions as an “inhibitor” of NTCP) above that concentration. In some embodiments, the polypeptide described herein may function as an enhancer of NTCP at or below 93 nmol/L and as an inhibitor of NTCP above 93 nmol/L. For example, the Cmyr-47 polypeptide described herein may function as an enhancer of NTCP at or below 500 ng/ml and as an inhibitor of NTCP above 500 ng/ml.
- In some embodiments, the polypeptide described herein may bidirectionally regulate NTCP-mediated uptake of bile acids into hepatocytes in vitro. The polypeptide described herein may promote in vitro NTCP-mediated bile acid uptake at or below a certain concentration, while the polypeptide may inhibit in vitro NTCP-mediated bile acid uptake above that concentration. In some embodiment, the polypeptide described herein may promote in vitro NTCP-mediated bile acid uptake at or below 93 nmol/L, while the polypeptide may inhibit in vitro NTCP-mediated bile acid uptake above 93 nmol/L. For example, the Cmyr-47 polypeptide described herein may promote in vitro NTCP-mediated bile acid uptake at or below 500 ng/ml and inhibit in vitro NTCP-mediated bile acid uptake above 500 ng/ml.
- In some embodiments, the polypeptide described herein may promote NTCP-mediated bile acid uptake in a subject treated with the polypeptide at or below a certain serum concentration of the administered polypeptide. The polypeptide may inhibit NTCP-mediated bile acid uptake in a subject treated with the polypeptide above that serum concentration of the administered polypeptide. In some embodiments, when the serum concentration of the polypeptide described herein is at or below 93 nmol/L in a subject treated with the polypeptide, the polypeptide is capable of enhancing NTCP-mediated uptake of bile acids in the subject. In some embodiments, when the serum concentration of the polypeptide described herein is above 93 nmol/L in a subject treated with the polypeptide, the polypeptide is capable of inhibiting NTCP-mediated uptake of bile acids in the subject. For example, the Cmyr-47 polypeptide described herein may be capable of enhancing NTCP-mediated uptake of bile acids in the subject at or below a serum concentration of 500 ng/ml, and inhibiting NTCP-mediated uptake of bile acids in the subject above a serum concentration of 500 ng/ml.
- The biological activity of the polypeptide described herein may also include the ability to treat a metabolic disease or to ameliorate one or more symptoms associated with the metabolic disease. The biological activity may further include the ability of the polypeptide described herein to prevent the development of a metabolic disease. In some embodiments, the biological activity of the polypeptide described herein may include the ability of the polypeptide to modulate the level or activity of one or more chemical or biological molecules associated with metabolism, and/or to modulate the level or value of one or more physiological parameters that measure metabolic changes. In some embodiments, the “biological activity” of the polypeptide described herein includes the ability of the polypeptide to reduce or stabilize the level or activity of one or more such chemical or biological molecules or physiological parameters. In some embodiments, metabolism refers to bile acid metabolism, glucose metabolism, lipid metabolism, and/or amino acid metabolism. The chemical or biological molecules associated with metabolism may include, e.g., glucose, triglyceride, cholesterol, free fatty acids, bile acids, amino acids, hormones, such as, e.g., insulin, LDL-C, HDL-C, HbA1c, blood urea nitrogen, and minerals. The physiological parameters that measure metabolic changes may include, e.g., glycemia, blood pressure, body weight, fat mass, body mass index (BMI), inflammation, atherosclerosis index (AI), heart index, kidney index, total fat index, and homeostatic model assessment (HOMA) index.
- In certain embodiments, the “biological activity” of the polypeptide described herein includes the ability of the polypeptide to increase the level of serum bile acid in a subject. In certain embodiments, the “biological activity” of the polypeptide described herein includes the ability of the polypeptide to enhance cholesterol elimination through bile acid synthesis in hepatocytes.
- In some embodiments, the biological activity of the polypeptide described herein may include the ability to lower the serum level of one or more chemical or biological molecules associated with lipid metabolism in a subject administered with the polypeptide. In some embodiments, the biological activity of the polypeptides described herein may include the ability to lower the serum level of serum lipids, such as, e.g., triglyceride, total cholesterol, or LDL-C in a subject administered with the polypeptide.
- In some embodiments, the biological activity of the polypeptide described herein may include the ability to lower the serum level of one or more chemical or biological molecules associated with glucose metabolism in a subject administered with the polypeptide. In some embodiments, the biological activity of the polypeptides described herein may include the ability to lower the serum level of glucose or HbA1c in a subject administered with the polypeptide. In some embodiments, the polypeptides described herein may be capable of stabilizing the serum level of insulin in a subject.
- In certain embodiments, the “biological activity” of the polypeptide described herein includes the ability of the polypeptide to treat a metabolic disorder in a subject. In some embodiments, the metabolic disorder involves dysregulation of lipid metabolism. The metabolic disease may include a cholesterol-related disorder, such as, e.g., hyperlipidemia (including hypertriglyceridemia, hypercholesterolemia, or both). In some embodiments, the metabolic disorder involves dysregulation of glucose metabolism. The metabolic disease may include, e.g., diabetes and obesity.
- In certain embodiments, the “biological activity” of the polypeptide described herein includes the ability of the polypeptide to ameliorate or prevent one or more symptoms or complications of such disorders. In certain embodiments, the “biological activity” of the polypeptide described herein includes the ability of the polypeptide to mitigate the negative impact of such disorders on the health of a patient or reduce the risk of developing such disorders. In certain embodiments, the “biological activity” of the polypeptide described herein also includes the ability of the polypeptide to reduce the severity of or the risk of developing other associated diseases, such as, e.g., atherosclerosis and/or cardiovascular diseases, heart diseases, kidney impairment, or obesity.
- Without being bound by theory, it is believed that these biological activities of the polypeptide described herein may result from bidirectional regulation of NTCP-mediated bile acid uptake in the subject by the polypeptide at the serum concentrations following administration of the polypeptide to the subject. In some embodiments, when the concentration of the polypeptide described herein in the blood stream of a subject administered with such polypeptide is at or below a certain concentration, bile acid uptake in the subject is enhanced. In some embodiments, when the concentration of the polypeptide described herein in the blood stream of the subject is above a certain concentration, bile acid uptake in the subject is inhibited. In some embodiments, when the concentration of the polypeptide described herein in the blood stream of a subject administered with such polypeptide is at or below 93 nmol/L, bile acid uptake in the subject is enhanced. In some embodiments, when the concentration of the polypeptide described herein in the blood stream of the subject is above 93 nmol/L, bile acid uptake in the subject is inhibited. For example, when the concentration of the Cmyr-47 polypeptide described herein in the blood stream of a subject administered with such polypeptide is at or below 500 ng/ml, bile acid uptake in the subject is enhanced. When the concentration of the Cmyr-47 polypeptide described herein in the blood stream of the subject is above 500 ng/ml, bile acid uptake in the subject is inhibited.
- Various in vivo, in vitro, and ex vivo assays to confirm the biological activity of the polypeptide described herein are contemplated. The biological activity of the polypeptide described herein may be confirmed in vivo, by collecting a sample from a subject treated with the polypeptide described herein. The sample may be a biopsy sample collected from a specific tissue such as, e.g., liver, muscle, fat, and pancreas, or a snap-frozen tissue collected from an animal post-mortem. In some embodiments, the sample may be a serum sample collected from blood drawn from a subject. Various methods for collecting a serum sample from a subject are known in the art, and include, e.g., tail-bleeding, retro-orbital puncture, and cardiopuncture. In some embodiments, the biological activity of the polypeptide described herein may be confirmed in vitro, by contacting the polypeptide described herein with a cell that is either a transformed cell line or a cell isolated from an animal. In some embodiments, the cell may be a primary hepatocyte isolated from an animal.
- Various methods can be used to confirm the ability of the polypeptide described herein to bidirectionally regulate NTCP in a quantitative manner. For instance, cells expressing NTCP (e.g., mammalian cells overexpressing NTCP or hepatocytes) may be treated in vitro with bile acids and increasing amounts of the polypeptide described herein. Bile acids added to the cells may be radiolabeled or chemically labeled for detection. The cells may be then harvested and the amount of bile acids taken up by the cells may be measured. The ability of the polypeptide described herein to bidirectionally regulate NTCP may be confirmed when the polypeptide enhances bile acid uptake at or below a certain concentration while inhibits bile acid uptake above that concentration.
- The exemplary assays useful to confirm the biological activity of the polypeptide may also include a functional analysis with a sample collected from a subject treated with the polypeptide described herein, including, e.g., glucose production assay, glucose uptake assay, fatty acid oxidation assay, cholesterol assay, bile acids assay, urea assay, and triglyceride assay. In some embodiments, the assays may also include, e.g., a binding analysis between the polypeptide and NTCP, an activity assay of NTCP for transporting bile acids, and an expression, localization, or activity analysis of molecular factors involved in metabolism, such as, e.g., bile acid metabolism, glucose metabolism, lipid metabolism, and amino acid metabolism. The foregoing techniques and procedures to confirm the biological activity of the polypeptides described herein may be performed by following methods known in the art and procedures provided in this specification.
- In some embodiments, the polypeptide described herein may comprise an amino acid sequence of the pre-S1 region of any HBV subtype. In some embodiments, the polypeptide described herein comprises the sequence of amino acids 13-59 of the pre-S1 region of HBV genotype C: GTNLSVPNPLGFFPDHQLDPAFGANSNNPDWDFNPNKDHWPEANQVG (SEQ ID NO: 23).
- In additional embodiments, the polypeptide described herein may comprise the corresponding pre-S1 sequence from another HBV genotype, such as, e.g., any one of genotypes A, B, D, E, F, G, and H. For example, in some embodiments, the polypeptide described herein may comprise:
-
pre-S1 amino acids 13-59 of HBV genotype A: (SEQ ID NO: 34) GTNLSVPNPLGFFPDHQLDPAFGANSNNPDWDFNPVKDDWPAANQVG, pre-S1 amino acids 13-59 of HBV genotype B: (SEQ ID NO: 35) GTNLSVPNPLGFFPDHQLDPAFKANSENPDWDLNPNKDNWPDANKVG, pre-S1 amino acids 2-48 of the HBV genotype D: (SEQ ID NO: 36) GQNLSTSNPLGFFPDHQLDPAFRANTANPDWDFNPNKDTWPDANKVG, pre-S1 amino acids 12-58 of the HBV genotype E: (SEQ ID NO: 37) GKNISTTNPLGFFPDHQLDPAFRANTRNPDWDHNPNKDHWTEANKVG, pre-S1 amino acids 13-59 of the HBV genotype F: (SEQ ID NO: 38) GQNLSVPNPLGFFPDHQLDPLFRANSSSPDWDFNTNKDSWPMANKVG, pre-S1 amino acids 12-58 of the HBV genotype G: (SEQ ID NO: 39) GKNLSASNPLGFLPDHQLDPAFRANTNNPDWDFNPKKDPWPEANKVG, or pre-S1 amino acids 13-59 of the HBV genotype H: (SEQ ID NO: 40) GQNLSVPNPLGFFPDHQLDPLFRANSSSPDWDFNTNKDNWPMANKVG. - In some embodiments, the polypeptide described herein may comprise a portion of the pre-S1 region of HBV, said portion comprising at least an amino acid sequence chosen from SEQ ID NOs: 23 and 34-40. In some embodiments, the polypeptide described herein may comprise the entire pre-S1 region of HBV.
- In some embodiments, the polypeptide described herein may be 10-100 amino acids in length. For example, the polypeptide may be 15-100, 15-80, 20-100, 20-80, 20-60, 25-60, 30-60, 35-60, or 40-60 amino acids in length, including all integers in between these ranges. In some embodiments, the polypeptide described herein may be at least 20, such as, e.g., at least 25, 30, 35, 40, amino acids in length. In some embodiments, the polypeptide described herein may be 20, 25, 30, 35, 40, 47, 55, 60 amino acids in length. In some embodiments, the polypeptide described herein may be 47 amino acids in length. The variants of the polypeptides described herein that differ in length retain one or more biological activities associated with the corresponding polypeptides, including at least the biological activity of binding to NTCP and bidirectionally regulating NTCP-mediated transport of bile acid into hepatocytes.
- In some embodiments, the polypeptide described herein may comprise an N-terminal modification with a hydrophobic group. For example, the hydrophobic group may be chosen from myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, cholesterol, and arachidonic acid. In some embodiments, the hydrophobic group may be chosen from myristic acid, palmitic acid, stearic acid, and cholesterol. In some embodiments, the hydrophobic group may be myristic acid. In certain embodiments, the polypeptide described herein may comprise an amino acid sequence chosen from SEQ ID NOs: 23 and 34-40, wherein the N terminus may be modified with a hydrophobic group chosen from myristic acid, palmitic acid, stearic acid, and cholesterol. In certain embodiments, the polypeptide described herein may comprise an amino acid sequence chosen from SEQ ID NOs: 23 and 34-40, wherein the N terminus may be myristoylated. In some embodiments, the polypeptide described herein may comprise the amino acid sequence of SEQ ID NO: 23, wherein the N terminus may be myristoylated. In some embodiments, the polypeptide described herein may comprise a C-terminal modification to stabilize the polypeptide. For example, the C-terminal modification may be chosen from amidation (amination), isopentanediolization, and any other C-terminal modification capable of stabilizing the polypeptide described herein. In some embodiments, the C-terminal modification may be amidation (amination). For example, the polypeptide described herein may comprise the amino acid sequence of NO: 23, wherein the N terminus may be myristoylated, and/or the C terminus may be amidated (aminated). In some embodiments, the polypeptide described herein may comprise the amino acid sequence of NO: 3 (Cmyr-47). In some embodiments, the polypeptide described herein may comprise an amino acid sequence chosen from SEQ ID NOs: 34-40, wherein the N terminus may be myristoylated, and/or the C terminus may be modified by amidated (aminated). In some embodiments, the polypeptide described herein may comprise an amino acid sequence chosen from SEQ ID NOs: 14-20. The variants of the polypeptide described herein that are modified at the N-terminus and/or the C-terminus retain one or more biological activities of the corresponding polypeptides that are not modified in the same manner, including at least the biological activity of binding to NTCP and bidirectionally regulating NTCP-mediated transport of bile acid into hepatocytes.
- Variants of the polypeptides described herein are also contemplated in the present disclosure, including variants with one or more amino acid deletions, substitutions, or insertions that retain one or more biological activities of the polypeptides, including at least the biological activity of binding to NTCP and bidirectionally regulating NTCP-mediated transport of bile acid into hepatocytes. The polypeptides described herein preferably retain the glycine corresponding to
amino acid 13 of the pre-S1 region of HBV genotype C (i.e., the N-terminal glycine of SEQ ID NO: 23). In some embodiments, the polypeptides described herein retain the asparagine corresponding toamino acid 20 of the pre-S1 region of HBV genotype C. In some embodiments, the polypeptide described herein may have one or more naturally-occurring mutations in the pre-S1 region of HBV. In some embodiments, the polypeptide described herein may have 1-30, such as, e.g., 1-20, 1-10, 1-8, 1-5, or 1-3, amino acid deletions, substitutions, or insertions relative to a sequence from the pre-S1 region of HBV, including all integers in between these ranges. In some embodiments, the polypeptide described herein may have 1-30, such as, e.g., 1-20, 1-10, 1-8, 1-5, or 1-3, amino acid deletions, substitutions, or insertions relative to an amino acid sequence chosen from SEQ ID NOs: 23 and 34-40, including all integers in between these ranges. In some embodiments, the polypeptide described herein may have 1-30, such as, e.g., 1-20, 1-10, 1-8, 1-5, or 1-3, amino acid deletions, substitutions, or insertions relative to the amino acid sequence of SEQ ID NO: 23, including all integers in between these ranges. In some embodiments, the polypeptide described herein may have 1-3 amino acid deletions, substitutions, or insertions from the amino acid sequence of SEQ ID NO: 23. In certain embodiments, the polypeptide described herein may have 1-30, such as, e.g., 1-20, 1-10, 1-8, 1-5, or 1-3, amino acid deletions or insertions at the C terminus of an amino acid sequence chosen from SEQ ID NOs: 23 and 34-40, including all integers in between these ranges. For example, the polypeptide described herein may comprise an amino acid sequence chosen from SEQ ID NOs: 21, 22, and 24-28. In some embodiments, the polypeptide described herein may comprise the amino acid sequence of any one of the polypeptides listed in Table 1. In some embodiments, the polypeptide described herein may be chosen from any one of the post-translationally modified polypeptides listed in Table 1. -
TABLE 1 List of Exemplary Polypeptides SEQ N-terminal C-terminal ID Modifi- Amino acid sequence Modifi- No. SEQ name cation 123456789012345678901234567890 cation SEQ origin 1 Cmyr-60 Myr GTNLSVPNPLGFFPDHQLDPAFGANSNNPD NH2 Genotype C WDFNPNKDHWPFANQVGAGAFGPGFTPPHG Pre-S1(13-72) 2 Cmyr-55 Myr GTNLSVPNPLGFFPDHQLDPAFGANSNNPD NH2 Genotype C WDFNPNKDHWPEANQVGAGAFGPGF Pre-S1(13-67) 3 Cmyr-47 Myr GTNLSVPNPLGFFPDHQLDPAFGANSNNPD NH2 Genotype C WDFNPNKDHWPEANQVG Pre-S1(13-59) 4 Cmyr-40 Myr GTNLSVPNPLGFFPDHQLDPAFGANSNNPD NH2 Genotype C WDFNPNKDHW Pre-S1(13-52) 5 Cmyr-35 Myr GTNLSVPNPLGFFPDHQLDPAFGANSNNPD NH2 Genotype C WDFNP Pre-S1(13-47) 6 Cmyr-30 Myr GTNLSVPNPLGFFPDHQLDPAFGANSNNPD NH2 Genotype C Pre-S1(13-42) 7 Cmyr-25 Myr GTNSVPNPLGFFPDHQLDPAFGAN NH2 Genotype C Pre-S1(13-37) 8 Cmyr-20 Myr GTNSVPNPLGETPDHQLDP NH2 Genotype C Pre-S1(13-32) 9 Cmyr-47+ Myr GGWSSKPRQGMGTNLSVPNPLGFFPDHQLD NH2 Genotype C (−10) PAFGANSNNPDWDFNPNKDHWPEANQVG Pre-S1(2-59) 10 Cmyr-47+ Myr GLSWTVPLEGTNLSVPNPLGFFPDHQLDP NH2 Genotype E or (−9) AFGANSNNPDWDFNPNKDHWPEANQVG G Pre-S1(2-11) + Genotype C Pre-S1(13-59) 11 Cplam-47 Plam GTNLSVPNPLGFFPDHQLDPAFGANSNNPD NH2 Genotype C WDFNPNKDHWPEANQVG Pre-S1(13-59) 12 Cstea-47 Stearoyl GTNLSVPNPLGFFPDHQLDPAFGANSNNPD NH2 Genotype C WDFNPNKDHWPEANQVG Pre-S1(13-59) 13 Cchol-47 Chol GTNLSVPNPLGFFPDHQLDPAFGANSNNPD NH2 Genotype C WDFNPNKDHWPEANQVG Pre-S1(13-59) 14 Amyr-47 Myr GTNLSVPNPLGFFPDHQLDPAFGANSNNPD NH2 Genotype A WDFNPVKDDWPAANQVG Pre-S1(13-59) 15 Bmyr-47 Myr GTNLSVPNPLGFFPDHQLDPAFKANSENPD NH2 Genotype B WDLNPNKDNWPDANKVG Pre-S1(13-59) 16 Dmyr-47 Myr GQNLSTSNPLGFFPDHQLDPAFRANTANPD NH2 Genotype D WDFNPNKDTWPDANKVG Pre-S1(2-48) 17 Emyr-47 Myr GKNISTTNPLGFFPDHQLDPAFRANTRNPD NH2 Genotype E WDHNPNKDHWTEANKVG Pre-S1(12-58) 18 Fmyr-47 Myr GQNLSVPNPLGFFPDHQLDPLFPANSSSPD NH2 Genotype F WDFNTNKDSWPKANKVG Pre-S1(13-59) 19 Gmyr-47 Myr GKNLSASNPLGFLPDHQLDPAFRANTNNPD NH2 Genotype G WDFNPKKDPWPEANKVG Pre-S1(12-58) 20 Hmyr-47 Myr GQNLSVPNPLGFFPDHQLDPLFRANSSSPD NH2 Genotype H WDFNTNKDNWPMANKVG Pre-S1(13-59) - In various embodiments, the polypeptide described herein may have at least about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to any of the polypeptides described herein. For example, the polypeptide may comprise an amino acid sequence at least about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 21-40. In some embodiments, the polypeptide may comprise an amino acid sequence at least about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 23 and 34-40. In some embodiments, the polypeptide may comprise an amino acid sequence at least about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 23. The variants having certain sequence identity to the polypeptides described herein retain one or more biological activities of the corresponding polypeptides, including at least the biological activity of binding to NTCP and bidirectionally regulating NTCP-mediated transport of bile acid into hepatocytes.
- Aspects of the present disclosure also include variants of the polypeptides described herein having a native flanking amino acid sequence from the HBV L protein, such as, e.g., from the pre-S1 region of the L protein, added to the N and/or C terminus. The native flanking amino acid sequence refers to the native sequence flanking the N or C terminus of the polypeptide described herein in the pre-S1 region of the corresponding HBV genotype or any other HBV genotypes. In some embodiments, the polypeptide described herein may comprise an amino acid sequence chosen from SEQ ID NOs: 23 and 34-40, and a native flanking amino acid sequence at the N and/or C terminus derived from the pre-S1 region of any one of HBV genotypes A-H. In some embodiments, the native flanking amino acid sequence may be derived from the consensus sequence of an HBV strain with the GenBank Accession No. KC875260 (genotype A; SEQ ID NO: 41), AY220704 (genotype B; SEQ ID NO: 42), AF461363 (genotype C; SEQ ID NO: 43), AY796030 (genotype D; SEQ ID NO: 44), AB205129 (genotype E; SEQ ID NO: 45), DQ823095 (genotype F; SEQ ID NO: 46), HE981176 (genotype G; SEQ ID NO: 47), or AB179747 (genotype H; SEQ ID NO: 48). For example, the polypeptide described herein may comprise the amino acid sequence of SEQ ID NO: 23, and a native flanking amino acid sequence at the N and/or C terminus derived from the pre-S1 region of HBV genotype C. Alternatively, the polypeptide described herein may comprise the amino acid sequence of SEQ ID NO: 23, and a native flanking amino acid sequence at the N and/or C terminus derived from the pre-S1 region of any one of HBV genotypes A, B, D, E, F, G, and H. In some embodiments, the N and/or C terminus of the polypeptide described herein may independently comprise a native flanking amino acid sequence having a length of 1-10, such as, e.g., 1-8, 1-5, or 1-3 amino acids, including all integers in between these ranges. For example, the polypeptide described herein may comprise the amino acid sequence of SEQ ID NO: 23 and a native flanking amino acid sequence of 10 amino acids at the N terminus from the pre-S1 region of HBV genotype C. In other words, the polypeptide may comprise amino acids 2-59 of the pre-S1 region of HBV genotype C (SEQ ID NO: 29). As another example, the polypeptide described herein may comprise the amino acid sequence of SEQ ID NO: 23 and a native flanking amino acid sequence of 9 amino acids at the N terminus from the pre-S1 region of HBV genotype E or G. In other words, the polypeptide may comprise amino acids 13-59 of the pre-S1 region of HBV genotype C and amino acids 2-11 of the pre-S1 region of HBV genotype E or G (SEQ ID NO: 30). It will be appreciated that, any polypeptides described herein can have native flanking amino acid sequences of any length extended from the N and/or C terminus, and the resulting polypeptides retain one or more biological activities of the original polypeptides, including at least the biological activity of binding to NTCP and bidirectionally regulating NTCP-mediated transport of bile acid into hepatocytes.
- In some embodiments, the polypeptides described herein are capable of bidirectionally regulating NTCP-mediated transport of bile acids into hepatocytes. When hepatocytes are in contact with the polypeptide described herein at or below a certain concentration, NTCP-mediated transport of bile acid into the hepatocytes may be enhanced as compared with hepatocytes that are not in contact with such polypeptide. When hepatocytes are in contact with the polypeptide described herein above the certain concentration, NTCP-mediated transport of bile acid into the hepatocytes may be inhibited as compared with hepatocytes that are not in contact with such polypeptide. In some embodiments, when hepatocytes are in contact with at or below 93 nmol/L of the polypeptide described herein, NTCP-mediated transport of bile acid into the hepatocytes may be enhanced as compared with hepatocytes that are not in contact with such polypeptide. In some embodiments, when hepatocytes are in contact with above 93 nmol/L of the polypeptide described herein, NTCP-mediated transport of bile acid into the hepatocytes may be inhibited as compared with hepatocytes that are not in contact with such polypeptide. For example, when hepatocytes are in contact with at or below 500 ng/ml of the Cmyr-47 polypeptide described herein, NTCP-mediated transport of bile acid into the hepatocytes may be enhanced as compared with hepatocytes that are not in contact with such polypeptide. In some embodiments, when hepatocytes are in contact with above 500 ng/ml of the Cmyr-47 polypeptide described herein, NTCP-mediated transport of bile acid into the hepatocytes may be inhibited as compared with hepatocytes that are not in contact with such polypeptide.
- In some embodiments, the polypeptides described herein may be capable of modulating, such as, e.g., reducing or stabilizing, the level or activity of one or more chemical or biological molecules associated with metabolism in a subject. In some embodiments, metabolism may include, e.g., bile acid metabolism, glucose metabolism, lipid metabolism, or amino acid metabolism. In some embodiments, the chemical or biological molecule is chosen from glucose, triglyceride, cholesterol, free fatty acids, bile acids, amino acids, hormones, LDL-C, HDL-C, HbA1c, blood urea nitrogen, and minerals. In some embodiments, the polypeptides described herein may be capable of modulating, such as, e.g., reducing or stabilizing, the level or value of one or more physiological parameters that measure metabolic changes such as, e.g., glycemia, blood pressure, body weight, fat mass, body mass index (BMI), inflammation, atherosclerosis index (AI), heart index, kidney index, total fat index, and homeostatic model assessment (HOMA) index. In some embodiments, the polypeptides described herein may be capable of increasing the serum level of bile acids in a subject. In some embodiments, the polypeptides described herein may be capable of reducing the level of serum lipids in a subject. In some embodiments, the polypeptides described herein may be capable of reducing the serum level of total cholesterol in a subject. In further embodiments, the polypeptides described herein may be capable of reducing the serum level of LDL-cholesterol in a subject. In some embodiments, the polypeptides described herein may be capable of reducing the serum level of triglyceride in a subject. In some embodiments, the polypeptides described herein may be capable of reducing the serum level of glucose in a subject. In some embodiments, the polypeptides described herein may be capable of reducing the serum level of HbA1c in a subject. In some embodiments, the polypeptides described herein may be capable of stabilizing the serum level of insulin in a subject. In some embodiments, the subject may be a mammal. In some embodiments, the subject may be a human. In some embodiments, the subject may suffer from a metabolic disease or may be at risk of developing such disease.
- As used herein, “modulate” or “alter,” all used interchangeably, includes “reducing,” “decreasing,” “lowering,” “down-regulating,” or “inhibiting” one or more quantifiable parameters optionally by a defined and/or statistically significant amount. The term “modulate” also includes “enhancing,” “increasing,” “elevating,” “up-regulating,” or “promoting” one or more quantifiable parameters optionally by a defined and/or statistically significant amount.
- The terms “reduce,” “decrease,” “lower,” “down-regulate,” and “inhibit,” all used interchangeably herein, mean that the level or activity of one or more chemical or biological molecules associated with metabolism such as, e.g., glucose, triglyceride, cholesterol, free fatty acids, bile acids, amino acids, or hormones, including, e.g., insulin, LDL-C, HDL-C, HbA1c, blood urea nitrogen, and minerals, is reduced below the level or activity observed in the absence of the polypeptides described herein or lower than a control polypeptide. In some embodiments, “reduce” may mean that the level or value of one or more physiological parameters that measure metabolic changes, such as, e.g., glycemia, blood pressure, body weight, fat mass, body mass index (BMI), inflammation, atherosclerosis index (AI), heart index, kidney index, total fat index, and homeostatic model assessment (HOMA) index, are reduced below the level or activity observed in the absence of the polypeptides described herein or lower than a control polypeptide. In certain embodiments, reduction with a polypeptide described herein is below the level or activity observed in the presence of an inactive or attenuated molecule. In some embodiments, the polypeptides described herein are capable of reducing the level of glucose, insulin, cholesterol, or triglyceride in the serum and/or in another tissue or organ, such as, e.g., liver, heart, muscle, visceral fat, subcutaneous fat, intestine, and brain.
- As used herein, the value of body mass index (BMI) of a subject can be calculated with the following formula: BMI=(Mass of the subject expressed in kg)/[(height of the subject expressed in m)2]. The level of inflammation can be measured by following various clinical tests available in the art. For instance, the level of C-reactive protein (CRP) in blood can be measured to quantitatively measure the level of inflammation in a subject. An erythrocyte sedimentation rate (ESR) test is another example of tests that measure the level of inflammation in a subject. The ESR test measures the rate of erythrocytes sediment in a set period. Upon obtaining the levels (such as, e.g., in mmol/L) of total cholesterol (TC) and HDL-C in a subject, the value of atherosclerosis index (AI) can be calculated by following the formula of AI=(TC−HDL-C)/HDL-C. As used herein, homeostatic model assessment (HOMA) index may refer HOMA-IR (quantifying the level of insulin resistance) index and/or HOMA-β index (quantifying the level of β-cell function). The value of HOMA-IR can be calculated by following the formula of: HOMA-IR=[(blood glucose expressed in mmol/L)×(serum insulin expressed in mU/L)]/22.5. The value of HOMA-β can be calculated by following the formula of: HOMA-β=[(20×serum insulin expressed in mU/L)/(blood glucose expressed in mmol/L−3.5)]%. The value of heart index refers to the ratio between the weight of heart and the total body weight and can be calculated by following the formula of: heart index (g/kg)=weight of heart in g/body weight in kg. The value of kidney index refers to the ratio between the weight of kidney and the total body weight and can be calculated by following the formula of: kidney index (g/kg)=weight of kidney in g/body weight in kg. The value of total fat index refers to the ratio between the weight of fat (e.g., abdominal and/or scapular fat) and the total body weight. As used herein, the fat index can be calculated by following the formula of: total fat index (g/kg)=total weight of abdominal fat and scapular fat in g/body weight in kg.
- Likewise, the terms “enhance,” “increase,” “elevate,” “up-regulate,” and “promote” all used interchangeably, mean that the level or activity of one or more chemical or biological molecules associated with metabolism, such as, e.g., glucose, triglyceride, cholesterol, free fatty acids, bile acids, amino acids, hormones, including, e.g., insulin, LDL-C, HDL-C, HbA1c, blood urea nitrogen, and minerals, is increased above the level or activity observed in the absence of the polypeptides described herein or higher than a control polypeptide. In some embodiments, “enhance” may mean that the level of value of one or more physiological parameters that measure metabolic changes, such as, e.g., glycemia, blood pressure, body weight, fat mass, body mass index (BMI), inflammation, atherosclerosis index (AI), heart index, kidney index, total fat index, and homeostatic model assessment (HOMA) index, are increased above the level or activity observed in the absence of the polypeptides described herein or higher than a control polypeptide. In certain embodiments, increase with a polypeptide described herein is above the level or activity observed in the presence of an inactive or attenuated molecule. In some embodiments, the polypeptides described herein are capable of increasing the level of bile acid in the serum and/or in another tissue or organ, such as, e.g., liver, heart, muscle, visceral fat, subcutaneous fat, intestine, and brain.
- The terms “stabilize,” “maintain,” “sustain,” and “preserve,” are used interchangeably in connection with one or more chemical or biological molecules associated with metabolism, and mean that the level or activity of the one or more chemical or biological molecules associated with metabolism, such as, e.g., glucose, triglyceride, cholesterol, free fatty acids, bile acids, amino acids, hormones, including, e.g., insulin, LDL-C, HDL-C, HbA1c, blood urea nitrogen, and minerals, shows a minimal difference from the level or activity observed in a healthy subject or a subject who is not suffering from a metabolic disease, or from the level or activity observed in the presence of a positive control polypeptide. In some embodiments, “stabilize” may mean that the level or value of one or more physiological parameters that measure metabolic changes, such as, e.g., glycemia, blood pressure, body weight, fat mass, body mass index (BMI), inflammation, atherosclerosis index (AI), heart index, kidney index, total fat index, and homeostatic model assessment (HOMA) index, shows a minimal difference from the level or value observed in a healthy subject or a subject who is not suffering from a metabolic disease, or from the level or value observed in the presence of a positive control polypeptide. In some embodiments, the polypeptides described herein are capable of stabilizing the level of insulin in the serum and/or insulin production from pancreas.
- The polypeptides described herein can be made by chemical synthesis or by employing recombinant technology.
- When recombinant procedures are selected, a synthetic gene may be constructed de novo or a natural gene may be mutated by, for example, cassette mutagenesis. The polypeptides described herein may be produced using recombinant DNA techniques. These techniques contemplate, in simplified form, taking the gene, either natural or synthetic, encoding the peptide; inserting it into an appropriate vector; inserting the vector into an appropriate host cell; culturing the host cell to cause expression of the gene; and recovering or isolating the peptide produced thereby. In some embodiments, the recovered peptide is then purified to a suitable degree.
- For example, the DNA sequence encoding a polypeptide described herein is cloned and manipulated so that it may be expressed in a convenient host. DNA encoding parent polypeptides can be obtained from an HBV genomic library, from cDNA derived from mRNA from cells expressing the polypeptide, or by synthetically constructing the DNA sequence. The parent DNA is then inserted into an appropriate plasmid or vector which is used to transform a host cell. In general, plasmid vectors containing replication and control sequences which are derived from species compatible with the host cell are used in connection with those hosts. The vector ordinarily carries a replication site, as well as sequences which encode proteins or peptides that are capable of providing phenotypic selection in transformed cells. The vector may be those commonly used in the art, or constructed using standard techniques by combining functional fragments of the vectors commonly used in the art.
- The host cell may be prokaryotic or eukaryotic. For example, prokaryotic host cells may include E. coli, Bacillus subtilis, and other enterobacteriaceae such as, e.g., Salmonella typhimurium or Serratia marcesans, and various Pseudomonas species. In addition to prokaryotes, eukaryotic organisms, such as yeast cultures, or cells derived from multicellular organisms, such as insect or mammalian cell cultures, may be used. Examples of such eukaryotic host cell lines include VERO and HeLa cells, Chinese Hamster Ovary (CHO) cell lines, W138, 293, BHK, COS-7, and MDCK cell lines.
- In some embodiments, the polypeptides described herein may be prepared using solid-phase synthesis, or other equivalent chemical syntheses known in the art. In some embodiments, solid-phase synthesis is initiated from the C-terminus of the peptide by coupling a protected α-amino acid to a suitable resin. Such a starting material can be prepared by attaching an α-amino-protected amino acid by an ester linkage to a chloromethylated resin or a hydroxymethyl resin, or by an amide bond to a BHA resin or IBHA resin. The amino acids are coupled to the peptide chain using techniques well known in the art for the formation of peptide bonds. One method involves converting the amino acid to a derivative that will render the carboxyl group more susceptible to reaction with the free N-terminal amino group of the peptide fragment. For example, the amino acid can be converted to a mixed anhydride by reaction of a protected amino acid with ethylchloroformate, phenyl chloroformate, sec-butyl chloroformate, isobutyl chloroformate, pivaloyl chloride or like acid chlorides. Alternatively, the amino acid can be converted to an active ester such as a 2,4,5-trichlorophenyl ester, a pentachlorophenyl ester, a pentafluorophenyl ester, a p-nitrophenyl ester, a N-hydroxysuccinimide ester, or an ester formed from 1-hydroxybenzotriazole. Another coupling method involves use of a suitable coupling agent such as N,N′-dicyclohexylcarbodiimide or N,N′-diisopropylcarbodiimide.
- In some embodiments, the α-amino group of each amino acid employed in the peptide synthesis may be protected during the coupling reaction to prevent side reactions involving their active α-amino function. For example, certain amino acids that contain reactive side-chain functional groups (e.g., sulfhydryl, amino, carboxyl, and hydroxyl) may be protected with suitable protecting groups to prevent a chemical reaction from occurring at that site during both the initial and subsequent coupling steps. The selection of a suitable side-chain protecting group is within the skill of the art. The protecting group will be readily removable upon completion of the desired amino acid peptide under reaction conditions that will not alter the structure of the peptide chain.
- After removal of the α-amino protecting group, the remaining α-amino and side-chain protected amino acids are coupled stepwise within the desired order. As an alternative to adding each amino acid separately in the synthesis, some may be coupled to one another prior to addition to the solid-phase synthesizer. The selection of an appropriate coupling reagent is within the skill of the art.
- Each protected amino acid or amino acid sequence is introduced into the solid-phase reactor in excess, and the coupling is suitably carried out in a medium of dimethylformamide (DMF) or CH2Cl2 or mixtures thereof. If incomplete coupling occurs, the coupling procedure is repeated before removal of the N-amino protecting group prior to the coupling of the next amino acid. The success of the coupling reaction at each stage of the synthesis may be monitored. The coupling reactions can be performed automatically using well known methods, for example, a BIOSEARCH 9500™ peptide synthesizer.
- Upon completion of the desired peptide sequence, the protected peptide must be cleaved from the resin support, and all protecting groups must be removed. The cleavage reaction and removal of the protecting groups is suitably accomplished simultaneously or stepwise. When the resin support is a chloro-methylated polystyrene resin, the bond anchoring the peptide to the resin is an ester linkage formed between the free carboxyl group of the C-terminal residue and one of the many chloromethyl groups present on the resin matrix. It will be appreciated that the anchoring bond can be cleaved by reagents that are known to be capable of breaking an ester linkage and of penetrating the resin matrix. It will also be recognized that the polypeptides may be modified (such as, e.g., modified at the N-terminus with a hydrophobic group, including, e.g., myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, cholesterol, arachidonic acid; modified at the C-terminus by amidation (amination), isopentanediolization, or other stabilizing C-terminal modification) either before or after the polypeptide is cleaved from the support.
- Purification of the polypeptides of the invention may be achieved using conventional procedures such as preparative HPLC (including reversed phase HPLC) or other known chromatographic techniques such as gel permeation, ion exchange, partition chromatography, affinity chromatography (including monoclonal antibody columns) or countercurrent distribution.
- The present disclosure also provides compositions, including pharmaceutical compositions, comprising a polypeptide described herein. In certain embodiments, the composition may comprise any one or more polypeptides described herein. In some embodiments, the composition may further comprise a suitable pharmaceutically acceptable carrier. In some embodiments, when administered to a subject in need thereof, the pharmaceutical composition provides serum concentrations of the polypeptide described herein that allow for bidirectional regulation of NTCP-mediated bile acid uptake in the subject.
- A “pharmaceutically acceptable carrier” refers to an inactive ingredient, such as, e.g., solid, semisolid, or liquid filler, diluent, encapsulating material, formulation auxiliary, excipient, or carrier, for use with a therapeutic agent that together comprise a “pharmaceutical composition” for administration to a subject. A pharmaceutically acceptable carrier is non-toxic to recipients at the dosages and concentrations employed, and is compatible with other ingredients of the formulation. The pharmaceutically acceptable carrier is appropriate for the formulation employed. For example, if the therapeutic agent is to be administered orally, the carrier may be a gel capsule. If the therapeutic agent is to be administered subcutaneously, the carrier ideally is not irritable to the skin and does not cause injection site reaction.
- Pharmaceutical compositions of the polypeptides described herein may be prepared by mixing such polypeptide having the desired degree of purity with one or more optional pharmaceutically acceptable carriers. Pharmaceutically acceptable carriers may include, e.g.: buffers (such as, e.g., phosphate, citrate, and other organic acids); antioxidants (such as, e.g., ascorbic acid and methionine); preservatives (such as, e.g., octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride, benzalkonium chloride, benzethonium chloride, phenol, butyl or benzyl alcohol, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, and m-cresol); low molecular weight (such as, e.g., less than about 10 residues) polypeptides; proteins (such as, e.g., serum albumin, gelatin, or immunoglobulins); hydrophilic polymers (such as, e.g., polyvinylpyrrolidone); amino acids (such as, e.g., glycine, glutamine, asparagine, histidine, arginine, or lysine); monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents (such as, e.g., EDTA); sugars (such as, e.g., sucrose, mannitol, trehalose or sorbitol); salt-forming counter-ions (such as, e.g., sodium); metal complexes (such as, e.g., Zn-protein complexes); and/or non-ionic surfactants (such as, e.g., polyethylene glycol (PEG)).
- Exemplary pharmaceutical carriers may also include binding agents (such as, e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (such as, e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (such as, e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (such as, e.g., starch, sodium starch glycolate, etc.); and wetting agents (such as, e.g., sodium lauryl sulphate, etc.).
- Exemplary pharmaceutically acceptable carriers may further include interstitial drug dispersion agents such as soluble neutral-active hyaluronidase glycoproteins (sHASEGP), for example, human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX®, Baxter International, Inc.). In some embodiments, a sHASEGP may be combined in the pharmaceutical composition with one or more additional glycosammoglycanases, such as, e.g., chondroitinases.
- The pharmaceutical compositions may also comprise more than one active ingredient suitable for the particular indication being treated, for example, those with complementary activities that do not adversely affect each other. Such active ingredients may be suitably present in combination in amounts that are effective for the purpose intended.
- In some embodiments, the active ingredients may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, such as, e.g., hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (such as e.g., liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules), or in macroemulsions.
- In some embodiments, the pharmaceutical composition may comprise sustained-release preparations. Suitable examples of sustained-release preparations include, e.g., semipermeable matrices of solid hydrophobic polymers containing the polypeptides described herein, which matrices may be in the form of shaped articles, such as, e.g., films or microcapsules.
- In some embodiments, the pharmaceutical compositions may be used for in vivo administration and may be sterile. Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes.
- The pharmaceutical compositions may be formulated into any of many possible dosage forms, such as, e.g., tablets, capsules, gel capsules, powders, or granules. The pharmaceutical compositions may also be formulated as solutions, suspensions, emulsions, or mixed media. In some embodiments, the pharmaceutical compositions may be formulated as lyophilized formulations or aqueous solutions.
- In some embodiments, the pharmaceutical compositions may be formulated as a solution. For example, the polypeptides described herein may be administered in an unbuffered solution, such as, e.g., in saline or in water. In some embodiments, the polypeptides may also be administered in a suitable buffer solution. For example, the buffer solution may comprise acetate, citrate, prolamine, carbonate, or phosphate, or any combination thereof. In some embodiments, the buffer solution may be phosphate buffered saline (PBS). The pH and osmolality of the buffer solution containing the polypeptides can be adjusted to be suitable for administering to a subject.
- In some embodiments, the pharmaceutical compositions may be formulated as suspensions in aqueous, non-aqueous, or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.
- In some embodiments, the pharmaceutical compositions may be formulated as emulsions. Exemplary emulsions include heterogeneous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 m in diameter. Emulsions may contain additional components in addition to the dispersed phases, and the active drug which may be present in a solution in the aqueous phase, the oily phase, or itself as a separate phase. Microemulsions are also included as an embodiment of the present disclosure. In some embodiments, the pharmaceutical compositions may also be formulated as liposomal formulations.
- Embodiments of the present disclosure include therapeutic uses of the polypeptides described herein. In one aspect, use of the polypeptides described herein as a medicament is provided. In another aspect, use of the polypeptides described herein in treating a metabolic disease is provided. In some embodiments, the metabolic disease involves dysregulation of lipid metabolism. In certain embodiments, the metabolic disease may be a cholesterol-related disorder. In some embodiments, the cholesterol-related disorder may be hyperlipidemia. In some embodiments, the hyperlipidemia may be hypertriglyceridemia, hypercholesterolemia, or a combination thereof. In some embodiments, use of the polypeptides described herein in treating conditions associated with elevated serum level of any one of total triglycerides, total cholesterol, and LDL-C is provided.
- In some embodiments, the metabolic disease involves dysregulation of glucose metabolism. In some embodiments, the metabolic disease is diabetes. In some embodiments, the metabolic disease is type II diabetes. In some embodiments, the metabolic disease is obesity. In some embodiments, use of the polypeptides described herein in treating conditions associated with elevated serum level of glucose or HbA1c is also provided.
- In another aspect, a method of treating a metabolic disease in a subject is provided, comprising administering to the subject a therapeutically effective amount of the polypeptides described herein or of a pharmaceutical composition of such polypeptide. In certain embodiments, the subject may suffer from a metabolic disease or may be at risk of developing such disease. In some embodiments, the subject may be a mammal. In some embodiments, the subject may be a human. In certain embodiments, the methods and uses described herein may further comprise administering to the subject a therapeutically effective amount of at least one additional therapeutic agent.
- In some embodiments, the metabolic disease involves dysregulation of lipid metabolism. In some embodiments, the metabolic disease may be a cholesterol-related disorder. In some embodiments, the cholesterol-related disorder may be hyperlipidemia. In some embodiments, the hyperlipidemia may be hypertriglyceridemia, hypercholesterolemia, or a combination thereof.
- In other aspects, a method of lowering the level of serum lipids, such as, e.g., the total cholesterol, total triglyceride, or LDL cholesterol level, in a subject in need thereof is provided, comprising administering to the subject a therapeutically effective amount of the polypeptide described herein or of a pharmaceutical composition of such polypeptide. In some embodiments, the subject is suffering or at risk of developing a metabolic disease involving dysregulation of lipid metabolism. In some embodiments, the subject is suffering or at risk of developing a cholesterol-related disorder. In some embodiments, the subject is suffering or at risk of developing hyperlipidemia. In some embodiments, the subject is suffering or at risk of developing hypertriglyceridemia, hypercholesterolemia, or a combination thereof.
- In some embodiments, the metabolic disease involves dysregulation of glucose metabolism. In some embodiments, the metabolic disease is diabetes. In some embodiments, the metabolic disease is type II diabetes. In some embodiments, the metabolic disease is obesity.
- In some aspects, a method of lowering the blood glucose or HbA1c level in a subject in need thereof is provided, comprising administering to the subject a therapeutically effective amount of the polypeptide described herein or of a pharmaceutical composition of such polypeptide. In some aspects, a method of stabilizing the serum level of insulin in a subject in need thereof is provided, comprising administering to the subject a therapeutically effective amount of the polypeptide described herein or of a pharmaceutical composition of such polypeptide. In some embodiments, the subject is suffering from or at risk of developing a metabolic disease involving dysregulation of glucose metabolism. In some embodiments, the subject is suffering or at risk of developing diabetes. In some embodiments, the subject is suffering from or at a risk of developing type II diabetes. In some embodiments, the subject is suffering from or at a risk of developing obesity.
- Without being bound by theory, it is believed that the polypeptide described herein may be capable of treating the metabolic diseases or modulating the serum level of metabolism-associated molecules in the subject by bidirectionally regulating NTCP-mediated bile acid uptake in the subject following administration of the polypeptide to the subject. In some embodiments, when the concentration of the polypeptide described herein in the blood stream of a subject administered with such polypeptide is at or below a certain concentration, bile acid uptake in the subject is enhanced. In some embodiments, when the concentration of the polypeptide described herein in the blood stream of the subject is above a certain concentration, bile acid uptake in the subject is inhibited. In some embodiments, when the concentration of the polypeptide described herein in the blood stream of a subject administered with such polypeptide is at or below 93 nmol/L, bile acid uptake in the subject is enhanced. In some embodiments, when the concentration of the polypeptide described herein in the blood stream of the subject is above 93 nmol/L, bile acid uptake in the subject is inhibited. For example, when the concentration of the Cmyr-47 polypeptide described herein in the blood stream of a subject administered with such polypeptide is at or below 500 ng/ml, bile acid uptake in the subject is enhanced. When the concentration of the Cmyr-47 polypeptide described herein in the blood stream of the subject is above 500 ng/ml, bile acid uptake in the subject is inhibited. In some embodiments, the serum concentration of the polypeptide described herein may be measured at least about 10, 20, 40, 60, 90, 120, 180, 240, or 360 minutes following the administration. In some embodiments, the serum concentration of the polypeptide described herein is above 93 nmol/L by certain time following the administration. In some embodiments, the serum concentration of the polypeptide described herein is at or below 93 nmol/L after that time following the administration. For example, the serum concentration of the Cmyr-47 polypeptide described herein is above 500 ng/ml by a certain time following the administration. In some embodiments, the serum concentration of the Cmyr-47 polypeptide described herein is at or below 500 ng/ml after that time following the administration. In some embodiments, such threshold serum concentration of the polypeptide occurs at about 20 minutes following the administration.
- As used herein, a “metabolic disease” or “metabolic disorder” includes any disease that may be caused by dysregulation of metabolic pathways, such as, e.g., pathways involved in bile acid metabolism, glucose metabolism, lipid metabolism, and amino acid metabolism. In some embodiments, the metabolic disease refers to a disease that involves dysregulation of lipid metabolism. In certain embodiments, the metabolic disease refers to a disease that comprises dysregulation in producing, clearing, and/or utilizing lipid metabolites including, e.g., bile acids, cholesterol, triglycerides, and fatty acids. The metabolic disease described herein therefore may refer to a cholesterol-related disorder. The metabolic disease described herein therefore may refer to hyperlipidemia, such as, e.g., hypertriglyceridemia, hypercholesterolemia, or a combination thereof. In some embodiments, the metabolic disease refers to a disease that involves dysregulation of glucose metabolism. In certain embodiments, the metabolic disease refers to a disease that comprises dysregulation in producing, clearing, and/or utilizing glucose metabolites, e.g., glucose, pyruvate, and glucose-6-phosphate. The metabolic disease described herein therefore may refer to diabetes and obesity.
- The metabolic disease described herein may be chosen from hyperglycemia; hypoglycemia; hyperinsulinemia; obesity, hyperlipidemia; hypertriglyceridemia; hypercholesterolemia; heart disease; metabolic syndrome; atherosclerotic disease; coronary heart disease; coronary artery disease; peripheral arterial disease; angina pectoris; cerebrovascular disease; acute coronary syndrome; myocardial infarction; stroke; cardiovascular disease; Alzheimer's disease; dyslipidemias; familial combined hyperlipidemia; familial hypertriglyceridemia; familial hypercholesterolemia; heterozygous hypercholesterolemia; homozygous hypercholesterolemia; familial defective apolipoprotein B-100; polygenic hypercholesterolemia; remnant removal disease; hepatic lipase deficiency; dyslipidemia caused by dietary indiscretion, hypothyroidism, drugs including estrogen and progestin therapy, beta-blockers, and thiazide diuretics; nephrotic syndrome; chronic renal failure; Cushing's syndrome; primary biliary cirrhosis; glycogen storage disease; hepatoma; cholestasis; acromegaly; insulinoma; isolated growth hormone deficiency; kidney impairment; obesity; and alcohol-induced hypertriglyceridemia.
- The term “metabolic disease” includes, e.g., type I diabetes, type II diabetes, hyperglycemia, hypoglycemia, hyperinsulinemia, obesity, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, heart disease, metabolic syndrome, coronary heart disease, stroke, cardiovascular diseases, Alzheimer's disease, and generally dyslipidemias, which can be manifested, for example, by an elevated total serum cholesterol, LDL, triglycerides, VLDL, and/or HDL. Some non-limiting examples of primary and secondary dyslipidemias that can be treated using the polypeptides described herein, either alone or in combination with one or more other agents include metabolic syndrome, diabetes, hyperlipidemia, familial combined hyperlipidemia, familial hypertriglyceridemia, familial hypercholesterolemia, including heterozygous hypercholesterolemia, homozygous hypercholesterolemia, familial defective apolipoprotein B-100; polygenic hypercholesterolemia; remnant removal disease, hepatic lipase deficiency; dyslipidemia secondary to any of the following: dietary indiscretion, hypothyroidism, drugs including estrogen and progestin therapy, beta-blockers, and thiazide diuretics; nephrotic syndrome, chronic renal failure, Cushing's syndrome, primary biliary cirrhosis, glycogen storage diseases, hepatoma, cholestasis, acromegaly, insulinoma, isolated growth hormone deficiency, and alcohol-induced hypertriglyceridemia.
- In some embodiments, the polypeptide described herein is useful in preventing or treating one or more metabolic diseases. In certain embodiments, the polypeptides described herein can also be useful in preventing or treating one or more symptoms or complications associated with a metabolic disease. For instance, the polypeptide can be used to prevent or treat cardiovascular diseases, including atherosclerotic diseases, such as, e.g., coronary heart disease, coronary artery disease, peripheral arterial disease, stroke (ischaemic and hemorrhagic), angina pectoris, or cerebrovascular disease and acute coronary syndrome, myocardial infarction. In certain embodiments, the polypeptides described herein can also be useful in preventing or treating heart diseases, kidney impairment, or obesity associated with a metabolic disorder.
- The term “diabetes” refers to a disease or condition generally characterized by metabolic defects in production and/or utilization of glucose that result in the failure to maintain appropriate blood sugar levels in the body. The results of these defects include elevated blood glucose, referred to as “hyperglycemia.” Two major forms of diabetes are Type I diabetes and Type II diabetes. Type I diabetes generally results from an absolute deficiency of insulin (e.g., the production from pancreatic R cells is extremely low or completely ablated), therefore failing to regulate glucose utilization. Type II diabetes often occurs in the face of normal or even elevated levels of insulin, and can result from the inability of tissues to respond appropriately to insulin. Most Type II diabetic patients are insulin resistant and have a relative deficiency of insulin in that insulin secretion cannot compensate for the resistance of peripheral tissues to respond to insulin.
- The term “hyperlipidemia” refers to a condition characterized by an abnormal increase in serum lipids. The lipids fractions in the circulating blood include, e.g., total cholesterol, certain lipoproteins, and triglycerides. Serum lipoproteins serve as carriers for lipids in the circulation and are classified by their density, including: chylomicrons, very low density lipoproteins (“LDL”), intermediate density lipoproteins (“IDL”), low density lipoproteins (“LDL”), and high density lipoproteins (“HDL”). The term “hyperlipidemia” encompasses primary and secondary hyperlipidemia. Primary hyperlipidemia is generally caused by genetic defects, while secondary hyperlipidemia is generally caused by other factors, such as various disease states, drugs, and dietary factors. For example, secondary hyperlipidemia may be caused by diabetes. Alternatively, hyperlipidemia can result from a combination of primary and secondary causes. Hyperlipidemia may encompass hypertriglyceridemia, hypercholesterolemia, or a combination thereof. The term “hypertriglyceridemia,” as used herein, refers to a condition in which serum total triglyceride levels are elevated above a desired level. The term “hypercholesterolemia,” as used herein, refers to a condition in which serum cholesterol levels are elevated above a desired level. In certain embodiments, the serum total cholesterol, HDL cholesterol (“HDL-C”), or LDL cholesterol (“LDL-C”) levels are elevated above the desired level in hypercholesterolemia. Hyperlipidemia also imposes a risk in and may encompass development of cardiovascular and atherosclerosis diseases. The term “cardiovascular disease” encompasses a disease of the blood vessels of the circulation system caused by abnormally high concentrations of lipids in the vessels. The term “atherosclerosis” refers to a disease of the arteries in which fatty plaques develop on the inner walls, with eventual obstruction of blood flow.
- “Patient” and “subject” may be used interchangeably to refer to an animal, such as a mammal or a human, being treated or assessed for a disease, disorder, or condition, at risk of developing a disease, disorder, or condition, or having or suffering from a disease, disorder, or condition. In some embodiments, such disease, disorder, or condition may include a metabolic disease. In some embodiments, the metabolic disease may involve dysregulation of lipid metabolism. In some embodiments, the metabolic disease may be a cholesterol-related disorder, such as hyperlipidemia (e.g., hypercholesterolemia, hypertriglyceridemia, or a combination thereof). In some embodiments, the metabolic disease may involve dysregulation of glucose metabolism. In some embodiments, the metabolic disease may be diabetes, including type I and type II diabetes.
- The term a “therapeutically effective amount” or “effective amount” of a polypeptide described herein or a composition comprising such polypeptide refers to an amount effective in the prevention or treatment of a disorder for the treatment of which the polypeptide or composition is effective. The term may include an amount of the polypeptide described herein that is effective in increasing the serum level of bile acid in a subject suffering from or at a risk of developing a metabolic disease. The term may include an amount of the polypeptide described herein that is effective in lowering the blood glucose or HbA1c level or stabilizing the serum level of insulin in a subject suffering from or at a risk of developing a metabolic disease, such as, e.g., diabetes and obesity. The term may also include an amount of the polypeptide described herein that is effective in lowering the level of serum lipids, such as, e.g., the total cholesterol, total triglycerides, LDL cholesterol level, in a subject suffering from or at a risk of developing a metabolic disease, such as, e.g., hyperlipidemia, including hypercholesterolemia, hypertriglyceridemia, or both. The term also includes an amount of a polypeptide described herein that, when administered to a subject for treating a metabolic disease, such as, e.g., diabetes and hyperlipidemia (e.g., hypercholesterolemia, hypertriglyceridemia, or both), is sufficient to effect treatment of the disease, e.g., by diminishing, ameliorating, or maintaining the existing disease or one or more symptoms of the disease, or by inhibiting the progression of the disease. The “therapeutically effective amount” or “effective amount” may vary depending on the polypeptide, the route of administration, the disease and its severity, and the health, age, weight, family history, genetic makeup, stage of pathological processes, the types of preceding or concomitant treatments, if any, and other individual characteristics of the subject to be treated.
- The “therapeutically effective amount” of the polypeptide described herein may allow the administered polypeptide to reach a concentration in the blood stream of the subject at which the polypeptide is capable of inhibiting NTCP-mediated bile acid uptake in the subject. In some embodiments, a therapeutically effective amount of the polypeptide described herein may allow the administered polypeptide to reach at least about 93 nmol/L in the blood stream of a subject administered with that amount. For example, a therapeutically effective amount of the Cmyr-47 polypeptide described herein may allow the administered polypeptide to reach at least about 500 ng/ml in the blood stream of a subject administered with that amount.
- In certain embodiments, a therapeutically effective amount of the polypeptide described herein refers to an amount such that the serum concentrations of the administered polypeptide allow for bidirectional regulation of NTCP-mediated bile acid uptake in the subject. For instance, when a subject is administered with a therapeutically effective amount of the polypeptide described herein, the initial serum concentration of the polypeptide in the subject may be above a certain concentration where the polypeptide inhibits NTCP-mediated bile acids uptake. The serum concentration of the polypeptide in the subject may gradually reduce and fall to or below a value where the polypeptide begins enhancing NTCP-mediated bile acids uptake. The serum concentration of the administered polypeptide may be assessed at least about 10, 20, 40, 60, 90, 120, 180, 240, or 360 minutes after the administration. In some embodiments, the therapeutically effective amount of the polypeptide described herein allows the polypeptide to reach a serum concentration above 93 nmol/L by certain time following the administration. In some embodiments, the therapeutically effective amount of the polypeptide described herein allows the polypeptide to reach a serum concentration at or below 93 nmol/L after that certain time following the administration. For example, the therapeutically effective amount of the Cmyr-47 polypeptide described herein allows the polypeptide to reach a serum concentration above 500 ng/ml by certain time following the administration. In some embodiments, the therapeutically effective amount of the Cmyr-47 polypeptide described herein allows the polypeptide to reach a serum concentration at or below 500 ng/ml after that certain time following the administration. In some embodiments, the therapeutically effective amount of the polypeptide described herein produces such threshold serum concentration of the polypeptide at about 20 minutes following the administration.
- In various embodiments, the term “treatment” includes treatment of a subject (e.g. a mammal, such as a human) or a cell to alter the current course of the subject or cell. Treatment includes, e.g., administration of a polypeptide described herein or a pharmaceutical composition comprising such polypeptide, and may be performed either prophylactically or subsequent to the initiation of a pathologic event or contact with an etiologic agent. Also included are “prophylactic” treatments, which can be directed to reducing the rate of progression of the disease or condition being treated, delaying the onset of that disease or condition, or reducing the severity of its onset. “Treatment” or “prophylaxis” does not necessarily indicate complete eradication, cure, or prevention of the disease or condition or the associated symptoms. In various embodiments, the term “treatment” may include relieving, slowing, or reversing the pathological processes or symptoms in a subject suffering from a metabolic disease, such as, e.g., diabetes and hyperlipidemia (e.g., hypercholesterolemia, hypertriglyceridemia, or both). In some embodiments, the term “treatment” may include improving at least one symptom or measurable parameter of a metabolic disease. It will be apparent to one of skill in the art which biological and/or physiological parameters can be used to access the pathological process of the metabolic disease. Such pathological processes or symptoms may include, e.g., excessive or increased levels compared with healthy subjects of one or more chemical or biological molecules associated with metabolism, such as, e.g., glucose, triglyceride, cholesterol, free fatty acids, bile acids, amino acids, hormones, including, e.g., insulin, LDL-C, HDL-C, HbA1c, blood urea nitrogen, and minerals; or of one or more physiological parameters that measure metabolic changes, such as, e.g., glycemia, blood pressure, body weight, fat mass, body mass index (BMI), inflammation, atherosclerosis index (AI), heart index, kidney index, total fat index, and homeostatic model assessment (HOMA) index.
- The terms “administering,” or “administer” include delivery of the polypeptide described herein to a subject either by local or systemic administration. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer, intratracheal, intranasal), epidermal, transdermal, oral, or parenteral. Parenteral administration includes intravenous, subcutaneous, intraperitoneal, or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration.
- In certain embodiments, the present disclosure provides use of the polypeptides described herein in modulating, such as, e.g., reducing or stabilizing, the level or activity of one or more chemical or biological molecules associated with metabolism, such as, e.g., glucose, triglyceride, cholesterol, free fatty acids, bile acids, amino acids, hormones, LDL-C, HDL-C, HbA1c, blood urea nitrogen, and minerals in a subject. In some embodiments, the present disclosure provides use of the polypeptides described herein in modulating, such as, e.g., reducing or stabilizing, the level or value of one or more physiological parameters that measure metabolic changes such as, e.g., glycemia, blood pressure, body weight, fat mass, body mass index (BMI), inflammation, atherosclerosis index (AI), heart index, kidney index, total fat index, and homeostatic model assessment (HOMA) index.
- In some embodiments, the present disclosure provides use of the polypeptides described herein in reducing the level of serum lipids in a subject. In some embodiments, the present disclosure provides use of the polypeptides described herein in reducing the serum level of total cholesterol in a subject. In further embodiments, the present disclosure provides use of the polypeptides described herein in reducing the serum level of LDL-cholesterol in a subject. In some embodiments, the present disclosure provides use of the polypeptides described herein in reducing the serum level of triglyceride in a subject. In some embodiments, the present disclosure provides use of the polypeptides described herein in reducing the serum level of glucose in a subject. In some embodiments, the present disclosure provides use of the polypeptides described herein in stabilizing the serum level of insulin in a subject. In some embodiments, the subject may be a mammal. In some embodiments, the subject may be a human.
- In some embodiments, the present disclosure provides use of the polypeptides described herein in reducing the risk of developing a metabolic disease. In certain embodiments, the present disclosure also provides use of the polypeptides described herein in reducing the risk of developing one or more symptoms or complications associated with a metabolic disease. In some embodiments, the metabolic disease involves dysregulation of lipid metabolism. In some embodiments, the metabolic disease is a cholesterol-related disorder. In some embodiments, the metabolic disease is hyperlipidemia. The hyperlipidemia may include hypertriglyceridemia, hypercholesterolemia, or both. In some embodiments, the metabolic disease involves dysregulation of glucose metabolism. In some embodiments, the metabolic disease is diabetes. The diabetes may include type I and type II diabetes. In some embodiments, the metabolic disease is obesity. The symptoms or complications associated with the metabolic disease may include, e.g., cardiovascular diseases such as atherosclerosis diseases, heart diseases, kidney impairment, or obesity, in a subject having such metabolic disease (such as, e.g., diabetes, hyperlipidemia, including hypertriglyceridemia, hypercholesterolemia, or both).
- The present disclosure also provides methods to carry out the above uses of the polypeptides described herein in a subject. Such methods may comprise administering to the subject a therapeutically effective amount of a polypeptide described herein or of a pharmaceutical composition comprising such polypeptide. In some embodiments, the subject may be a mammal. In some embodiments, the subject may be a human. In some embodiments, the subject may suffer from a metabolic disease or may be at risk of developing such disease.
- In a further aspect, the present disclosure provides for the use of the polypeptides described herein in the manufacture or preparation of a medicament. In some embodiments, the medicament may be for treatment of a metabolic disease. The metabolic disease may involve dysregulation of lipid metabolism. In some embodiments, the medicament may be for treatment of a cholesterol-related disorder. In some embodiments, the cholesterol-related disorder may be hyperlipidemia. The hyperlipidemia may be hypertriglyceridemia, hypercholesterolemia, or a combination thereof. In yet another embodiment, the medicament is for use in a method of lowering the level of serum lipids, such as, e.g., the total cholesterol, total triglyceride, or LDL cholesterol level, in a subject, comprising administering to the subject a therapeutically effective amount of the medicament.
- In some embodiments, the metabolic disease may involve dysregulation of glucose metabolism. In some embodiments, the medicament may be for treatment of diabetes e.g., type I or type II diabetes. In some embodiments, the medicament may be for treatment of obesity. In another embodiment, the medicament is for use in a method of lowering the blood glucose or HbA1c level in a subject, comprising administering to the subject a therapeutically effective amount of the medicament.
- In certain embodiments, the disorder treated may be any disease or condition which can be improved, ameliorated, inhibited, or prevented by bidirectionally regulating NTCP activity. In certain embodiments, disorders or disease that can benefit from the regulation of bile acid intake by hepatocytes can also be treated by the polypeptides described herein. In certain embodiments, subjects treatable by the polypeptides and methods and uses described herein may include subjects indicated for LDL apheresis, subjects with diabetes, subjects with primary hyperlipidemia (including hypercholesterolemia, hypertriglyceridemia, or a combination thereof) who are intolerant or uncontrolled by other therapeutic agent, and subjects at risk for developing hyperlipidemia who may be preventably treated. Other indications include dyslipidemia associated with secondary causes such as
Type 2 diabetes mellitus, cholestatic liver diseases (primary biliary cirrhosis), nephrotic syndrome, hypothyroidism, obesity, and the prevention and treatment of cardiovascular diseases (e.g., atherosclerotic diseases), heart diseases, and kidney impairment. - In certain embodiments, the methods and uses described herein may further comprise administering to the subject an effective amount of at least one additional therapeutic agent. In certain embodiments, the additional therapeutic agent may be for preventing and/or treating one or more diseases associated with the metabolic diseases described herein, such as, e.g., one or more diseases associated with diabetes or hyperlipidemia. In certain embodiments, the additional therapeutic agent may be for preventing and/or treating cardiovascular diseases (e.g., atherosclerotic diseases). In certain embodiment, the additional therapeutic agent may be for reducing the risk of recurrent cardiovascular events. In certain embodiments, the additional therapeutic agent may be for preventing and/or treating heart diseases, kidney impairment, or obesity. The polypeptides described herein can be used either alone or in combination with other agents in a therapy. For instance, any of the polypeptides described herein may be administered before, concurrently with, or after administration of at least one additional therapeutic agent. In certain embodiments, the additional therapeutic agent may be chosen from e.g., an antihyperlipidemic agent, an antihyperglycemic agent, an antidiabetic agent, an antiobesity agent, and a bile acid analogue.
- In some embodiment, the antihyperglycemic agent may be chosen from, e.g., a biduanide (e.g., metformin, phenformin, and buformin), insulin (e.g., regular human insulin, NPH insulin, insulin aspart, insulin lispro, insulin glargine, insulin detemir, and insulin levemir), a glucagon-like peptide 1 receptor agonist (GLP-1RA; e.g., albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, and extended-release glucagon), a sodium-glucose cotransporter 2 inhibitor (SGLR2I; e.g., canagliflozin, empagliflozin, dapagliflozin, empagliflozin, and ipragliflozin), a dipeptidyl peptidase 4 inhibitor (DPP4I; e.g., bromocriptine, sitagliptin, vildagliptin, saxagliptin, linagliptin, anagliptin, teneligliptin, alogliptin, trelagliptin, gemigliptin, dutogliptin, omarigliptin, berberine, and lupeol), an α-glucosidase inhibitor (AGI; e.g., miglitol, acarbose, and voglibose), a thiazolidinedione (TZD; e.g., pioglitazone, rosiglitazone, lobeglitazone, troglitazone, ciglitazone, darglitazone, englitazone, netoglitazone, rivoglitazone, and mifepristone), a meglitinide (e.g., repaglinide, nateglinide, and mitiglinide), a sulfonylurea (SU; e.g., carbutamide, acetohexamide, chlorpropamide, tolbutamide, tolazamide, glipizide (glucotrol), gliclazide, glibenclamide, glyburide (e.g. Micronase), glibornuride, gliquidone, glisoxepide, glyclopyramide, glimepiride, amaryl, and glimiprime), an amylin analogue (e.g., pramlinitide), a proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9I; e.g., evolocumab, bococizumab, alirocumab, 1D05-IgG2, RG-7652, LY3015014, RNAi therapeutic ALN-PCSO2, AMG-145, and REGN727/SAR236553), a glucokinase activator (GKA; e.g., MK-0941, RO-28-1675, and AZD1656), a PPAR agonist/modulator, a glucagon receptor antagonist, a C-C chemokine receptor type 2 (CCR2) antagonist, an Interleukin-1 modulator, a G-protein coupled receptor agonist, a gastrointestinal peptide agonist other than GLP-1, an SGLT1 and dual SGLT1/SGLT2 inhibitor (excluding an SGLT2-only inhibitor), an 11beta-HSD1 inhibitor, a diacylglycerol acyltransferase (DGAT)-1 inhibitor, a cannabinoid, a hepatic carnitine palmitoyltransferase 1 (CPT1) inhibitor, a fibroblast growth factor (FGF)-21 agonist, a glucocorticoid receptor antagonist, a heat shock protein (HSP) inducer, a melanocortin-4 receptor (MC4R) agonist, a tetrahydrotriazin containing oral antidiabetic, glimin, a protein tyrosine phosphatase 1B (PTP1B) inhibitor, a sirtuin1 (SIRT1) activator, and a microbiome modulator.
- In some embodiment, the additional therapeutic agent is an antihyperlipidemic agent and may be chosen from, e.g., a statin (e.g., HMG-CoA reductase inhibitor; e.g., smvastatin, atorvastatin, rosuvastatin, pravastatin, pitavastatin, lovastatin, atorvastatin, fluvastatin, cerivastatin, mevastatin, pantethine, elastase, and probucol), a fibric acid (e.g., bezafibrate (e.g., Bezalip), ciprofibrate (e.g., Modalim), clofibrate, gemfibrozil (e.g., Lopid), fenofibrate (e.g., TriCor), clinofibrate (e.g., Lipoclin), lifibrate, alufibrate, simfibrate, etofylline clofibrate, and gemfibrozil), a nicotinic acid (e.g., niacin, inositol hexanicotinate, nicotinamide, and acipimox), a bile acid sequestrant (e.g., cholestyramine (e.g., Questran®), colesevelam (e.g., Welchol®), colestipol (e.g., Colestid®), polidexide, dholestyramine, and divistyramine), ezetimibe (e.g., Zetia), a proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9I; e.g., evolocumab, bococizumab, alirocumab, 1D05-IgG2, RG-7652, LY3015014, RNAi therapeutic ALN-PCSO2, AMG-145, and REGN727/SAR236553), a microsomal triglyceride transfer protein inhibitor (MTTPI; e.g., lomitapide and JTT-130), an apolipoprotein B inhibitor (apoBI; e.g., mipomersen (e.g., Kynamro)), a diacylglycerol acyltransferase 1 (DGAT1) inhibitor (e.g., pradigastat), an angiopoietin-like protein 3 inhibitor (e.g., REGN1500), a cholesteryl ester transfer protein (CETP) inhibitor (e.g., anacetrapib and evacetrapib), a peroxisome proliferator-activated receptor (PPAR) α/γ agonist, an acyl-CoA inhibitor, an incretin mimetics inhibitor, an angiopoietin-like protein 3 (ANGPTL3) inhibitor, an angiopoietin-like protein 4 (ANGPTL4) inhibitor, an apoC-III-targeted inhibitor, and a selective peroxisome proliferator-activated receptor modulator (SPPARM).
- In some embodiment, the additional therapeutic agent is an antiobesity agent and may be chosen from, e.g., orlistat (e.g., Xenical), lorcaserin (e.g., Belviq), phentermine, topiramate, diethylpropion, phendimetrazine, benzphetamine, and a combination of phendimetrazine and benzphetamine.
- In some embodiment, the additional therapeutic agent is a bile acid analogue and may be chosen from, e.g., obeticholic acid, ursodeoxycholic acid, and cholylsarcosine.
- In some embodiments, the additional therapeutic agent may also be chosen from, e.g., a farnesoid X receptor (FXR) agonist, an FXR inhibitor, a transmembrane G protein-coupled receptor 5 (TGR5) agonist, and a TGR5 inhibitor.
- In some embodiments, the additional therapeutic agent may be chosen from insulin, metformin, sitagliptin, colesevelam, glipizide, simvastatin, atorvastatin, ezetimibe, fenofibrate, nicotinic acid, orlistat, lorcaserin, phentermine, topiramate, obeticholic acid, and ursodeoxycholic acid.
- Such combination therapies described herein may encompass combined administration (where two or more therapeutic agents are included in the same or separate formulations), and separate administration, in which case, administration of the polypeptides described herein can occur prior to, simultaneously, and/or following, administration of the additional therapeutic agent.
- The polypeptides described herein (and any additional therapeutic agent) can be administered by any suitable means, including parenteral, intrapulmonary, and intranasal, and, if desired for local treatment or intralesional administration. In some embodiments, the polypeptides described herein may be parenterally administered. Parenteral administration may include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. In some embodiments, the polypeptides described herein may administered subcutaneously. In some embodiments, the polypeptides described herein may administered intravenously. Dosing can be by any suitable route, such as, e.g., by injections or infusions, such as intravenous or subcutaneous injections or infusions, depending in part on whether the administration is brief or chronic. Various dosing schedules including e.g. single or multiple administrations over various time-points, bolus administration, and pulse infusion are also contemplated.
- The polypeptides described herein would be formulated, dosed, and administered in a fashion consistent with common medical practice. Factors for consideration in this context may include, e.g., the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The polypeptides described herein need not be but can be optionally formulated with one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents depends on the amount of the polypeptide described herein present in the formulation, the type of disorder or treatment, and other factors discussed above.
- For the prevention or treatment of disease, the appropriate dosage of a polypeptide described herein (when used alone or in combination with one or more other additional therapeutic agents) may depend on the type of disease to be treated, the severity and course of the disease, whether the polypeptide is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the polypeptide, and the discretion of the attending physician. The polypeptides described herein may be suitably administered to the patient at one time or over a series of treatments. Depending on the type and severity of the disease, the polypeptide described herein may be administered to the patient, for example, by one or more separate administrations, or by continuous infusion. For repeated administrations over several days or longer, depending on the condition, the treatment may be sustained until a desired suppression of disease symptoms occurs. The polypeptide described herein may be administered intermittently, e.g. every day, every two days, every three days, every week, or every two or three weeks (e.g. such that the patient receives from more than one, such as, e.g., about two to about twenty, or e.g. about six doses of the polypeptide). An initial higher loading dose, followed by one or more lower doses, may be administered.
- In certain embodiments, a flat-fixed dosing regimen may be used to administer the polypeptide described herein to a subject. However, other dosage regimens may also be useful depending on the factors discussed above. The progress of this therapy can be easily monitored by conventional techniques and assays for the disease or condition treated.
- The following Examples may be used for illustrative purposes and should not be deemed to narrow the scope of the invention.
- Polypeptides as shown in Table 1 were synthesized according to the standard Fmoc protocol for polypeptide synthesis. Generally, individual amino acid residues were extended from the carboxyl terminus to the amino terminus, starting from a MBHA resin. The N terminus was then modified by myristoylation. After completion of peptide synthesis, the polypeptides were cleaved from the resin by a cleavage solution and the C terminus of the polypeptides was further modified by amination. The resin was removed by filtering with G6 sand-core funnel and the filtrate containing the polypeptides was dried under vacuum. The polypeptide product was dissolved in deionized water, and purified in
AKTA explorer 100 type medium pressure liquid chromatograph equipped with C18 column. The main peaks were recovered stepwise. The samples collected from the target peak were analyzed by Agilent 1100 type reversed phase high pressure liquid chromatography (HPLC) equipped with C18 column for their purities and confirmed by mass spectrometry for their molecular weights. The collected solutions purified by medium pressure liquid chromatography were freeze-dried for storage. The dried samples were dissolved in PBS and then filtered through a 0.20 μM membrane. The polypeptide stocks dissolved in PBS were stored at −80° C. before use.FIG. 1A shows an exemplary graph depicting the purity of the synthesized polypeptide, Cmyr-47, as measured by HPLC.FIG. 1B shows an exemplary graph confirming the correct molecular weight of Cmyr-47 (5398.8 Da) as measured by mass spectrometry. - To demonstrate that a polypeptide derived from HBV can bind to NTCP, various cell-lines expressing NTCP were treated with Cmyr-47. To visualize Cmyr-47, the polypeptide was labeled with FITC. Because NTCP expresses highly in the liver, primary hepatocytes from tupaia and human hepatocyte cell line HepG2 cells were prepared for the study. As shown in
FIGS. 2A and 2B , FITC labeled Cmyr-47 binds to hepatocytes from two different species (FIG. 2A depicting binding of Cmyr-47 to tupaia primary hepatocytes;FIG. 2B depicting binding of Cmyr-47 to HepG2 cells). To demonstrate that Cmyr-47 specifically binds to NTCP, NTCP expressing L02 cells (NTCP-L02) were established by transfecting NTCP expressing vector. L02 cells transfected with a vector that does not express NTCP (BLANK-L02) were used as a negative control. As shown inFIG. 3 , Cmyr-47 labeled with FITC binds to NTCP-L02 cells, but failed to bind to BLANK-L02 cells. To confirm the specificity of Cmyr-47, HEK293 cells, a cell-line that is not derived from the liver, were prepared for the study. NTCP expressing HEK293 cells (NTCP-293) were established by transfecting the cells with an NTCP expressing vector. HEK293 cells transfected with a control vector that does not express NTCP (BLANK-293) were used as a negative control. As shown inFIG. 4 , Cmyr-47 labeled with FITC binds to NTCP-293 cells, but not BLANK-293 cells. In contrast, as expected based on a previous finding that an avian HBV does not infect mammals (Gripon et al., J. Virol. 79(3):1613-22 (2005)), a control polypeptide of 47 amino acid residues derived from heron HBV pre-S1 region (myristoylated-GLNQSTFNPLGFFPSHQLDPLFKANAGSADWDKNPNKDPW PQAHDTA-amidated, SEQ ID NO: 49) failed to bind to NTCP-293 cells. These results demonstrate that Cmyr-47 specifically binds to NTCP. - To further study the effect of the polypeptide derived from HBV on bile acids transport, NTCP-293 cells were incubated with bile acids labeled with 3H (3H-TA; taurocholate). By using 3H-TA, the amount of bile acids absorbed by the cells can be quantified by measuring the level of radioactivity of the cells. Since HEK293 cells are not capable of absorbing bile acids without NTCP expression, any bile acids taken up by NTCP-293 cells can be contributed to NTCP. TA at 10 umol/L (radioactively labeled as 3H-TA at 0.5 uCi/ml) and increasing amounts of Cmyr-47 were simultaneously added to cultured cells for 10 minutes. Cyclosporine A (CsA), known to inhibit bile acids transport, was used as a positive control at a concentration of 50 μM. As shown in
FIG. 5A , compared with BLANK-293 cells, NTCP-293 cells were capable of absorbing a significant amount of bile acids. When NTCP-293 cells were treated with Cmyr-47, the uptake of bile acids was bidirectionally regulated at different concentrations of Cmyr-47. As shown inFIG. 5B , Cmyr-47 enhanced NTCP transport of bile acids into hepatocytes at a concentration at and below 500 ng/ml, while Cmyr-47 significantly reduced TA absorption at a concentration more than 500 ng/ml. Notably, 62.5 ng/ml of Cmyr-47 increased TA absorption by more than 50%, while 2 μg/ml of Cmyr-47 effectively inhibited the uptake of bile acids as compared with the positive control, CsA. Based on the escalating dose study shown inFIG. 5B , Cmyr-47 was determined to have an IC50 value of 0.15 μM in blocking bile acids transport. - In contrast to bidirectional regulation of NTCP-mediated transport of bile acids by Cmyr-47, one-way inhibition of TA absorption was induced by CsA (
FIGS. 5C and 5D ). CsA did not enhance NTCP-mediated transportation of TA at either a low concentration of 10 ng/ml or a high concentration of 100 μg/ml. Based on the escalating dose study shown inFIG. 5D , the calculated IC50 value of CsA for inhibiting bile acids transport was 3.05 M. - To further analyze the bidirectional effect of HBV-derived polypeptides on NTCP-mediated uptake of bile acids, two different concentrations (62.5 ng/ml as a representative low concentration and 1 μg/ml as a representative high concentration) of Cmyr-47 and other HBV-derived polypeptides were tested in the in vitro bile acids assay by following the protocol described above. Two control treatments, CsA and quinidine, were also tested for comparison. Quinidine is a class I antiarrhythmic agent and was previously shown to enhance NTCP-mediated TA uptake (see Kim et al, J. Pharmacol. Exp. Ther. 291(3): 1204-09 (1999)). CsA and quinidine were purchased from Sigma-Aldrich (Sigma-30024 and Sigma-Q3625, respectively).
- As shown in
FIG. 5E , CsA at 100 ng/ml had no significant effect on TA absorption, while quinidine enhanced TA absorption at 0.1 μmol/L. HBV-derived polypeptides listed in Table 1 (Cmyr-60, Cmyr-55, Cmyr-47, Cmyr-40, Cmyr-35, Cmyr-30, Cmyr-25, Cmyr-20, Cmyr-47+(−10), Cmyr-47+(−9), Cplam-47, Cstea-47, Cchol-47, Amyr-47, Bmyr-47, Dmyr-47, Emyr-47, Fmyr-47, Gmyr-47 or Hmyr-47) enhanced TA absorption at a low concentration molarly equivalent to 62.5 ng/ml (11.58 nmol/L) of Cmyr-47, confirming that HBV-derived polypeptides are capable of enhancing NTCP-mediated uptake of bile acids at a low concentration. - In contrast, when HBV-derived polypeptides (Cmyr-60, Cmyr-55, Cmyr-47, Cmyr-40, Cmyr-35, Cmyr-30, Cmyr-25, Cmyr-20, Cmyr-47+(−10), Cmyr-47+(−9), Cplam-47, Cstea-47, Cchol-47, Amyr-47, Bmyr-47, Dmyr-47, Emyr-47, Fmyr-47, Gmyr-47 or Hmyr-47) were tested at a higher concentration molarly equivalent to 1 μg/ml (185.23 nmol/L) of Cmyr-47, all the polypeptides effectively inhibited TA absorption (
FIG. 5F ), confirming that HBV-derived polypeptides are capable of inhibiting NTCP-mediated uptake of bile acids at a high certain concentration. For comparison, CsA at 50 μg/ml inhibited TA absorption, while quinidine at 20 μmol/L enhanced TA absorption. These results confirm that HBV-derived polypeptides are capable of bidirectionally regulating NTCP-mediated uptake of bile acids in a dose-dependent manner. - To determine the toxicity of Cmyr-47 and confirm that Cmyr-47 can regulate bile acids uptake in vivo, 190 Sprague Dawley rats with equal number of males and females were subjected to a 6-month chronic toxicity test. Each rat was subcutaneously injected daily with either PBS as a control or Cmyr-47 of 1, 3, or 9 mg/kg for 180 days. The experimental scheme is shown in Table 2.
-
TABLE 2 Experimental Design Scheme of 180-Day Long Chronic Toxicity Test in Rats Dosage/injection Concentration Clinic equivalent Rats number (n) Group (mg · kg−1) (mg · ml−1) dosage multiplied by ♀ ♂ I. Control 0 0 0 20 20 II. Low- dose 1 0.4 2.3 20 + 5 20 + 5 III. Middle- dose 3 1.2 7.0 20 + 5 20 + 5 IV. High- dose 9 3.6 20.9 20 + 5 20 + 5 - At the end of the experiment, a blood sample from each rat was collected by tail-bleeding. Serums from the blood samples were further separated out by centrifugation at 3,000 rpm for 10 min. The serum samples were then analyzed a total bile acid assay kit (Nanjing Jiancheng Bioengineering Institute) in order to determine the level of total bile acids (TBA). As shown in Tables 3 and 4, both female and male rats treated with Cmyr-47 displayed an increased level of total bile acids in the serum as compared with the control group, indicating that Cmyr-47 is capable of effectively blocking the bile acids uptake in vivo. The increase of total bile acids was dose-dependent.
-
TABLE 3 Serum TBA Concentrations of 180-Day Long Chronic Toxicity Test in Rats (Male, μM/L) 95% Confidence Interval for Mean Std. Upper Group N Mean Deviation Std. Error Lower Bound Bound Minimum Maximum Control 10 7.920 3.5401 1.5832 3.524 12.316 5.2 14.0 Low- dose 10 15.480 6.5975 2.9505 7.288 23.672 9.5 23.6 Middle- dose 10 17.240 8.3575 3.7376 6.863 27.617 11.1 30.9 High- dose 10 20.640 11.5881 5.1823 6.252 35.028 13.5 41.2 -
TABLE 4 Serum TBA Concentrations of 180-Day Long Chronic Toxicity Test in Rats (Female, μM/L) 95% Confidence Interval for Mean Lower Upper Group N Mean Std. Deviation Std. Error Bound Bound Minimum Maximum Control 10 13.180 3.4354 1.5364 8.914 17.446 7.8 16.8 Low- dose 10 16.460 5.1189 2.2892 10.104 22.816 11.1 22.5 Middle- dose 10 21.860 7.5477 3.3754 12.488 31.232 12.9 32.7 High- dose 10 26.800 15.4932 6.9288 7.563 46.037 13.8 51.0 - The levels of total cholesterol (TC), triglyceride (TG), and glycemia (GLU) of each animal tested in Example 2.1 are summarized in Tables 5 and 6. As shown in Tables 5 and 6, the low dose, middle dose, or high dose of Cmyr-47 had no significant effect on serum TC, TG or GLU, as compared with the control group (all values of P>0.05). Therefore, Cmyr-47 does not affect normal levels of serum TC, TG or GLU at physiological conditions.
-
TABLE 5 Serum TC, TG, GLU Concentrations of 180-Day Long Chronic Toxicity Test in Rats (Male, mmol/L, χ ± SEM)Group n TC TG GLU Control 10 1.62 ± 0.37 0.56 ± 0.20 7.15 ± 1.74 Low- dose 10 1.58 ± 0.21 0.61 ± 0.26 6.89 ± 1.24 middle- dose 10 1.5 ± 0.18 0.49 ± 0.18 6.76 ± 1.05 High- dose 10 1.58 ± 0.33 0.56 ± 0.26 6.69 ± 0.53 Note: compared with normal control group, #P < 0.05, ##P < 0.01; compared with model control group, *P < 0.05, **P < 0.01 -
TABLE 6 Serum TC, TG, GLU Concentrations of 180-Day Long Chronic Toxicity Test in Rats (Female, mmol/L, χ ± SEM)Group n TC TG GLU Control 10 2.28 ± 0.54 0.78 ± 0.25 6.41 ± 0.38 Low- dose 10 1.97 ± 0.36 0.68 ± 0.33 6.34 ± 0.55 middle- dose 10 1.98 ± 0.49 0.75 ± 0.29 6.17 ± 0.69 High- dose 10 1.80 ± 0.50 0.56 ± 0.21 6.11 ± 0.42 Note: compared with normal control group, #P < 0.05, ##P < 0.01; compared with model control group, *P < 0.05, **P < 0.01 - To further determine the toxicity of Cmyr-47 and confirm whether Cmyr-47 can regulate bile acids uptake in vivo, 56 Beagle dogs, with equal number of males and females, were subjected to a 9-month chronic toxicity test. Each dog was subcutaneously injected daily with either PBS as a control or Cmyr-47 of 0.25, 0.75, or 2 mg/kg per injection for 270 days. The experimental scheme is shown in Table 7.
-
TABLE 7 Experimental Design Scheme of 270- day Chronic Toxicity Test in Dogs Clinic Dosage/ equivalent Dogs number injection dosage (n) Group (mg · kg−1) multiplied by ♀ ♂ I. Control 0 0 7 7 II. Low-dose 0.25 2 7 7 III. Middle-dose 0.75 6 7 7 IV. High- dose 2 16 7 7 - At the end of the experiment, a blood sample from each dog was collected by vein puncture, and serum from the collected blood samples was separated as described above. The serum samples were then analyzed to determine the concentration of total bile acids levels as described above. As shown in Table 8, Cmyr-47 increased the serum level of total bile acids in dogs in a dose-dependent manner as compared with the control group. The levels of total cholesterol (TC), triglyceride (TG), and glycemia (GLU) of each animal are summarized in Table 9. As shown in Table 9, the low dose, middle dose, or high dose of Cmyr-47 had no significant effect on serum TC, TG or GLU, as compared with the control group (all values of P>0.05). Therefore, Cmyr-47 does not affect normal levels of serum TC, TG or GLU at physiological conditions.
-
TABLE 8 Serum TBA Concentration of 270-day Long Chronic Toxicity Test in Dogs for Day 91 Phased Detection (μM/L) Group Animal Low- Middle- High- Gender No. control dose dose dose Female 1 2.6 3.2 2.4 2.1 7 1.2 3.7 1.0 1.1 3 1.0 7.8 1.0 20.4 4 0.9 2.2 1.8 13.2 5 1.0 2.3 4.1 4.2 6 2.1 22.3 2.3 1.4 7 1.6 3.0 2.9 7.3 Male 8 1.4 1.8 1.9 1.2 9 1.7 1.7 2.1 1.7 10 1.4 3.2 3.7 3.0 11 0.8 2.9 1.2 1.3 12 1.3 1.6 2.4 3.0 13 0.8 1.1 15.3 5.9 14 1.9 1.2 2.1 2.4 x ± s 1.41 ± 4.14 ± 3.16 ± 4.87 ± 0.53 5.48 3.61 5.56 P value — 0.086 0.084 0.037 -
TABLE 9 Serum TC, TG, GLU Concentration of 270-day Long Chronic Toxicity Test in Dogs for Day 91 Phased Detection (mmol/L, χ ± SEM)Group n TC TG GLU Control 14 2.93 ± 0.66 0.39 ± 0.08 4.50 ± 0.68 Low- dose 14 3.07 ± 0.44 0.49 ± 0.13 4.26 ± 0.51 middle- dose 14 3.20 ± 0.61 0.45 ± 0.10 4.52 ± 0.41 High- dose 14 3.16 ± 0.36 0.46 ± 0.12 4.69 ± 0.41 Note: compared with normal control group, #P < 0.05, ##P < 0.01; compared with model control group, *P < 0.05, **P < 0.01 - Fifty-six Beagle dogs, with equal number of males and females, were subjected to a 1-month chronic toxicity test. Each dog was subcutaneously injected every day with either PBS as a control or Cmyr-47 of 0.4, 1.2, or 3.6 mg/kg per injection for 30 days. The experimental scheme is shown in Table 10.
-
TABLE 10 Experimental Design Scheme of Pharmacokinetic Analysis in Dogs Dosage/injection Dogs number (n) Group (mg · kg−1) ♀ ♂ I. Control 0 3 3 II. Low-dose 0.4 3 3 III. Middle-dose 1.2 3 3 IV. High-dose 3.6 3 3 - During the experiment, blood samples from each dog was collected by vein puncture at 0, 10, 20, 40, 60, 90, 120, 180, 240, 360, 1440 min after the first dose and last dose. The serum from the collected blood samples was separated as described above. The serum samples were then analyzed to determine the concentration of Cmyr-47 by radioimmunoassay (RIA) using anti-PreS1 antibody 125E11 (Wei et al., Clinica. Chimica. Acta. 317:159-69 (2002)). Tables 11-13 show the serum concentrations of each animal administered with 0.4, 1.2, or 3.6 mg/kg, respectively. As shown in Table 13, dogs administered with 3.6 mg/kg of Cmyr-47 well tolerated the dosage and no serious toxicity was observed. The peak concentration (i.e. Cmax) of Cmyr-47 in blood stream was reached at 20 minutes (i.e. Tmax) following the administration. A Cmax refers to the peak serum concentration that a drug achieves after a dosing. A Tmax refers to the time at which the Cmax is observed. As shown in Table 13, for instance, the highest dose of Cmyr-47 was able to reach the Cmax of above 500 ng/ml at 20 minutes, indicating the Tmax of Cymr-47 is about 20 minutes in this test condition. As shown in Tables 11-13, only the highest dose, 3.6 mg/kg, was able to reach the peak concentration above 500 ng/ml.
-
TABLE 11 The serum Cmyr-47 concentration in Beagle dogs with sc 0.4 mg · kg − 1 Time post dose Serum concentration of Cmyr-47 (ng · mL−1) min L7 L8 L9 L10 L11 L12 MEAN ± SD CV % FIRST 0 ND ND ND ND ND ND — — DOSE 10 86.9 91.3 82.7 103.1 126.5 123.2 102.3 ± 18.8 18.4 20 165.2 142.7 116.7 162.1 155.8 137.2 146.6 ± 18.3 12.5 40 108.9 100.0 78.6 112.2 97.4 108.4 100.9 ± 12.3 12.2 60 50.5 60.2 48.1 62.0 47.5 69.5 56.3 ± 8.9 15.9 90 34.6 31.1 37.4 32.3 36.4 30.3 33.7 ± 2.9 8.7 120 23.3 21.6 24.4 21.6 24.2 19.7 22.5 ± 1.8 8.1 180 11.6 12.9 13.3 11.1 10.9 13.9 12.3 ± 1.2 10.1 240 2.4 1.5 2.3 2.0 2.6 1.9 2.1 ± 0.4 17.7 360 0.62 0.59 0.33 0.43 0.31 0.72 0.50 ± 0.17 33.7 1440 ND ND ND ND ND ND — — LAST 0 ND ND ND ND ND ND — — DOSE 10 98.8 76.5 81.0 75.3 124.3 78.9 89.1 ± 19.2 21.6 20 139.0 127.3 134.0 180.1 146.5 117.7 140.8 ± 21.7 15.4 40 95.6 112.2 90.4 100.8 137.2 96.3 105.4 ± 17.2 16.3 60 59.0 47.5 56.9 50.7 56.8 58.9 55.0 ± 4.8 8.6 90 45.0 24.8 22.7 25.8 38.5 29.9 31.1 ± 8.8 28.4 120 20.9 21.6 26.0 19.4 25.8 17.4 21.8 ± 3.5 15.8 180 14.3 9.9 13.2 8.7 8.2 10.9 10.8 ± 2.5 22.7 240 2.3 2.0 2.9 2.9 2.7 2.0 2.5 ± 0.4 16.8 360 0.59 0.53 0.34 0.39 0.35 0.61 0.47 ± 0.12 26.3 1440 ND ND ND ND ND ND — — Note: ND = undetectable -
TABLE 12 The serum Cmyr-47 concentration in Beagle dogs with sc 1.2 mg · kg−1 Time post dose Serum concentration of Cmyr-47 (ng · mL−1) min M13 M14 M15 M16 M17 M18 MEAN ± SD CV % FIRST 0 ND ND ND ND ND ND — — DOSE 10 289.9 340.3 249.3 374.1 272.9 327.2 308.9 ± 46.4 15.0 20 433.6 450.2 365.0 540.9 457.4 422.1 444.9 ± 57.3 12.9 40 333.9 323.0 259.9 314.9 287.1 292.8 302.0 ± 27.2 9.0 60 140.9 166.6 180.7 127.3 123.3 198.5 156.2 ± 30.5 19.5 90 90.6 108.9 113.2 82.4 78.9 122.6 99.4 ± 17.9 18.0 120 57.2 67.4 54.3 70.9 50.2 61.0 60.2 ± 7.9 13.1 180 41.8 35.2 31.6 38.6 33.9 49.0 38.3 ± 6.4 16.6 240 5.6 2.2 7.0 7.9 4.5 6.6 5.6 ± 2.1 36.7 360 2.0 1.6 1.8 2.2 1.6 1.9 1.8 ± 0.2 13.5 1440 ND ND ND ND ND ND — — LAST 0 ND ND ND ND ND ND — — DOSE 10 300.6 301.8 235.7 335.3 305.4 344.9 304.0 ± 38.3 12.6 20 374.1 418.2 327.2 492.8 407.6 392.8 402.1 ± 54.8 13.6 40 300.9 279.6 235.7 283.7 266.3 259.9 271.0 ± 22.4 8.3 60 128.1 149.5 162.1 112.5 109.0 170.9 138.7 ± 26.0 18.8 90 79.1 90.9 90.5 71.6 68.6 108.3 84.8 ± 14.8 17.4 120 51.0 59.9 48.3 63.4 45.0 54.3 53.6 ± 7.0 13.1 180 37.4 30.5 27.2 34.8 29.0 41.8 33.4 ± 5.6 16.7 240 3.3 4.7 5.7 6.9 5.1 4.5 5.0 ± 1.2 23.7 360 1.7 1.4 1.6 2.0 1.4 1.7 1.6 ± 0.2 13.4 1440 ND ND ND ND ND ND — — Note: ND = undetectable -
TABLE 13 The serum Cmyr-47 concentration in Beagle dogs with sc 3.6 mg · kg − 1 Time post dose Serum concentration of Cmyr-47 (ng · mL−1) min H19 H20 H21 H22 H23 H24 MEAN ± SD CV % FIRST 0 ND ND ND ND ND ND — — DOSE 10 617.8 510.6 739.4 542.7 569.9 697.1 612.9 ± 89.8 14.7 20 958.4 739.4 698.7 1117.3 1206.0 849.6 928.2 ± 204.1 22.0 40 810.7 620.0 739.4 646.3 840.6 543.6 700.1 ± 116.0 16.6 60 305.4 344.9 340.4 382.7 425.0 286.4 347.5 ± 50.6 14.6 90 218.9 237.5 262.8 201.9 190.3 187.4 216.5 ± 29.5 13.6 120 132.9 109.0 156.0 117.0 148.5 90.7 125.7 ± 124.8 19.7 180 68.5 44.5 83.2 56.9 75.4 66.0 65.8 ± 13.7 20.8 240 12.8 16.2 11.2 15.0 10.1 13.2 13.1 ± 2.3 17.4 360 3.1 3.3 2.6 3.5 3.0 3.1 3.1 ± 0.3 9.6 1440 ND ND ND ND ND ND — — LAST 0 ND ND ND ND ND ND — — DOSE 10 543.6 433.2 635.1 490.3 501.2 588.1 531.9 ± 72.6 13.6 20 874.7 673.9 620.0 921.7 1129.9 746.1 827.7 ± 187.5 22.7 40 730.7 545.5 674.4 562.1 746.4 493.1 625.4 ± 105.9 16.9 60 272.3 293.4 272.8 343.2 394.0 252.8 304.7 ± 53.6 17.6 90 195.9 209.4 236.5 173.7 197.5 166.2 196.5 ± 25.3 12.9 120 112.5 92.2 132.9 104.5 127.9 97.2 111.2 ± 16.4 14.8 180 53.6 25.9 72.2 56.0 70.3 53.6 55.3 ± 16.7 30.1 240 10.9 13.8 10.0 13.2 8.6 11.7 11.4 ± 1.9 17.0 360 2.4 3.6 2.4 3.2 3.2 2.8 2.9 ± 0.5 16.3 1440 ND ND ND ND ND ND — — Note: ND = undetectable - To analyze the in vivo effects of Cmyr-47 on lipid metabolism, a hyperlipidemic golden hamster model was established by feeding hamsters with a high-fat diet for 2 weeks (after adaptive feeding for 10 days). Male Golden hamsters (N=70, 90-110 g) were purchased from Beijing Vital River (SCXK (Jing) 2012-0001) with animal quality certificate number 11400700093338. Animals were housed at 23±1° C. with 50-70% humidity under a 12 hour light:dark cycle (150-200 Lx), in a noise-controlled room (<50 dB) at the Zhejiang Traditional Chinese Medicine University Animal Experimental Research Center (SYXK (Zhe) 2013-0184). The composition of the high-fat diet included 1.25% cholesterol and 20.06% fat (soybean oil 2.79%, cocoa butter 17.27%) and the diet was purchased from Research Diets Inc. (New Brunswick, NJ) and stored at 4° C. As a normal non-hyperlipidemic control (“a normal control group”), a group of golden hamsters was fed with a regular chow diet. A full nutritional rat pellet was used as a normal chow diet after sterilization with Co60 irradiation. Animals were provided with filtered and sterilized tap water ad libitum. All food was available ad libitum and animals were housed 4 to 5 per cage. Weight and food consumption of each hamster fed with the high-fat diet was monitored on a weekly basis. All animals were treated humanely and care was taken to minimize pain and suffering in accordance with the principle of the 3Rs (replacement, reduction, and refinement).
- After 2 weeks of the high-fat diet treatment, the hyperlipidemic phenotype of hamsters was confirmed when the animals had serum total cholesterol (TC) levels higher than 10 mmol/L. A total of 40 hyperlipidemic hamsters were randomly stratified into 5 groups (N=8/group): a model control group (10 mL/kg PBS, subcutaneous administration (sc)), a positive treatment control group (fenofibrate, 50 mg/kg/day, peroral intragastrical administration (po)), a low-dose treatment group (Cmyr-47, 10 mg/kg/day, sc), a high-dose treatment group (30 mg/kg/day Cmyr-47, sc), and a CsA treatment group (CsA, 5 mg/kg/day, po). 10 hamsters fed with the normal chow diet were used as a normal control group (10 mL/kg PBS, sc).
- By following the protocol described above, Cmyr-47 was synthesized as a white powder by HEP Pharmaceutical (Shanghai, China; Lot number: 14011801). For each treatment, Cmyr-47 was freshly prepared in PBS and used immediately after preparation. PBS was prepared by formulating a 20×PB solution (Na2HPO4·12H2O (64.4652 g) and NaH2PO4·2H2O (3.1202 g) in water to 500 mL). Then, 1 volume of 20×PB, 4 volumes of pure water, and 15 volumes of 0.9% normal saline were mixed together to obtain PBS for dissolving the test drug. Fenofibrate (FENO) of Fenolip tablet used as a positive control in this study was purchased from Laboratoires FOURNIER S.A. CsA (Sandimmune®) was purchased from Novartis.
- PBS, Cmyr-47, FENO, and CsA were respectively administered for 4 consecutive weeks. During the experiment, all animals in the model control group, low and high dose group, and positive control group were fed with the high fat diet while the normal control group was fed with the normal chow diet. Cmyr-47 or PBS was subcutaneously injected to the hamsters twice a day (9:00-10:00 in the morning and 16:00-17:00 in the afternoon). A positive treatment control group was provided with FENO via peroral intragastrical administration. A CsA treatment group was provided with CsA via peroral intragastrical administration. Each morning, food and water consumption, feces, and animal grooming were monitored. All animals were weighed weekly.
- After 2 weeks of treatment, serum TC and triglycerides (TG) levels of all animals were measured. After 4 weeks of treatment, serum TC, TG, LDL-C, and HDL-C levels of all animals were measured. Prior to measurement, all animals were fasted for 12 h with an access to water prior to blood collection. A blood (0.3 mL) sample from each animal was obtained via retro-orbital plexus and serums from the samples were further isolated by centrifugation at 3,000 rpm for 10 min. Kits for measuring lipids were purchased from Shenneng DESAY Diagnostic Technology Co. Ltd. (Shanghai, China) and all measurements were conducted by following the manufacturer's protocols. 7020 automatic biochemical analyzer was used for the measurements. An atherosclerosis index (AI) of each animal was calculated by following the formula of AI=(TC−HDL-C)/HDL-C. The AI is considered as one of the most reliable indicators of an increased risk developing atherosclerosis.
- An SQP Electronic scale from Sartorius Scientific Instruments Co., Ltd. (Beijing, China) was used, as was a MLS-3750 high pressure sterilizing chamber from Sanyo Company (Japan). An RO-MB-50 Ultrapure water system was from Yongjieda Purification Technology Co. Ltd. (Hangzhou, Zhejiang, China). KQ-300DE ultrasound was purchased from Kunshan Ultrasonic Instrument Co., Ltd. (Kunshan, Jiangsu, China) and a Hitachi 7020 automatic biochemical analyzer from Hitachi Ltd. (Japan). The multifunctional ELISA machine was from Thermo Fisher Scientific Inc. (USA).
- SPSS19.0 software was used to analyze data, expressed as means±standard deviation or mean±SEM. ANOVA variance analysis was used to evaluate the data from the test results. LSD test was used for pairwise comparisons. Values of the statistical analyses were rounded to 2 decimal places.
- As shown in Table 14 and
FIG. 6 , the serum TC levels in the model controls were significantly higher than those in the normal controls during the experiment, confirming that the animals fed with the high-fat diet were hyperlipidemic (all values of P<0.01). The administration of FENO significantly lowered the serum TC levels as compared with the model control group (all of P values less than 0.01). Hyperlipidemic animals treated with Cmyr-47 also displayed lower serum TC levels than the model control group, and the effect of Cmyr-47 was dose-dependent. In contrast, hyperlipidemic animals treated with CsA showed significantly elevated serum TC levels as compared with the model control group. -
TABLE 14 Effect of Cmyr-47 on Serum TC (mmol/L, χ ± S)TC level after weeks of dosing Group Dosage/injection n Before dosing 2 w 4 w Normal control 10 mL/ kg PBS 10 4.25 ± 0.41 4.09 ± 0.34 4.39 ± 0.43 Model control 10 mL/ kg PBS 8 11.12 ± 0.47## 19.67 ± 4.05## 19.58 ± 4.72## Positive control 50 mg/ kg FENO 8 11.34 ± 0.50 6.63 ± 4.40** 7.42 ± 1.70** Low- dose 10 mg/kg Cmyr-47 8 11.10 ± 0.44 15.53 ± 4.51* 16.00 ± 5.17* High- dose 30 mg/kg Cmyr-47 8 11.10 ± 0.46 12.67 ± 2.98** 11.54 ± 1.67** CsA treatment 5 mg/ kg CsA 8 11.24 ± 0.40 22.53 ± 2.50 24.46 ± 3.35* Note: compared with normal control group, #P < 0 05, ##P < 0.01; compared with model control group, *P < 0.05, **P < 0.01 - Additional polypeptides derived from HBV listed in Table 1 were also tested to confirm their effects on serum TC in vivo. The experiment was conducted by following the same experimental protocol described above. All polypeptide was administrated at a dose molarly equivalent to 30 mg/kg/day of Cmyr-47.
-
FIGS. 7A and 7B confirmed that animals fed with the high-fat diet were hyperlipidemic (compare the serum TC levels of normal controls and model controls). As previously shown, FENO was capable of decreasing the serum TC levels in the animals. Atweek 4, animals treated with other HBV-derived peptides (Cmyr-60, Cmyr-55, Cmyr-40, Cmyr-35, Cmyr-30, Cmyr-25, Cmyr-20, Cmyr-47+(−10), Cmyr-47+(−9), Cplam-47, Cstea-47, Cchol-47, Amyr-47, Bmyr-47, Dmyr-47, Emyr-47, Fmyr-47, Gmyr-47 or Hmyr-47) also showed lower serum TC levels than that of the model controls. - As shown in Table 15 and
FIG. 8 , the serum TG levels in the model controls were significantly higher than the normal controls throughout the experiment (all values of P<0.01). Measurements atweek 2 andweek 4 confirmed that FENO significantly decreased the serum TG levels in the animals (all of P values less than 0.01). The high dose of Cmyr-47 also significantly lowered the serum TG levels in the animals as compared with the model controls. Similar to the effect on serum TC, the effect of Cmyr-47 on serum TG were also dose-dependent. Of note, CsA treatment increased the serum TG levels in the animals as compared with the model controls. -
TABLE 15 Effect of Cmyr-47 on Serum TG (mmol/L, χ ± S)TG level after weeks of dosing Group Dosage/injection n Before dosing 2 w 4 w Normal control 10 mL/ kg PBS 10 2.85 ± 1.24 2.23 ± 0.76 2.29 ± 0.84 Model control 10 mL/ kg PBS 8 5.65 ± 1.78## 7.81 ± 3.24## 7.54 ± 3.10## Positive Control 50 mg/ kg FENO 8 6.16 ± 1.30 3.14 ± 0.4** 2.68 ± 0.30** Low- dose 10 mg/kg Cmyr-47 8 6.15 ± 1.14 6.29 ± 2.48 4.39 ± 1.21 High- dose 30 mg/kg Cmyr-47 8 6.35 ± 2.00 5.31 ± 1.76* 3.81 ± 0.95* CsA treatment 5 mg/ kg CsA 8 6.23 ± 0.90 8.81 ± 0.50 10.23 ± 0.61** Note: compared with normal control, #P < 0.05, ##P < 0.01; compared with model control, *P < 0.05, **P < 0.01 - The serum TG levels of animals treated with additional polypeptides derived from HBV (Cmyr-60, Cmyr-55, Cmyr-40, Cmyr-35, Cmyr-30, Cmyr-25, Cmyr-20, Cmyr-47+(−10), Cmyr-47+(−9), Cplam-47, Cstea-47, Cchol-47, Amyr-47, Bmyr-47, Dmyr-47, Emyr-47, Fmyr-47, Gmyr-47 or Hmyr-47) were also measured by following the protocol described above. As shown in
FIGS. 9A and 9B , the serum TG levels of animals treated with these HBV-derived polypeptides were lower than that of the model controls, indicating all the tested polypeptides derived from HBV are capable of lowering serum TG in vivo. - Table 16 and
FIG. 10 summarize the measurements of serum LDL-C levels from the animals treated with PBS, FENO, or Cmyr-47. As expected, the serum LDL-C levels in the model controls significantly increased as compared with the normal controls, confirming the hyperlipidemic phenotype (P<0.01). The positive controls treated with FENO displayed significantly lower serum LDL-C levels than the model controls. Consistent with the effect of Cmyr-47 on serum TC and TG, animals treated with Cmyr-47 (particularly with the high dose of 30 mg/kg) showed significantly decreased serum LDL-C levels as compared with the model controls. -
TABLE 16 Effect of Cmyr-47 on Serum LDL-C (4 weeks post the treatment) LDL-C Group Dosage/injection n (mmol/L) Normal control 10 mL/ kg PBS 10 1.09 ± 0.11 Model control 10 mL/ kg PBS 8 9.38 ± 3.75## Positive Control 50 mg/ kg FENO 8 1.88 ± 0.40** Low- dose 10 mg/kg Cmyr-47 8 7.33 ± 3.40 High- dose 30 mg/kg Cmyr-47 8 4.34 ± 1.36** Note: compared with normal control, #P < 0.05, ##P < 0.01; compared with model control, *P < 0.05, **P < 0.01 - The serum LDL-C levels of animals treated with additional polypeptides derived from HBV (Cmyr-60, Cmyr-55, Cmyr-40, Cmyr-35, Cmyr-30, Cmyr-25, Cmyr-20, Cmyr-47+(−10), Cmyr-47+(−9), Cplam-47, Cstea-47, Cchol-47, Amyr-47, Bmyr-47, Dmyr-47, Emyr-47, Fmyr-47, Gmyr-47 or Hmyr-47) were also measured by following the protocol described above. As shown in
FIGS. 11A and 11B , the serum LDL-C levels of those animals were lower than that of the model controls. - Table 17 and
FIG. 12 provide the measurements of serum HDL-C levels. Based on the values obtained in this study, an AI value of each animal was calculated by following the formula discussed above. The average AI value of each group is provided in Table 17 andFIG. 13 . Although Cmyr-47 did not lower serum HDL-C in vivo, the average AI value of animals treated with Cmyr-47 was significantly lower than the average value of the model controls, indicating that Cmyr-47 may be protective against atherosclerosis and other vascular disease including cardiovascular diseases that are caused by accumulation of fat. -
TABLE 17 Effect of Cmyr-47 on Serum HDL-C and AI (4 weeks post the treatment) HDL-C Group Dosage/injection n (mmol/L) Al Normal control 10 mL/ kg PBS 10 2.29 ± 0.27 0.92 ± 0.11 Model control 10 mL/ kg PBS 8 3.44 ± 0.19## 4.75 ± 1.59## Positive Control 50 mg/ kg FENO 8 3.13 ± 0.30** 1.36 ± 0.38** Low- dose 10 mg/kg Cmyr-47 8 3.45 ± 0.22 3.62 ± 1.49* High- dose 30 mg/kg Cmyr-47 8 3.41 ± 0.18 2.39 ± 0.55** Note: compared with normal control, #P < 0.05, ##P < 0.01; compared with model control, *P < 0.05, **P < 0.01 - Table 18 and
FIG. 14 provide the measurements of serum TBA levels. As expected, the serum TBA levels in the model controls were higher than the normal controls. As compared with the model control group, the serum TBA levels of animals treated with Cmyr-47 were further elevated in a dose-dependent fashion, confirming that Cmyr-47 is capable of inhibiting bile acid uptake in vivo. Measurements atweek 4 confirmed that the high dose of Cmyr-47 significantly increased the serum TBA levels (P values less than 0.05). CsA and the low dose of Cmyr-47 also moderately elevated the serum TBA levels after 4 weeks of treatment, though the significance was not reached. -
TABLE 18 Effect of Cmyr-47 on Serum TBA (mmol/L, χ ± S)TG level after weeks of dosing Group Dosage/injection n Before dosing 2 w 4 w Normal control 10 mL/ kg PBS 10 24.61 ± 3.69 23.14 ± 2.65 18.13 ± 3.81 Model control 10 mL/ kg PBS 8 36.19 ± 7.00 39.35 ± 12.04## 41.63 ± 18.61## Positive Control 50 mg/ kg FENO 8 35.74 ± 4.47 25.74 ± 4.25* 24.45 ± 2.52* Low- dose 10 mg/kg Cmyr-47 8 37.28 ± 7.55 39.42 ± 11.18 53.94 ± 32.15 High- dose 30 mg/kg Cmyr-47 8 32.15 ± 7.82 40.43 ± 5.96 64.08 ± 5.47* CsA treatment 5 mg/ kg CSA 8 34.55 ± 6.67 41.38 ± 11.83 52.73 ± 9.83 Note: compared with normal control, #P < 0.05, ##P < 0.01; compared with model control, *P < 0.05, **P < 0.01 - As shown in Table 19, hyperlipidemic animals did not show any significant hyperglycemic phenotype as compared with the normal controls (all values of P>0.05). The high and low doses of Cmyr-47 did not reduce the serum GLU levels below the normal glycemia displayed in the normal controls and the model controls (all values of P>0.05).
-
TABLE 19 Effect of Cmyr-47 on Serum GLU in Golden Hamster (mmol/L, χ ± SEM)GLU level after weeks of dosing Group Dosage/injection n Before dosing 2 w 4 w Normal control 10 mL/ kg PBS 10 4.09 ± 0.3 4.63 ± 0.8 4.99 ± 1.4 Model control 10 mL/ kg PBS 8 3.99 ± 0.4 4.52 ± 0.9 4.34 ± 0.7 Low- dose 10 mg/kg Cmyr-47 8 4.18 ± 0.3 3.87 ± 0.7 4.55 ± 1.0 High- dose 30 mg/kg Cmyr-47 8 4.11 ± 0.5 4.10 ± 0.7 4.38 ± 0.4 Note: compared with normal control group, #P < 0.05, ##P < 0.01; compared with model control group, *P < 0.05, **P < 0.01 - As discussed above, Cmyr-47 was capable of reversing hyperlipidemic phenotype in golden hamsters fed with a high-fat diet. In particular, the high dose of Cmyr-47 was capable of lowering all biological indicators measured in this study. In contrast, CsA, a bile acid uptake inhibitor, failed to produce a similar effect. Furthermore, despite the effective inhibition of bile acid uptake demonstrated by CsA in vitro, CsA treatment in vivo caused an increase of the serum TG and TC levels, confirming the hyperlipidemic effect of CsA.
- Consistent with the effects on serum TC and TG levels of Cmyr-47, the AI values of Cmyr-47 treated animals were significantly lower than that of the non-treated hyperlipidemic animals, further demonstrating the efficacy of Cmyr-47 as a preventive medicine in cardiovascular diseases. In addition, other polypeptides derived from HBV showed similar efficacy in lowering serum TG, TC, and LDL-C, indicating that those polypeptides are also capable of reversing hyperlipidemic phenotype in vivo.
- The hyperlipidemic golden hamster model was established as described in Example 3.1. After 2 weeks of the high-fat diet treatment, the hyperlipidemic phenotype of hamsters was confirmed when the animals had serum total cholesterol (TC) levels higher than 10 mmol/L. A total of 32 hyperlipidemic hamsters were randomly stratified into 4 groups (N=8/group): a model control group (10 mL/kg PBS, subcutaneously (sc)), a low-dose treatment group (Cmyr-47, 1 mg/kg/day, sc), a middle-dose treatment group (Cmyr-47, 3 mg/kg/day, sc) and a high-dose treatment group (10 mg/kg/day Cmyr-47, sc). Eight hamsters fed with the normal chow diet were used as a normal control group (10 mL/kg PBS, sc).
- By following the protocol described in Example 3.1, Cmyr-47 was administered for 4 consecutive weeks. During the experiment, all animals in the model control group, low, middle and high dose groups were fed with the high fat diet, while the normal control group was fed with the normal chow diet. Cmyr-47 or PBS was subcutaneously injected to the hamsters twice a day (9:00-10:00 in the morning and 16:00-17:00 in the afternoon). Each morning, food and water consumption, feces, and animal grooming were monitored. The serum TC and TG levels of all animals were measured on
week 2 andweek 4 of treatment as described in Example 3.1 and the results are summarized in Tables 20 and 21. The data was analyzed as described in Example 3.1. - As shown in Table 20 and
FIG. 15 , the serum TC levels in the model controls were significantly higher than those in the normal controls during the experiment (all values of P<0.01). The treatment with Cmyr-47 at a dose of 1 mg/kg or 3 mg/kg had no effect on serum TC. However, hyperlipidemic animals treated with 10 mg/kg Cmyr-47 for 4 weeks showed moderately reduced levels of serum TC as compared with the model control group (P<0.05). -
TABLE 20 Effect of Cmyr-47 on Serum TC (mmol/L, χ ± S)TC level after weeks of dosing Group Dosage/injection n Before dosing 2 w 4 w Normal control 10 mL/ kg PBS 8 2.21 ± 0.3 4.3 ± 0.3 4.25 ± 0.3 Model control 10 mL/ kg PBS 8 13.45 ± 1.6## 19.47 ± 4.9## 19.88 ± 3.9## Low- dose 1 mg/kg Cmyr-47 8 13.42 ± 1.5 19.75 ± 2.5 20.88 ± 4.0 Middle- dose 3 mg/kg Cmyr-47 8 13.33 ± 1.4 18.88 ± 2.1 20.99 ± 6.9 High- dose 10 mg/kg Cmyr-47 8 13.34 ± 1.4 16.47 ± 5.1 16.21 ± 4.2* Note: compared with normal control group, #P < 0.05, ##P < 0.01; compared with model control group, *P < 0.05, **P < 0.01 - As shown in Table 21 and
FIG. 16 , the serum TG levels in the model controls were significantly higher than the normal controls throughout the experiment (all values of P<0.01). The treatment with Cmyr-47 at dose of 1 mg/kg or 3 mg/kg had no effect on serum TG. Hyperlipidemic animals treated with 10 mg/kg Cmyr-47 for 4 weeks expressed moderately lowered serum TG levels comparing to the model control group (P<0.05). These data suggest that administering a therapeutically effective amount of Cmyr-47 to reach serum concentrations of Cmyr-47 capable of bidirectionally regulating NTCP-mediated bile acid uptake may be beneficial for lowering serum TC and TG levels in hyperlipidemic patients. -
TABLE 21 Effect of Cmyr-47 on Serum TG (mmol/L, χ ± S)TG level after weeks of dosing Group Dosage/injection n Before dosing 2 w 4 w Normal control 10 mL/ kg PBS 8 2.04 ± 0.8 1.46 ± 0.3 1.11 ± 0.2 Model control 10 mL/ kg PBS 8 5.28 ± 1.0## 6.48 ± 1.6## 7.92 ± 5.2## Low- dose 1 mg/kg Cmyr-47 8 4.78 ± 0.8 7.11 ± 2.1 7.41 ± 2.1 Middle- dose 3 mg/kg Cmyr-47 8 5.37 ± 1.3 7.21 ± 2.7 6.91 ± 1.9 High- dose 10 mg/kg Cmyr-47 8 5.52 ± 1.3 5.55 ± 2.4 4.44 ± 2.1* Note: compared with normal control group, #P < 0.05, ##P < 0.01; compared with model control group, *P < 0.05, **P < 0.01 - The efficacy of Cmyr-47 as an anti-diabetic, anti-hyperlipidemic, and/or anti-hypercholesterolemic agent was tested in Zucker Diabetic Fatty (ZDF) rats, a spontaneous type II diabetes animal model. Male 60-days old ZDF rats (n=40) and Zucker Lean (ZL) rats (n=6) were purchased from Vital River Laboratory Animal Technology Co., Ltd. (SCXK (Beijing) 2012-0001) with animal quality certification numbers 11400700109970 and 11400700109972. All animals were housed at 23±1° C. with 50-70% humidity under specific-pathogen-free (SPF) environment and under a 12 hour light:dark cycle (150-200 Lx), in a noise-controlled room (<50 dB) at the Zhejiang Traditional Chinese Medicine University Animal Experimental Research Center [SYXK(Zhe) 2013-0184]. Animals had a free access to filtered and sterilized water in autoclaved water bottle. ZDF rats were fed with Purina #5008 diet purchased from Specialty Feeds, Inc. (Memphis, TN; Purina 5008; Catalogue No. SF06-019). ZL rats were fed with a normal chow diet (basic feed) sterilized by Co60 gamma irradiation. Two ZDF rats or ZL rats were housed in each cage and cage bedding was changed once every 2 days. The experimental rat breeding and all other operations were in accordance with the principle of 3R with humane care.
- After 2 weeks of Purina #5008 diet or the normal chow diet, all animals were fasted for 10 h with access to water. Each animal was then weighed and tail-bled to collect 0.3 mL of blood. The blood samples were further analyzed for glycated hemoglobin (HbA1c). Additional 0.5 mL of blood was collected and centrifuged at 3,000 rpm for 10 min in order to separate serum. The HbA1c, serum glucose (GLU), and insulin levels in the animals were measured by kits provided below. Hitachi 7020 automatic biochemical analyzer was used for all the measurements.
- 30 animals with the fasting serum GLU levels close to the average level were selected and randomly divided into 5 groups: a model control group (10 ml·kg−1 PBS), a low-dose treatment group (10 mg·kg−1 Cmyr-47), a high-dose treatment group (30 mg·kg−1 Cmyr-47), a positive control group (300 mg·kg−1 Metformin), and a CsA treatment group (20 mg·kg−1 CSA) with 6 animals per group. Six ZL rats were used as a normal control group (10 ml·kg−1 PBS). PBS or Cmyr-47 was injected to animals subcutaneously twice per day (at 09:00 and 17:00). Meformin (MET) and CsA solutions were given via oral gavage twice per day in the morning and afternoon. The dosing was conducted for 4 weeks. During the experiment, ZDF rats were fed with Purina #5008 diet while ZL rats were fed the normal chow diet.
- Cmyr-47 was synthesized as described above, purified as a white powder by Shanghai HEP Pharmaceutical Co., Ltd (Shanghai, China; Lot number 14011801), and stored at −20° C. Cmyr-47 was weighed and dissolved in PBS right before use. MET was manufactured by Bristol-Myers Squibb Co., Ltd. (Shanghai, China) with approval number H20023370 and lot number of AAD7878. CsA (Sandimmune®) was purchased from Novartis.
- At the second-week of dosing, the animals were fasted for 10 h with free access to water, and 0.3 mL of blood from each animal was collected via tail vein bleeding for measuring serum GLU, total cholesterol (TC), triglycerides (TG) and blood urea nitrogen (BUN). At the fourth-week of dosing, the animals were fasted for 10 h and the blood was then collected for the measurement of serum GLU, TC, TG and BUN, HbA1c and insulin. After the last dose of drugs, the animals were fasted for 12 h and then anesthetized via intraperitoneal injection of 3% sodium pentobarbital and cervical dislocation. Heart, kidneys, scapular fat, and abdominal fat of each animal were dissected for visual observation and weighed to calculate heart, kidney, and total fat index.
- Pentobarbital sodium (content ≥95.0%; Lot number 20130112) was purchased from Merck. TC, TG, GLU and BUN kits were purchased from DiaSys Diagnostic Systems (Shanghai, China). HbA1c detection reagent was purchased from Trinity Biotech Inc., Ireland. Insulin ELISA detection kit (Lot number: 0469636-1) was purchased from Bertin Pharma (France). All measurements using the purchased kits were conducted following the manufacturers' protocols provided in the kits.
- SQP electronic balance was purchased from Sartorius Scientific Instruments (Beijing) Co., Ltd. (Beijing, china). ILS-3750 autoclave was purchased from Sanyo, Japan. RO-MB-50 ultrapure water system was manufactured by Hangzhou Yongjieda Cleaning Science and Technology, Co., Ltd. (Zhejiang, China). KQ-300DE ultrasound was purchased from Kunshan Ultrasonic Instruments Co., Ltd. (Jiangsu, China). Hitachi 7020 automatic biochemical analyzer was purchased from Hitachi, Japan. Hb9210 glycated hemoglobin analyzer, Trinity Biotech Inc, Ireland. Multifunctional microplate reader was purchased from Thermo Fisher Scientific, Co. (MA, USA).
- SPSS 19.0 software (SPSS, Chicago, IL) was used for statistical analysis. All data were presented as mean±standard error mean (
χ ±SEM). ANOVA variance analysis was used to evaluate the data from the test results. LSD test was used for pairwise comparisons. Values of the statistical analyses were rounded to 2 decimal places. - Hyperglycemia (i.e., increased blood glucose) is one of the most prominent symptoms of type II diabetes. As shown in Table 22 and
FIG. 17 , hyperglycemic phenotype of ZDF rats was confirmed by comparing the serum GLU levels of the model controls with the normal controls (all values of P<0.01). MET is a well-known anti-diabetic agent that effectively lowers glycemia in diabetic patients. As expected, ZDF rats treated with MET showed significantly decreased fasting serum GLU as compared with the model controls. Cmyr-47 was also capable of lowering glycemia in ZDF rats. In particular, by 4 weeks of treatments, both low and high doses of Cmyr-47 effectively reduced the serum GLU levels in the animals. The effect of Cmyr-47 on glycemia was dose-dependent. In contrast, CsA treatment significantly elevated the serum GLU levels in the animals as compared with the model control. -
TABLE 22 Effect of Cmyr-47 on Fasting Serum GLU in ZDF Rats (mmol/L, χ ± SEM)GLU level after weeks of dosing Group Dosage/ injection 0 2 4 Normal control 10 mL/kg PBS 6.91 ± 0.22 6.23 ± 0.27 6.51 ± 0.19 Model control 10 mL/kg PBS 9.68 ± 0.90# 19.36 ± 3.35## 27.03 ± 1.07## Positive control 300 mg/kg Met 9.71 ± 0.96 7.98 ± 1.02** 8.35 ± 0.58** Cmyr- 47Lo 10 mg/kg Cmyr-47 9.82 ± 1.19 14.74 ± 0.68 19.16 ± 1.23** Cmyr- 47Hi 30 mg/kg Cmyr-47 9.73 ± 1.01 9.50 ± 1.72* 10.50 ± 2.34** CsA treatment 20 mg/kg CsA 9.76 ± 1.22 22.38 ± 3.08 33.75 ± 6.68* Note: compare to normal control group, #P < 0.05, ##P < 0.01; compare to model control group, *P < 0.05, **P < 0.01 - Additional polypeptides derived from HBV listed in Table 1 were also tested in order to analyze their effects on glycemia in vivo by following the same protocol described above. All polypeptide was administrated at a dose molarly equivalent to 30 mg/kg/day of Cmyr-47.
- As shown in
FIGS. 18A and 18B , hyperglycemic phenotype of ZDF rats was confirmed. As observed in the study above, the treatment with MET significantly decreased fasting serum GLU in vivo. After 4 weeks of treatment with HBV-derived peptides (Cmyr-60, Cmyr-55, Cmyr-40, Cmyr-35, Cmyr-30, Cmyr-25, Cmyr-20, Cmyr-47+(−10), Cmyr-47+(−9), Cplam-47, Cstea-47, Cchol-47, Amyr-47, Bmyr-47, Dmyr-47, Emyr-47, Fmyr-47, Gmyr-47 or Hmyr-47), the fasting serum GLU levels of ZDF rats decreased as compared with the model controls, indicating the efficacy of the polypeptides as an anti-diabetic agent. - HbA1c refers to glycated hemoglobin, and its level significantly increases when a subject is experiencing chronic hyperglycemia. As shown in Table 23 and
FIG. 19 , consistent with hyperglycemic phenotype of ZDF rats, the HbA1c levels in the model controls were significantly higher than the normal control throughout the study (all values of P<0.01). Also, consistent with the effect of MET on glycemia, the treatment with MET significantly decreased the HbA1c levels in ZDF rats (P<0.01). ZDF rats treated with Cmyr-47 also showed significantly reduced HbA1c levels as compared with the model controls in a dose-dependent fashion, confirming the efficacy of Cmyr-47 as an anti-diabetic agent that regulates glycemia in vivo. Consistent with the effect of CsA on the serum GLU levels, CsA treatment significantly increased the serum HbA1c after 4 weeks of treatment. -
TABLE 23 Effect of Cmyr-47 on HbA1c Level in ZDF Rats (%, χ ± SEM)HbA1c level after weeks of dosing Group Dosage/ injection 0 4 Normal control 10 mL/kg PBS 4.28 ± 0.02 4.55 ± 0.02 Model control 10 mL/kg PBS 6.27 ± 0.25## 9.33 ± 0.40## Positive control 300 mg/kg Met 6.25 ± 0.31 5.07 ± 0.23** Cmvr- 47Lo 10 mg/kg Cmyr-47 6.27 ± 0.24 6.82 ± 0.44** Cmyr- 47Hi 30 mg/kg Cmyr-47 6.25 ± 0.31 5.73 ± 0.39** CsA treatment 20 mg/kg CsA 6.23 ± 0.44 11.60 ± 1.03** Note: compare to normal control, #P < 0.05, ##P < 0.01; compare to model control, *P < 0.05, **P < 0.01 - Additional polypeptides derived from HBV listed in Table 1 also showed a similar effect on HbA1c when tested in the same animal model as described above. As shown in
FIGS. 20A and 20B , the HbA1c levels of the model controls were higher than that of the ZDF rats treated with the polypeptides. These results demonstrate that the polypeptides derived from HBV are capable of effectively lowering glycemia and HbA1c, and confirm the hyperglycemic effect of CsA. - Type II diabetic patients experience insulin resistance, overproduction of insulin, and ultimately insulin depravation due to pancreatic damage. To confirm that Cmyr-47 is capable of modulating insulin by preventing pancreatic damage, the insulin levels of animals treated with Cmyr-47 were compared with animals treated with PBS or MET. As shown in Table 24 and
FIG. 21 , the initial serum insulin levels of ZDF rats were significantly higher than the normal controls. While the insulin levels of ZDF rats remained higher than the normal controls atweek 4, the absolute levels significantly dropped as compared with the initial levels. This change indicates that insulin resistance in ZDF rats progressed during the study, resulting in pancreatic failure. The treatment with MET appeared to be protective against the loss of serum insulin, although the difference between the fasting insulin levels of the model controls and positive controls was not statistically significant (P>0.05). Cmyr-47 treatment, however, completely stabilized insulin secretion, if not increased, at both doses, indicated by the significant difference between the model controls and the Cmyr-47 treated animals (all values of P<0.05). These results demonstrate that Cmyr-47 may prevent pancreatic damage and therefore help a diabetic patient to maintain proper insulin secretion. -
TABLE 24 Effect of Cmyr-47 on Serum Insulin in ZDF Rats (ng/mL, χ ± SEM)Insulin level after weeks of dosing Group Dosage/ injection 0 4 Normal control 10 mL/kg PBS 0.46 ± 0.06 0.84 ± 0.06 Model control 10 mL/kg PBS 7.15 ± 1.38## 3.85 ± 1.25## Positive control 300 mg/kg Met 6.74 ± 0.62 8.36 ± 3.68 Cmyr- 47Lo 10 mg/kg Cmyr-47 7.99 ± 1.17 8.57 ± 2.18* Cmyr- 47Hi 30 mg/kg Cmyr-47 8.55 ± 1.07 9.56 ± 4.26* Note: compared with normal control group, #P < 0.05, ##P < 0.01; compared with model control group, *P < 0.05, **P < 0.01 - As discussed above, diabetic phenotypes include lipid dysregulation including elevated cholesterol and triglycerides in the blood stream. As shown in Table 25 and
FIG. 22 , the serum TC levels in the model controls were consistently elevated as compared with the normal controls (all values of P<0.05). In contrast to the effect of MET on glycemia, however, MET appeared to be completely ineffective in lowering the serum TC levels in ZDF rats. CsA was also ineffective in lowering the serum TC levels in ZDF rats and by 4 weeks of treatment, CsA significantly increased the serum TC levels as compared with the model control. Notably, the high dose of Cmyr-47 significantly reduced the serum TC levels in ZDF rats as compared with the model controls, confirming that Cmyr-47 can regulate a wide array of biomarkers that are severely elevated in diabetic patients. -
TABLE 25 Effect of Cmyr-47 on Serum TC in ZDF Rats (mmol/mL, χ ± SEM)TC level after weeks of dosing Group Dosage/ injection 0 2 4 Normal control 10 mL/kg PBS 2.85 ± 0.03 3.18 ± 0.06 3.22 ± 0.04 Model control 10 mL/kg PBS 3.68 ± 0.46# 4.95 ± 0.15## 6.95 ± 0.21## Positive control 300 mg/kg Met 3.82 ± 0.11 5.24 ± 0.35 6.95 ± 0.54 Cmyr- 47Lo 10 mg/kg Cmyr-47 3.72 ± 0.15 4.97 ± 0.19 6.63 ± 0.18 Cmyr- 47Hi 30 mg/kg Cmyr-47 3.60 ± 0.18 4.25 ± 0.27* 5.52 ± 0.41** CsA treatment 20 mg/kg CsA 3.65 ± 0.48 6.54 ± 0.63** 8.33 ± 0.65** Note: compared with normal control group, #P < 0.05, ##P < 0.01; compared with model control group, *P < 0.05, **P < 0.01 - Animals treated with additional polypeptides derived from HBV also showed that those polypeptides are capable of reducing serum TC in vivo. As shown in
FIGS. 23A and 23B , after 4 weeks of treatment with HBV-derived peptides (Cmyr-60, Cmyr-55, Cmyr-40, Cmyr-35, Cmyr-30, Cmyr-25, Cmyr-20, Cmyr-47+(−10), Cmyr-47+(−9), Cplam-47, Cstea-47, Cchol-47, Amyr-47, Bmyr-47, Dmyr-47, Emyr-47, Fmyr-47, Gmyr-47 or Hmyr-47), the serum TC levels of ZDF rats were lower than that of the model controls. These results demonstrate that while MET may target only one particular symptom, a polypeptide derived from HBV is capable of targeting multiple pathways and therefore beneficial to manage diabetes-related symptoms simultaneously. - In addition to serum TC, serum TG is also a biomarker for hyperlipidemia that may be caused by diabetes. As expected, Table 26 and
FIG. 24 show that the serum TG levels in the model controls were significantly higher than that of the normal controls throughout the study (all values of P<0.01). Of note, MET significantly elevated the serum TG levels in ZDF rats at week 2 (P<0.01). While the difference was not significant, the serum TC levels in ZDF rats treated with MET remained higher than the model controls atweek 4. Consistent with the effect on serum TC levels, CsA further increased the serum TG levels in ZDF rats. In contrast, both doses of Cmyr-47 were capable of lowering the serum TG levels of ZDF rats and the effect of Cmyr-47 was dose-dependent. -
TABLE 26 Effect of Cmyr-47 on Serum TG in ZDF Rats (mmol/mL, χ ± SEM)Dosage/ TG level after weeks of dosing Group injection 0 2 4 Normal 10 mL/ 0.58 ± 0.03 0.96 ± 0.08 1.47 ± 0.15 control kg PBS Model 10 mL/ 9.80 ± 2.95## 12.23 ± 1.36## 13.43 ± 2.21## control kg PBS Positive 300 mg/ 8.32 ± 0.65 17.10 ± 2.02** 14.74 ± 1.99 control kg Met Cmyr- 10 mg/kg 9.78 ± 0.48 9.50 ± 0.58 8.62 ± 0.41* 47Lo Cmyr-47 Cmyr- 30 mg/kg 8.11 ± 0.72 6.42 ± 0.92** 6.26 ± 0.64** 47Hi Cmyr-47 CsA 20 mg/kg 9.04 ± 0.84 14.34 ± 1.8** 19.03 ± 2.65** treatment CsA Note: compared with normal control, #P <0.5, ##P <0.01; compared with model control, *P <0.05, **P <0.01 - Additional polypeptides derived from HBV were also capable of reducing serum TG in vivo when tested in the same animal model described above. As shown in
FIGS. 25A and 25B , the serum TG levels of the model controls remained higher than ZDF rats treated with HBV-derived peptides (Cmyr-60, Cmyr-55, Cmyr-40, Cmyr-35, Cmyr-30, Cmyr-25, Cmyr-20, Cmyr-47+(−10), Cmyr-47+(−9), Cplam-47, Cstea-47, Cchol-47, Amyr-47, Bmyr-47, Dmyr-47, Emyr-47, Fmyr-47, Gmyr-47 or Hmyr-47), further confirming that polypeptides derived from HBV are capable of regulating glucose metabolism and lipid metabolism simultaneously. - Elevated serum BUN reflects impaired renal function, which often occurs in human diabetic patients. In ZDF model, diabetic phenotypes lead to renal dysfunction and the correlative elevation of serum BUN. As expected, Table 27 and
FIG. 26 show that the serum BUN levels in the model controls were significantly higher than that of the normal controls throughout the study. The treatment of MET was not capable of reversing renal dysfunction as no significant BUN difference was found between the model controls and the positive controls. However, the high dose of Cmyr-47 significantly lowered the serum BUN levels in ZDF rats at week 4 (P<0.01), indicating that Cmyr-47 may protect a diabetic subject against kidney damage and renal dysfunction. -
TABLE 27 Effect of Cmyr-47 on Serum BUN in ZDF Rats (mmol/mL, χ ± SEM)BUN level after weeks of dosing Group Dosage/ injection 0 2 4 Normal control 10 mL/kg PBS 4.71 ± 0.22 5.54 ± 0.06 4.48 ± 0.09 Model control 10 mL/kg PBS 6.13 ± 0.51# 6.62 ± 0.35 7.96 ± 0.18## Positive control 300 mg/kg Met 5.52 ± 0.21 6.58 ± 0.52 7.09 ± 0.36 Cmyr- 47Lo 10 mg/kg Cmyr-47 5.26 ± 0.29 6.83 ± 0.48 7.93 ± 0.38 Cmyr- 47Hi 30 mg/kg Cmyr-47 5.83 ± 0.37 6.44 ± 0.45 6.65 ± 0.20** Note: compared with normal control group, #P < 0.05, ##P < 0.01; compared with model control group, *P < 0.05, **P < 0.01 - Diabetic patients have an increased risk of developing cardiovascular diseases, renal dysfunction, and obesity. As discussed above, various indexes such as heart index (HI), kidney index (KI), and total fat index (TFI) can be used as a quantitative indicator of the risk. As shown in Table 28 and
FIG. 27A , the HI values of the model controls were higher than the normal controls. The treatment with MET had no effect on the HI values. Surprisingly, both doses of Cmyr-47 significantly decreased the HI values of ZDF rats, indicating that Cmyr-47 can be beneficial to prevent adverse cardiovascular events. - As shown in Table 28 and
FIG. 27B , the KI values of the model controls were significantly higher than the normal controls (P<0.01), confirming that ZDF rats developed renal dysfunction during the study. Consistent with the effect of Cmyr-47 on serum BUN, Cmyr-47 treatment also lowered the KI values in ZDF rats, although the difference did not meet the statistical significance. - Table 28 and
FIG. 27C show that the TFI values of the model controls were significantly higher than normal controls (P<0.01), indicating that ZDF rats reached morbid obesity. Although not significant, ZDF rats treated with Cmyr-47 showed a trend of TFI values lower than the model controls. Of note, MET did not show the similar trend and rather, it appeared to increase the TFI values in ZDF rats. -
TABLE 28 Effect of Cmyr-47 on Organ Index in ZDF Rats After 4 Weeks of Treatment (g/kg, χ ± SEM)Group Dosage/injection Heart index Kidney index Total fat index Normal control 10 mL/kg PBS 3.48 ± 0.09 6.64 ± 0.13 27.47 ± 1.63 Model control 10 mL/kg PBS 3.63 ± 0.19 8.39 ± 0.41# 93.70 ± 5.01## Positive control 300 mg/kg Met 3.63 ± 0.24 7.26 ± 0.55 94.64 ± 3.79 Cmyr- 47Lo 10 mg/kg Cmyr-47 2.90 ± 0.13* 7.86 ± 0.63 89.18 ± 4.95 Cmyr- 47Hi 30 mg/kg Cmyr-47 3.05 ± 0.10* 7.36 ± 0.44 86.61 ± 5.03 Note: compared with normal control, #P < 0.05, ##P < 0.01; compared with model control, *P < 0.05, **P < 0.01 - To confirm that Cmyr-47 is capable of regulating the serum TBA level, the serum TBA level of each animal was measured. As shown in Table 29 and
FIG. 28 , the serum TBA levels in the model controls were higher than the normal controls. As compared with the model control group, the serum TBA levels of ZDF rats treated with Cmyr-47 were further elevated in a dose-dependent fashion. Measurements atweek 4 confirmed that the high dose of Cmyr-47 significantly increased the serum TBA levels (P values less than 0.05). Also, CsA significantly elevated the serum TBA levels after 4 weeks of treatment (P values less than 0.01). -
TABLE 29 Effect of Cmyr-47 on Serum TBA in ZDF Rats (mmol/mL, χ ± SEM)TBA level after weeks of dosing Group Dosage/ injection 0 2 4 Normal control 10 mL/kg PBS 42.61 ± 10.94 44.52 ± 8.62 28.51 ± 8.13 Model control 10 mL/kg PBS 55.51 ± 36.96 76.24 ± 31.22 59.15 ± 22.38# Positive control 300 mg/kg Met 32.83 ± 12.29 82.48 ± 27.02 82.97 ± 15.82* Cmyr- 47Lo 10 mg/kg Cmyr-47 37.51 ± 13.17 74.04 ± 33.35 74.38 ± 28.53 Crayr- 47Hi 30 mg/kg Cmyr-47 44.09 ± 12.20 85.47 ± 24.03 114.58 ± 45.31* CsA treatment 20 mg/kg CsA 40.29 ± 6.69 78.53 ± 7.38 117.35 ± 9.33** Note: compared with normal control group, #P < 0.05, ##P < 0.01; compared with model control group, *P < 0 05, **P < 0.01 - MET is a widely used antidiabetic drug that can efficiently modulate glycemia in vivo. As presented above, the efficacy of MET in glycemia regulation was also confirmed in this study. However, MET failed to provide benefits against lipid dysregulation and associated diseases, as evident by the results that MET was not capable of lowering serum TC, TG, and BUN levels, and HI values in ZDF rats. As shown in hyperlipidemic animal models, CsA treatment not only increased the serum TG and TC levels, but further increased the serum GLU levels, suggesting that effective inhibition of bile acid uptake in vitro does not always translate to a therapeutic effect on lipid and glucose metabolism in vivo. In contrast, Cmyr-47 performed well all across the tests. As demonstrated above, Cmyr-47 was capable of modulating glycemia and lipid metabolism while providing protection against pancreas damage, renal dysfunction, and cardiovascular diseases. Thus, Cmyr-47 performed superior as an anti-hyperglycemia, anti-hypercholesterolemia, anti-hyperlipidemia, and anti-adiposity agent over MET and showed a comprehensive effect on multiple diabetic phenotypes simultaneously.
Claims (20)
1. A method of treating or preventing a metabolic disease, a cardiovascular disease, a heart diseases, or a kidney impairment in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a polypeptide or a pharmaceutical composition comprising the polypeptide to produce a serum concentration of the administered polypeptide at a concentration above a concentration threshold of 93 nmol/L, wherein the polypeptide comprises an amino acid sequence derived from Hepatitis B virus (HBV); wherein the metabolic disease chosen from diabetes; hyperglycemia; hypoglycemia; hyperinsulinemia; hyperlipidemia; hypertriglyceridemia; hypercholesterolemia; heart disease; metabolic syndrome; atherosclerotic disease; coronary heart disease; coronary artery disease; peripheral arterial disease; angina pectoris; cerebrovascular disease; acute coronary syndrome; myocardial infarction; stroke; cardiovascular disease; Alzheimer's disease; dyslipidemias; familial combined hyperlipidemia; familial hypertriglyceridemia; familial hypercholesterolemia; heterozygous hypercholesterolemia; homozygous hypercholesterolemia; familial defective apolipoprotein B-100; polygenic hypercholesterolemia; remnant removal disease; hepatic lipase deficiency; dyslipidemia caused by dietary indiscretion, hypothyroidism, drugs including estrogen and progestin therapy, beta-blockers, and thiazide diuretics; nephrotic syndrome; chronic renal failure; Cushing's syndrome; primary biliary cirrhosis; glycogen storage disease; hepatoma; cholestasis; acromegaly; insulinoma; isolated growth hormone deficiency; kidney impairment; obesity; and alcohol-induced hypertriglyceridemia; wherein the cardiovascular disease is an atherosclerotic disease.
2. The method of claim 1 , wherein the metabolic disease involves dysregulation of lipid metabolism and/or dysregulation of glucose metabolism.
3. The method of claim 1 , wherein the polypeptide is capable of reducing or stabilizing the level or activity of one or more chemical or biological molecules associated with metabolism in the subject, wherein the chemical or biological molecule is chosen from glucose, cholesterol, triglycerides, free fatty acids, amino acids, hormones, LDL-C, HDL-C, HbA1c, blood urea nitrogen, and minerals; or the polypeptide is capable of lowering the level of total cholesterol, triglycerides, and/or LDL-C in the subject.
4. The method of claim 1 , wherein the polypeptide is capable of lowering the level of glucose and/or HbA1c in the subject, or the polypeptide is capable of stabilizing the level of insulin in the subject.
5. The method of claim 1 , wherein the polypeptide is capable of reducing or stabilizing the level or value of one or more physiological parameters that measure metabolic changes chosen from glycemia, blood pressure, body weight, fat mass, body mass index (BMI), inflammation, atherosclerosis index, heart index, kidney index, total fat index, and homeostatic model assessment (HOMA) index.
6. The method of claim 1 , wherein the polypeptide comprises an amino acid sequence of the pre-S1 region of HBV genotype A, B, C, D, E, F, G, or H.
7. The method of claim 1 , wherein the polypeptide comprises the sequence of amino acids 13-59 of the pre-S1 region of HBV genotype C.
8. The method of claim 1 , wherein the polypeptide comprises an amino acid sequence selected from SEQ ID NOs: 21-40, or has at least about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%% identity to an amino acid sequence selected from SEQ ID NOs: 21-40.
9. The method of claim 6 , wherein the polypeptide comprises at the N-terminus and/or the C-terminus a native flanking amino acid sequence from the pre-S1 region of HBV.
10. The method of claim 9 , wherein the native flanking amino acid sequence from the pre-S1 region of HBV has 1-10, 1-8, 1-5, or 1-3 amino acids in length.
11. The method of claim 1 , wherein the polypeptide comprises the glycine corresponding to amino acid 13 of the pre-S1 region of HBV genotype C, and or the asparagine corresponding to amino acid 20 of the pre-S1 region of HBV genotype C.
12. The method of claim 1 , wherein the polypeptide comprises an N-terminal modification with a hydrophobic group, and/or a C-terminal modification that is capable of stabilizing the polypeptide.
13. The method of claim 12 , wherein the hydrophobic group is chosen from myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, cholesterol, and arachidonic acid; and the C-terminal modification is amidation (amination) or isopentanediolization.
14. The method of claim 1 , wherein the polypeptide comprises SEQ ID NO: 23, and wherein the polypeptide further comprises an N-terminal modification with myristic acid and a C-terminal modification with amination; or wherein the polypeptide comprises SEQ ID NO: 3.
15. The method of claim 1 , wherein the polypeptide is capable of binding to sodium taurocholate cotransporting polypeptide (NTCP).
16. The method of claim 1 , wherein the serum concentration of the administered polypeptide in the subject is above 500 ng/ml.
17. The method of claim 1 , wherein the polypeptide or the pharmaceutical composition comprising the polypeptide is administered to the subject before, concurrently with, or after the administration of a therapeutically effective amount of at least one second agent.
18. The method of claim 17 , wherein the second agent is chosen from an antihyperlipidemic agent, an antihyperglycemic agent, an antidiabetic agent, an antiobesity agent, and a bile acid analogue.
19. The method of claim 18 , wherein the second agent is chosen from insulin, metformin, sitagliptin, colesevelam, glipizide, simvastatin, atorvastatin, ezetimibe, fenofibrate, nicotinic acid, orlistat, lorcaserin, phentermine, topiramate, obeticholic acid, and ursodeoxycholic acid.
20. The method of claim 1 , wherein the polypeptide or the pharmaceutical composition comprising the polypeptide is administered to the subject by at least one mode chosen from parenteral, intrapulmonary, intranasal, intralesional, intramuscular, intravenous, intraarterial, intraperitoneal, and subcutaneous administration.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/296,454 US20230414706A1 (en) | 2016-05-30 | 2023-04-06 | Compositions and methods for treating metabolic diseases |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610370442.4 | 2016-05-30 | ||
CN201610370442 | 2016-05-30 | ||
PCT/CN2017/086558 WO2017206898A1 (en) | 2016-05-30 | 2017-05-31 | Compositions and methods for treating metabolic diseases |
US201816305790A | 2018-11-29 | 2018-11-29 | |
US18/296,454 US20230414706A1 (en) | 2016-05-30 | 2023-04-06 | Compositions and methods for treating metabolic diseases |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/086558 Division WO2017206898A1 (en) | 2016-05-30 | 2017-05-31 | Compositions and methods for treating metabolic diseases |
US16/305,790 Division US11633454B2 (en) | 2016-05-30 | 2017-05-31 | Compositions and methods for treating metabolic diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230414706A1 true US20230414706A1 (en) | 2023-12-28 |
Family
ID=60479717
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/305,790 Active 2038-05-31 US11633454B2 (en) | 2016-05-30 | 2017-05-31 | Compositions and methods for treating metabolic diseases |
US18/296,454 Pending US20230414706A1 (en) | 2016-05-30 | 2023-04-06 | Compositions and methods for treating metabolic diseases |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/305,790 Active 2038-05-31 US11633454B2 (en) | 2016-05-30 | 2017-05-31 | Compositions and methods for treating metabolic diseases |
Country Status (8)
Country | Link |
---|---|
US (2) | US11633454B2 (en) |
EP (1) | EP3463422A4 (en) |
JP (1) | JP2019520341A (en) |
KR (1) | KR102627084B1 (en) |
CN (1) | CN109310737B (en) |
AU (1) | AU2017274094B2 (en) |
CA (1) | CA3026140A1 (en) |
WO (1) | WO2017206898A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20240058393A1 (en) * | 2020-12-28 | 2024-02-22 | Md Healthcare Inc. | Composition comprising micrococcus luteus-derived extracellular vesicle for prevention or treatment of metabolic disease |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102675430B (en) * | 2005-08-12 | 2014-08-27 | 上海贺普药业股份有限公司 | Hepatitis B virus surface L protein related peptide |
CN104130316B (en) * | 2005-08-12 | 2017-04-19 | 上海贺普药业股份有限公司 | Hepatitis B virus (HBV) surface L protein related peptide |
CN102241744B (en) * | 2010-05-14 | 2015-03-04 | 上海贺普药业股份有限公司 | Virus infection blocker, and its drug composition and application |
WO2014072524A1 (en) * | 2012-11-12 | 2014-05-15 | Ruprecht-Karls-Universität Heidelberg | Lipopetides for use in treating liver diseases and cardiovascular diseases |
SG10202100667SA (en) | 2012-12-27 | 2021-02-25 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
KR20230156963A (en) | 2014-10-07 | 2023-11-15 | 엠와이알 게엠베하 | Combination therapy of hbv and hdv infection |
EP3181146A1 (en) | 2015-12-16 | 2017-06-21 | Ruprecht-Karls-Universität Heidelberg | Cyclic ntcp-targeting peptides and their uses as entry inhibitors |
EP3189850A1 (en) | 2015-12-16 | 2017-07-12 | Ruprecht-Karls-Universität Heidelberg | Liver targeting of cyclic pres-derived peptides of hbv |
-
2017
- 2017-05-31 WO PCT/CN2017/086558 patent/WO2017206898A1/en unknown
- 2017-05-31 US US16/305,790 patent/US11633454B2/en active Active
- 2017-05-31 EP EP17805843.4A patent/EP3463422A4/en active Pending
- 2017-05-31 CN CN201780033504.5A patent/CN109310737B/en active Active
- 2017-05-31 CA CA3026140A patent/CA3026140A1/en active Pending
- 2017-05-31 JP JP2018562995A patent/JP2019520341A/en active Pending
- 2017-05-31 KR KR1020187037955A patent/KR102627084B1/en active IP Right Grant
- 2017-05-31 AU AU2017274094A patent/AU2017274094B2/en active Active
-
2023
- 2023-04-06 US US18/296,454 patent/US20230414706A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200323951A1 (en) | 2020-10-15 |
WO2017206898A1 (en) | 2017-12-07 |
CN109310737A (en) | 2019-02-05 |
KR20190015392A (en) | 2019-02-13 |
EP3463422A1 (en) | 2019-04-10 |
CN109310737B (en) | 2023-05-05 |
EP3463422A4 (en) | 2020-02-26 |
AU2017274094A1 (en) | 2019-02-14 |
CA3026140A1 (en) | 2017-12-07 |
KR102627084B1 (en) | 2024-01-19 |
US11633454B2 (en) | 2023-04-25 |
JP2019520341A (en) | 2019-07-18 |
AU2017274094B2 (en) | 2020-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200338158A1 (en) | Therapeutic Drug for Non-Alcoholic Fatty Liver Disease | |
CN107921085B (en) | Methods and compositions for treating aging-related disorders | |
CN103402536A (en) | Methods for treating metabolic disorders and obesity with GIP and GLP-1 receptor-active glucagon-based peptides | |
EP3685847B1 (en) | Modulators of complement activity | |
JP6120782B2 (en) | Interleukin-1 receptor antagonist | |
US20210196786A1 (en) | Therapy of atherosclerosis, primary biliary cirrhosis and nrlp3 inflammasome-associated disease by htcp inhibitors | |
US11827690B2 (en) | ApoC-II mimetic peptides | |
US20230414706A1 (en) | Compositions and methods for treating metabolic diseases | |
EP1634605A2 (en) | Treatment of dyslipidemia in a patient having type 2 diabetes | |
KR20140071272A (en) | Apolipoprotein aiv as an antidiabetic peptide | |
US20070218504A1 (en) | Human leptin-derived polypeptides and uses thereof | |
JP2021500411A (en) | Drugs and methods to treat hepatitis B virus-related liver disease under all dose conditions | |
JP6262661B2 (en) | A therapeutic agent for amyotrophic lateral sclerosis | |
AU2012385960B2 (en) | Method of treating hyperglycemic disorders using apolipoprotein AIV | |
WO2018204918A1 (en) | Treatment of hepatic disorders | |
WO2008115880A2 (en) | Use of leptin for the treatment or prevention of parkinson's disease | |
WO2012142083A2 (en) | C1q/tnf-related protein 12 and compositions and methods of using same | |
Claudia | Targeting Microsomal Triglyceride Transfer Protein for the treatment of Homozygous Familial Hypercholesterolaemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |